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Abstract: Does accelerated long term forgetting occur in patients 
recently diagnosed with localisation related epilepsy?  
Marion Ashe 
 
Purpose: Memory difficulties are a problem for many people with epilepsy, caused 
by a variety of factors. Research has identified „accelerated long term forgetting‟ as a 
possible cause for discrepancy between subjective and objective memory 
performance in patients with epilepsy, with research focusing on refractory 
epilepsy.  The aim of this study was to examine the objective and subjective 
memory performance of patients recently diagnosed with epilepsy, including long 
term forgetting rates.   
Methods: Newly diagnosed patients with localisation related epilepsy (n=14), and 
healthy controls (n=13) matched to age, gender and education level were assessed 
for intellectual functioning, general memory, subjective memory, and anxiety and 
depression. Furthermore, they were asked to learn a story and a set of visual scenes 
to a pre-set criterion level, with recall and recognition of both tested after 30 
minutes and after three weeks.  
Results: Patients and controls did not differ in their performance as measured by 
general memory score on Wechsler Memory Scale (WMS) (p=0.281).  However, 
patients demonstrated significantly impaired retention on the learnt story over 30 
minutes (p=0.024) and significantly impaired recall over three weeks (p=0.021), 
when compared to controls. In the visual scenes test, patients demonstrated 
impaired initial learning (p=0.018), but once learnt, retained the same amount of 
information as controls over a 30 min period (p=0.652). However, patients had 
significantly poorer recall (p=0.002) and increased forgetting rates (p=0.003) after 
three weeks, which correlated with lifetime number of generalised seizures 
(p=0.040). Seizures during the three week delay had no relationship to three week 
forgetting scores. Subjective memory scores did not differ between patients and 
controls, and were correlated with anxiety but not long term forgetting. 
Conclusion: Compared to controls, recently diagnosed patients demonstrated 
impaired delayed recall of a story, and accelerated long term forgetting of a visual 
scenes task. Caution is needed interpreting these results because of the small 
numbers, and difficulty accounting for contributing factors to cognitive impairment 
(such as AED use and pathology). However these are the first results of long term 
forgetting investigations in recently diagnosed patients, and bring into question the 
need for memory testing over extended delays.  
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Chapter 1   Introduction 
 
 
This chapter will briefly introduce the main issues to be discussed in this thesis and 
provide a short summary of the structure. 
 
Affecting around 50 million people around the world, epilepsy is one of the most 
common neurological problems. Epilepsy describes a diverse family of disorders, 
characterised by at least one seizure and an enduring alteration in the brain 
increasing the likelihood of further seizures (Fisher et al., 2005). However, there are 
many other ways that epilepsy can impact on a patient‟s life, which has been 
recognised by the ILAE (International League Against Epilepsy) in their move 
towards a new definition of epilepsy, encompassing the neurobiological, cognitive, 
psychological and social consequences of epilepsy (Fisher et al., 2005). A general 
overview of epilepsy and its diagnosis and management will be given in Chapter 2.  
 
The focus of this thesis will be the effects of epilepsy on cognitive functioning, with 
particular attention to memory functioning. Memory is our mental ability to retain 
and retrieve information, and is what allows us to change our behaviour according 
to past experience. It is a vital part of being able to function in the world, allowing 
us to form an idea of ourselves and also to form relationships with others. Memory 
difficulties can affect relationships, education and employment as well as our 
psychological well being and quality of life, so it is an area worthy of investigation. 
Chapter 3 will give an overview of types of memory and some of the theories 
behind memory processes. 
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Epilepsy has an effect on memory, but there are many potential inter-related causes 
which are difficult to disentangle (see figure 1.1). Chapter 4 will discuss objective 
memory problems in temporal lobe epilepsy, and their relationship to various 
factors including pathology, seizures, anti-epileptic drugs (AEDs) and mood factors.  
 
Epilepsy seems to affect both objective and subjective memory, but it has been 
found that complaints often do not correlate with performance on 
neuropsychological tests. Subjective memory complaints in people with epilepsy 
and their relationship to neuropsychological assessment performance will be 
discussed in Chapter 5.  
 
Chapter 6 will then discuss further one possible explanation for this discrepancy – 
Accelerated Long-term Forgetting (ALF). This is the idea of an impairment – 
possibly a consolidation problem – causing people to forget information 
significantly more over an extended period of time, when their memory over short 
intervals (as measured in neuropsychological tests) is intact. Studies that have 
Figure 1.1: Relationship of epilepsy factors and cognition (Aldenkamp, 2006) 
    3 
examined memory performance over extended delays will be reviewed, along with 
potential theories behind ALF.  
 
ALF has been demonstrated in people who have had epilepsy for a number of 
years, but it has not been investigated in newly diagnosed patients. Cognitive 
functioning more generally in newly diagnosed patients with epilepsy has been 
examined in a number of studies, and these will be reviewed and discussed in 
Chapter 7. A number of problems have been identified but, similar to most 
neuropsychological studies in epilepsy patients, there are many confounding factors 
and potential methodological flaws that can affect the interpretation of the results, 
which will be discussed in this chapter. 
 
The aim of this thesis is to examine memory functioning, both subjective and 
objective, in patients recently diagnosed with localisation related epilepsy. Memory 
functioning will be examined over an extended period, to investigate long term 
forgetting rates, as it is felt that this will provide an interesting insight into 
mechanisms of memory problems in epilepsy patients and also assess the clinical 
need for extended delay memory testing. The aims and hypotheses of the study will 
be outlined in more detail in Chapter 8, and the research methods employed to 
achieve those aims outlined in Chapter 9. A series of analyses of the results of the 
study will be undertaken, to assess the findings regarding each hypothesis, which 
will be reported in Chapter 10. Chapter 11 will discuss these results, and how they 
help to contribute to our understanding of memory functioning in recently 
diagnosed epilepsy, as well as examining the limitations of the research and 
considering clinical implications and potential future research directions. 
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Chapter 2   Epilepsy 
 
 
2.1 Definition 
 
Epilepsy is a family of chronic neurological disorders characterised by recurrent, 
unprovoked seizures. A seizure can be defined as „a transient occurrence of signs 
and/or symptoms due to abnormal excessive or synchronous neuronal activity in 
the brain‟ (Fisher et al., 2005).  
 
The word „epilepsy‟ comes from a Greek word meaning „to be seized by forces from 
without‟ (Browne & Holmes, 2004). It was initially recognised by Hippocrates as an 
organic process of the brain. However, many ancient writers considered seizures to 
be caused by supernatural forces, a view that still persists in some developing 
countries (for example, in Kenya there is a poor understanding of the condition, and 
five people were recently burned alive for being labelled witches as they were 
accused of casting a spell on a boy who had an epileptic seizure (Joseph, 2009)).  
 
John Hughlings Jackson, a pioneer of epileptology, made unparalleled contributions 
to furthering the understanding of epilepsy in the late 19th century, defining 
epilepsy as „occasional, sudden, excessive, rapid and local discharges of the grey 
matter‟ (Sengoku, 2002). By studying individual clinical cases he endeavoured to 
find the mode of onset and pattern of seizures, leading to the concept of focal 
epilepsies. 
 
We now understand epilepsy as a complex symptom which can be caused by a 
variety of pathological processes in the brain. Clinicians might define it as „the 
recurrent paroxysmal transient disturbance of brain function due to disturbance of 
electrical activity in the brain, where the disturbance is unrelated to infection or 
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acute cerebral insult‟ which can manifest through clinical seizures (GPnotebook). 
On the other hand, a person with epilepsy may look at the disorder in a very 
different way, defining it according to their experiences of attacks and the impact 
the disorder has on their life, their self-image, and their psychosocial wellbeing 
(Browne & Holmes, 2004). Epilepsy can be for some people (but not all) a very 
disruptive problem, affecting all areas of a person‟s life, and limiting their 
independence and quality of life. 
 
Epilepsy is a common neurological disorder, with around 50 million people 
worldwide living with epilepsy (WHO, 2009). In the UK, active epilepsy has a 
lifetime prevalence of around 400 per 100,000 people (Sander, 2003). However, we 
all have around a 10% lifetime risk of having a seizure, and around 3% risk of 
developing epilepsy (Pohlmann-Eden et al., 2006). The onset of epilepsy is most 
common in young children and older adults (see figure 2.1). 
 
Figure 2.1: Prevalence, cumulative incidence and incidence rates of epilepsy (Hauser & 
Annegers, 1993) 
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2.2 Classification 
 
Two systems of classification can be used for epilepsy: classification of the seizures 
themselves and classifications of the epilepsy type or syndrome. Classification of 
seizures allows them to be viewed as single independent events based on clinical 
and electroencephalographic information. The International League Against 
Epilepsy (ILAE) has standardised what was once a minefield of terminology (see 
table 2.1) (Bancaud et al., 1981). Seizures are initially classified into one of two broad 
groups, partial seizures (seizures that can be localised to a particular area of the 
brain) and generalised seizures (seizures that are bilaterally symmetrical and cannot 
be localised to a particular area or hemisphere of the brain), and further classified 
according to other features such as impairment of consciousness and type of clinical 
manifestation (Browne & Holmes, 2008). 
 
Partial  seizures beginning in one area of the brain can be simple (no impairment of 
consciousness) or complex (with impairment of consciousness or altered awareness, 
often complicated by automatisms like lip-licking or fiddling) and can progress to 
become secondary generalised. This is when a simple or complex partial seizure 
progresses to a generalised tonic-clonic seizure (rhythmic jerky contraction and 
relaxation of muscles alongside autonomic features such as increased heart rate, 
blood pressure and flushing, followed by relaxation, drowsiness or confusional 
state). Generalised seizures can be absence (sudden short-lasting impaired 
responsiveness), myoclonic (sudden brief muscle contractions), tonic (sudden 
increased tone), atonic (sudden loss of muscle tone) or tonic-clonic (Browne & 
Holmes, 2008). 
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Table 2.1: International Classification of Epileptic Seizures (Bancaud et al., 1981)- 
reproduced with permission 
I. Partial seizures  
 
A. Simple partial 
seizures 
1. With motor signs a) Focal motor without 
march 
b) Focal motor with 
march (Jacksonian) 
c) Versive 
d) Postural  
e) Phonatory 
 
2. With somatosensory or 
special-sensory 
symptoms 
a)  Somatosensory 
b)  Visual  
c)  Auditory  
d) Olfactory 
e) Gustatory  
f) Vertiginous 
 
3. With autonomic 
symptoms or signs  
 
 
4. With psychic symptoms a)  Dysphasia  
b)  Dysmnesic  
c)   Cognitive 
d)  Affective  
e) Illusions  
f) Structured 
hallucinations 
 
B. Complex partial 
seizures 
1. Simple partial seizures at 
onset, followed by 
impairment of 
consciousness 
a)   With simple partial 
features  
b)   With automatisms 
 
2. With impairment of 
consciousness at onset  
 
a) With impairment of 
consciousness only  
 
b)  With automatisms 
 
C. Partial seizures 
evolving to 
secondarily 
generalized 
seizures  
1. Simple partial seizures 
evolving to generalized 
seizures  
 
 
2. Complex partial seizures 
evolving to generalized 
seizures  
 
3. Simple partial seizures 
evolving to complex 
partial seizures evolving 
to generalized seizures 
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II. Generalized 
seizures  
 
A. Absence seizures  1. Typical absence seizures  a)   Impairment of 
consciousness only  
b) With mild clonic 
components  
c) With atonic 
components 
d) With tonic 
components  
e) With automatisms  
f) With autonomic 
components 
 
2.  Atypical absence 
seizures 
 
 
 B.   Myoclonic 
seizures  
  
 C.   Clonic seizures    
 D.  Tonic seizures    
 E.   Tonic-clonic 
seizures  
  
 F.   Atonic seizures   
III. Unclassified 
epileptic seizures 
   
 
 
With regard to classifying type of epilepsy, it can be categorised as „localisation 
related‟, when the seizures can be localised to one area of the brain (ie partial 
seizures) or „generalised‟, when there are primary generalised seizures (ILAE, 1989). 
Epilepsy can also be classified by the cause as far as it is known (idiopathic, 
cryptogenic or symptomatic) and type of epilepsy, or epilepsy syndrome. If a cause, 
such as a brain tumour or arterio-venous malformation, is found then epilepsy is 
said to be „symptomatic‟, whereas epilepsy is „cryptogenic‟ if there is likely to be a 
cause but it cannot be identified. „Idiopathic‟ epilepsy is thought to be caused by 
genetic factors, and is associated with no structural brain abnormality (ILAE, 1989). 
For example, „symptomatic localisation-related epilepsy‟ would involve seizures 
arising from a known localised structural abnormality, with or without spread to 
the rest of the brain. 
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This allows common patterns of seizure types to be categorised further according to 
other factors like aetiology, age of onset, classic EEG findings etc, as epileptic 
syndromes such as childhood absence epilepsy, juvenile myoclonic epilepsy and 
Lennox-Gastaut syndrome. Whilst many patients will not fit into the classification 
of an epilepsy syndrome, if they do it can be a useful tool for assessing management 
and prognosis, as effective medication and the progression of the disorder can to an 
extent be predicted by the syndrome. 
 
2.3 How do seizures happen? 
 
There are numerous causes of epilepsy, but the primary disorder is due to abnormal 
neuronal discharges. Focal seizures are caused by abnormal neuron discharge and 
seizure activity in specific areas of the brain. The basic mechanism of neuronal 
excitability is the action potential, transmitted down the axon of a neuron to 
stimulate neurotransmitter release at the synapse (Browne & Holmes, 2008). 
Seizures occur due to a combination of high-frequency bursts of action potentials, 
associated with a spike on EEG (electroencephalogram), and hypersynchronisation 
of a population of neurons, and recruitment of adjacent neurons, to create 
abnormally linked discharges from a large number of cells together. The abnormal 
neuronal activity which leads to this „electrical storm‟ can come about due to either 
abnormal neuronal membranes or an imbalance in inhibitory and excitatory 
influences (Browne & Holmes, 2008). Anti-epileptic drugs tend to work by affecting 
one of these processes, either modulating ion channels in the membrane, or 
affecting the activity of inhibitory or excitatory neurotransmitters (Browne & 
Holmes, 2008). 
 
2.4 What causes epilepsy? 
 
The potential to have an epileptic seizure is present throughout the population. 
In as many as 60% of people with epilepsy no identifiable aetiology is found 
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(Sander & Hart, 1990). However, epilepsy can be due to an underlying brain 
disorder and these causes can be split into a number of areas. Congenital 
malformations, or damage to a baby‟s brain during pregnancy, at delivery or 
shortly after can cause epilepsy by scar formation. Head injuries, central 
nervous system infections, cerebrovascular disease and tumours are all potential 
causes of epilepsy (see figure 2.2 for relative risks of various predisposing 
factors).  
 
Figure 2.2: Factors associated with an increased risk of epilepsy relative to people without 
those adverse exposures. Produced using data from (Hauser & Annegers, 1993) 
 ** Not statistically significant. ***One pint of 80% proof alcohol, 2.5 bottles of wine/day.  
 
Certain drugs, toxins, or metabolic disturbances can also provoke seizures, or 
lower the seizure threshold, although this is not the same as causing epilepsy. 
One of the most common causes of provoked seizures is alcohol use or 
withdrawal, but withdrawal or use of other toxins can also cause seizures, 
including heavy metals or organophosphates (Allen et al., 2006). Some drugs 
such as antipsychotics or antidepressants can also lower a person‟s seizure 
threshold, making it more likely they will have a seizure if there is a 
precipitating factor. Metabolic disturbances that can cause seizures include 
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hypoglycaemia, hyponatraemia, hypomagnesaemia, hypocalcaemia, renal 
failure and liver failure (Allen et al., 2006). 
 
2.5 Diagnosis 
 
Making a correct diagnosis of epilepsy is very important, as an erroneous diagnosis 
could result in not only needless distress but also unnecessary medication with 
serious side effects, potential loss of a driving licence and possible loss of a job 
(Browne & Holmes, 2008). It is also important to try and find a cause for the 
epilepsy, otherwise disease processes underlying seizures that are potentially 
treatable could be overlooked. A diagnosis of epilepsy type, and, where possible, 
syndrome, can also be helpful in directing treatment. 
 
A diagnosis of epilepsy is largely clinical, based on a thorough history of seizures 
given by an eye-witness. There are some important differential diagnoses that 
should be ruled out depending on the presentation, including syncope, migraine, 
non-epileptic attacks and cardiac arrhythmias (Browne & Holmes, 2008). 
Investigations can be undertaken to rule out other causes of seizures, such as 
biochemical tests for electrolyte or glucose abnormalities, and a 12 lead ECG 
(electrocardiogram) looking for arrhythmias. An EEG, which provides a graphical 
representation of electrical activity in the cortex, can be useful in identifying some 
syndromes (such as idiopathic generalised epilepsy) but an interictal EEG is 
unlikely to capture all seizure activity so is often inconclusive. If further clarification 
is needed for diagnosis or seizure type, EEG recording can be taken during sleep, 
over longer periods, alongside video recording, or in conditions likely to initiate 
seizures (such as sleep deprivation) (Browne & Holmes, 2008). Imaging such as MRI 
(Magnetic Resonance Imaging) or CT (Computed Tomography) can also be used to 
look for any possible underlying cause of seizures by identifying structural 
abnormalities (Browne & Holmes, 2008). 
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2.6 Management 
 
The management of epilepsy is based not only around eliminating or reducing 
seizures as far as possible, but also ameliorating or minimising the psychological 
and social problems the disease and its stigma can cause (Browne & Holmes, 2008). 
This includes issues such as loss of driving licence, self esteem issues, and common 
comorbidities like anxiety and depression. 
 
Treatment of seizures themselves is usually pharmacological. The medications used 
will be guided by the seizure type and considerations regarding side effects, with 
monotherapy (single-drug therapy) whenever possible. Monotherapy with an 
appropriate drug is able to achieve seizure control in 60-90% of patients, without 
the added risks they are exposed to from multiple drugs (Browne & Holmes, 2008). 
However, if monotherapy is ineffective at the maximum dose, additional therapy 
can be added, following the principle of adding drugs with different mechanisms of 
action, or „rational polytherapy‟ (Lee & Dworetzky, 2010). Antiepileptic drugs of 
choice for different seizure types are shown in table 2.2. They have various 
mechanisms of action, including inactivating sodium channels, attaching to GABA 
receptors to inhibit depolarisation, reducing calcium currents into cells and 
antagonising the excitatory neurotransmitter glutamate. These all have the effect of 
preventing excessive excitability, which can prevent seizures but also may have 
other unwanted effects, such as drowsiness. 
 
Anticonvulsants also have other negative effects including, depending on the drug: 
allergic rashes, weight gain, irritability and importantly teratogenicity, among 
others. Certain anti-epileptic medications can be very detrimental to a foetus when 
taken during pregnancy, causing physical malformations or cognitive and 
behavioural difficulties (Morrow et al., 2006; Bromley et al., 2009). This means that 
the choice of medication in women prior to and of child-bearing age is a particularly 
important and difficult decision, requiring thorough discussion of potential risks 
and benefits with the patient (Winterbottom et al., 2009). 
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The recent SANAD trial was a large multicentre randomised controlled trial 
assessing a number of the standard and newer anti-epileptic medications. The arm 
studying patients with generalised seizures found sodium valproate to be the most 
effective drug, it being more efficacious than lamotrigine and better tolerated and 
more efficacious than topiramate, although the potential difficulties using valproate 
in women of childbearing age were noted (Marson et al., 2007b). The arm studying 
patients with partial epilepsies showed lamotrigine to be the drug of choice, as it 
was as effective as carbamazepine and better tolerated, as well as being better 
tolerated than topiramate, gabapentin and oxcarbazepine (Marson et al., 2007a). 
 
Table 2.2: Antiepileptic drugs of choice, using information from (BNF, 2010)  
Seizure type 1st line medication 2nd line medication 
Partial seizures with or without 
secondary generalisation 
Carbamazepine 
Lamotrigine  
Oxcarbazepine 
Sodium Valproate 
Clobazam 
Gabapentin 
Levetiracetam 
Pregabalin 
Tiagabine 
Topiramate 
Zonisamide 
Generalised 
seizures 
Generalised tonic 
clonic 
Carbamazepine 
Lamotrigine  
Sodium Valproate 
 
Clobazam 
Levetiracetam 
Oxcarbazepine 
Topiramate 
Absence Ethosuximide 
Sodium Valproate 
Clonazepam 
Lamotrigine 
Myoclonic Sodium Valproate Clonazepam 
Lamotrigine 
Levetiracetam 
Topiramate 
Atypical absence, 
atonic and tonic 
Sodium Valproate 
Lamotrigine 
Clonazepam 
Clobazam 
Ethosuximide 
Levetiracetam 
Topiramate 
 
 
If epilepsy is not adequately controlled by medication, there are potentially other 
options, depending on the epilepsy type. Surgery can be considered in patients with 
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medically intractable partial epilepsy who have a localised seizure focus on MRI or 
EEG, if their seizures are significantly affecting their quality of life. Removing the 
area of cortex where seizures are initiating, so long as it can be well identified 
(through EEG, clinical history, neurological examination, neuropsychological 
assessment and both anatomical and functional neuroimaging) and safely resected, 
offers a potential opportunity for seizure freedom (Browne & Holmes, 2008). 
However, it is not always successful and can also leave patients with significant 
deficits, for example memory problems when surgery is undertaken for temporal 
lobe epilepsy. 
 
Vagus nerve stimulation (VNS) and ketogenic diets are potential treatment options 
in certain types of epilepsy (Browne & Holmes, 2008). VNS involves implantation of 
a programmable stimulator subcutaneously in the chest, which stimulates the vagus 
nerve when activated. Reports of outcomes are mixed but mildly positive (Fisher & 
Handforth, 1999; DeGiorgio et al., 2000; Ben-Menachem, 2002), but it is often used as 
a final resort when nothing else has worked. A ketogenic diet, involving eating a 
high proportion of fats to a small amount of carbohydrate and proteins, leads to the 
brain shifting to ketones as a major energy source rather than glucose, causing 
increased cerebral energy reserves and GABA shunt activation (Browne & Holmes, 
2008). This can bring about seizure control in certain types of epilepsy without the 
side effects of medication or surgery (Cross & Neal, 2008). New treatment options 
are also being investigated for their effectiveness in epilepsy, including deep brain 
stimulation, which is successful in movement disorder treatment (Schulze-Bonhage, 
2009). 
 
2.7 Temporal lobe epilepsy 
 
This project will focus on temporal lobe epilepsy (TLE) as this is the population in 
which the majority of research on long term forgetting has been done (Martin et al., 
1991; Giovagnoli et al., 1995; Bell et al., 2005; Bell, 2006; Mameniskiene et al., 2006; 
Wilkinson et al., under review), and it will therefore be considered in a little more 
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detail. TLE was first recognised by John Hughlings Jackson in 1881 as a „dreamy 
state‟ arising from the temporal lobe, and is now recognised as recurrent 
unprovoked seizures arising from the medial or lateral temporal lobe. It is probably 
the most common form of focal epilepsy, but the true prevalence of TLE is 
unknown (Ko & Sahai-Srivastava, 2009). 
 
The temporal lobe is separated from the frontal and parietal lobes by the Sylvian, or 
lateral fissure (see figure 2.3). Portions of the temporal lobe are involved in episodic 
and semantic memories, emotions, and smell, which can help explain why some 
temporal lobe seizures can include memory phenomena like déjà vu and jamais vu, 
olfactory hallucinations and sensations of panic (Zeman, 2005). In the superior part 
of the temporal lobe, around the lateral fissure, is the auditory cortex. This can 
explain why in some temporal lobe seizures patients can experience auditory 
hallucinations, dysphasia or speech arrest (Zeman, 2005). 
 
Figure 2.3: Lobes of the cerebrum (EpilepsyFoundation, 2010) 
  
 
 
As for the causes of TLE, there is a link between the development of temporal lobe 
epilepsy and complex febrile seizures (febrile seizures lasting over 15 minutes, with 
focal features or recur within 24 hours). However, it is debatable whether it is the 
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febrile seizures that lead to epilepsy or rather they are just the first sign of the 
condition (see discussion in Chapter 4). The pathological change occurring most 
commonly in TLE is hippocampal sclerosis (HS), present in as many as 70% of 
patients treated surgically (Najm et al., 2006). Similar to with febrile seizures, there 
is some debate as to whether the HS causes the epilepsy or is a result of it (Cendes, 
2005). Other potential causative factors include: infections (herpes encephalitis, 
bacterial meningitis), trauma resulting in cortical scarring (eg forceps delivery), 
hamartomas, malignancies, vascular malformations, or rarely familial causes, but 
most commonly the epilepsy is cryptogenic (Ko & Sahai-Srivastava, 2009). 
 
TLE can occur in any age group. Clinically, it can present with a variety of features 
dependent on the function of the area affected. Around 80% of patients will have 
some form of simple partial seizure, or aura, first – this can be somatosensory, 
sensory, autonomic or psychic (Ko & Sahai-Srivastava, 2009). Somatosensory or 
sensory auras would be things like gustatory or olfactory hallucinations, auditory 
hallucinations, disorders of perception like distortion of shape or size. Autonomic 
phenomena include changes in heart rate, sweating, and nausea, or an epigastric 
rising sensation. Psychic phenomena include feelings of déjà vu, jamais vu, 
derealisation, detachment, feeling familiarity or unfamiliarity, or even feelings of 
impending doom. These auras are simple partial seizures, and they may or may not 
progress to a complex partial seizure or on to a secondary generalised tonic-clonic 
seizure (Ko & Sahai-Srivastava, 2009). 
 
Complex partial seizures involve impairment of consciousness, so the patient may 
stare motionlessly, be unresponsive, and demonstrate certain typical automatisms 
such as lip-smacking, chewing or making repetitive hand movements. Following a 
complex partial seizure, there will be a period of post-ictal confusion, often longer 
than the seizure itself. This post-ictal phase can help to distinguish complex partial 
seizures from absence seizures (Browne & Holmes, 2008). A complex partial seizure 
may also progress to a secondary generalised tonic-clonic seizure. In this case, it is 
likely that the generalised seizure may be all that is reported if a very careful history 
is not taken. 
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The initial management of TLE is similar to other epilepsies, and begins with 
antiepileptic medication (if the seizures warrant treatment). Carbamazepine or 
lamotrigine are generally used first line, and many of the newer anti-epileptic drugs 
are also licensed for use as second line agents. 
 
If seizures are refractory, as is more likely if there is HS (Semah et al., 1998), TLE can 
be responsive to surgical resection of the epileptogenic region. Extensive pre-
operative testing is required, by MRI, video EEG and telemetry, neuropsychological 
testing and, where required, a Wada test to assess the functionality of the tissue to 
be removed (Browne & Holmes, 2008). 
 
Apart from the direct effects of seizures, there are other ways that epilepsy impacts 
on a patient‟s life, for example via stigmatisation, poorer quality of life, driving and 
job issues, and cognitive complaints. One of the most commonly reported cognitive 
problems in epilepsy, particularly TLE, is with memory. In the next chapter, I will 
consider memory as a concept and discuss types and theories of memory. 
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Chapter 3   Memory 
 
 
In this chapter memory will be considered as a concept, with a discussion of 
different types of memory as well as a brief overview of some of the theories of 
memory formation. 
 
Memory is one of the highly interdependent features of cognition, alongside 
features including consciousness, orientation, attention, executive function, 
language, praxis, calculation and perception (Zeman, 2009). It is the capacity that 
allows our behaviour to change in relation to what has happened in the past using 
neural plasticity, and it has a relationship to learning (Zeman, 2009).  
 
Learning is the process by which new information is acquired, whereas memory is 
the persistence of learning in a state that can be revealed at a later time (Squire, 
1987). Thus, memory is the outcome of learning, and memories are only created 
when learning happens (Gazzaniga et al., 2009). As memory cannot exist without 
learning and learning relies on memory, they are often thought of and tested 
together. 
 
Learning and memory can be divided into stages, as a series of processes that come 
together to form a memory (see figure 3.1). In order to successfully utilise learning, 
each stage of the process must be intact. 
 
Figure 3.1: The stages of remembering (from information given by Zeman (Zeman, 2009)) 
 
 
 
Perception 
 
Encoding Consolidation Storage Retrieval 
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3.1 Models of Memory 
 
Memory can be classified in various ways, according to different aspects of the 
material remembered and the processes involved. Memory is by its nature 
something that persists over time, so memories can be classified according to how 
long they are remembered for.  
 
There are two broad categories of memory: declarative and procedural (see figure 
3.2). Declarative (or explicit) memory is memory for facts or knowledge that we 
have conscious access to, whereas procedural (or motor) memory is unconscious 
memory for learned tasks or skills, or „knowing how‟ memory (Cohen & Squire, 
1980; Longstaff, 2005). Within declarative memory, there is a temporal component, 
so declarative memory can be split up according to how long something is 
remembered for, into sensory memory, short-term memory and long-term memory. 
It can also be split according to the information remembered into episodic memory, 
or memory for specific events associated with a particular time and place, and 
semantic memory, memory of facts unrelated to specific events (Tulving, 1972). The 
focus of this introduction will be declarative memory, as this is the main focus 
within the current study. Whilst it is beyond the scope of this study, readers are 
directed to (Gazzaniga et al., 2009) for a more detailed outline of further types of 
memory. Firstly, temporal classifications of memory and how they interact will be 
considered.  
 
Sensory memory is over milliseconds or seconds, and does not require specific 
paying of attention.  The auditory „echo‟ that persists for a few seconds can be 
retrieved, even if attention is not paid, and is known as the sensory memory trace or 
sensory register. For audition, it is echoic memory whereas for vision it would be 
iconic memory (Gazzaniga et al., 2009). These sensory traces are thought to decay 
very quickly, and are considered not accessible to conscious awareness, but can 
hold more information than can be converted into short term memory and reported 
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on (Sperling, 1960; Gazzaniga et al., 2009). Iconic memory is visual information 
present for only a few hundred milliseconds which then rapidly decays, whereas 
the echoic trace for auditory information is thought to last up to 10 seconds (Sams et 
al., 1993; Gazzaniga et al., 2009). 
Figure 3.2: Tree of memory 
 
Short term memory is, in contrast to sensory memory, freely available to our 
conscious awareness, however it has a much more limited capacity. It is only a 
temporary store, viable for seconds to minutes, and material requires repeated 
rehearsal to keep it there. Material in short term memory is thought to be lost by 
decay of information (hence the need for repeated rehearsal) or by disruption from 
other input, or a combination of both (Gazzaniga et al., 2009). Primacy and recency 
effects are demonstrated in normal subjects when testing short term memory, for 
example by repeating back a list of unrelated words (Glanzer & Cunitz, 1966). 
Primacy is greater recall of material at the start of the list, because these have been 
rehearsed most and been transferred to long term memory, whereas recency is 
greater recall of material at the end of the list, because this has had less time to 
decay so is still in short term memory. This is known as the serial position effect (see 
Memory 
Declarative Procedural 
Short term 
memory 
Long term memory 
Working 
memory 
Sensory  Episodic 
memory 
Semantic 
memory 
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figure 3.3) (Glanzer & Cunitz, 1966). Primacy is affected by the speed of 
presentation, and is eliminated if the material is presented too quickly, whereas 
recency is eliminated by distraction tasks after the presentation (Gazzaniga et al., 
2009).  
 
 
 
Figure 3.3: Serial Position Effect (Glanzer & Cunitz, 1966)- reproduced with permission 
  
 
N.B. Spacing refers to the length of time between presentation of the words in the word list 
 
There are several models of short term memory. The Atkinson and Shiffrin modal 
model (Atkinson & Shiffrin, 1968) suggests sensory information first enters a 
sensory register, or sensory memory, and then attentional processes move certain 
items into the short term memory. Items then move into the long term memory by 
repeated rehearsal, and at each stage information can be lost by interference, decay 
or a combination of the two. By this hierarchical model, items are passed from 
sensory memory to short term memory, and only then to long term memory, but 
this view is disputed by other experimental evidence, particularly studies of 
patients with brain damage which have been useful in examining how memory 
functions. Case studies of patients with very limited short term memory but almost 
intact abilities to form long term memories suggest that short term memory cannot 
be the only gateway to long term memory (Shallice & Warrington, 1970; 
Markowitsch et al., 1999). A possible alternative view is that short-term memory is 
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based on the same neural networks as long term memory, but they are not activated 
in quite the same way (Zola-Morgan & Squire, 1993; Ranganath & Blumenfeld, 
2005). 
 
Another proposed model is the levels of processing model (Craik & Lockhart, 1972). 
This model proposes that there are other factors influencing what information is 
passed to long term storage, including that the „deeper‟ an item is processed, the 
better it is stored in long term memory. This suggests elaborate encoding and 
relating information to previously acquired knowledge provides better learning 
than storing information as simple visual or verbal codes. 
 
The working memory model (Baddeley & Hitch, 1974) is a widely accepted model 
proposed to explain some of the shortcomings of short-term memory models. 
Working memory is seen as a limited capacity store for both retaining information 
in the short term, and also processing that information during complicated tasks. It 
can involve information straight from the sensory input and information retrieved 
from the long term memory put together to enable processing complex tasks, such 
as driving (Longstaff, 2005). A multi-component model of working memory has 
been proposed (Baddeley & Hitch, 1974) and since updated (Baddeley, 2000; Repovs 
& Baddeley, 2006) to explain the shortcomings of the unitary model proposed by 
Atkinson and Shiffrin in 1968, initially comprising of a central executive assisted by 
two storage systems: the phonological loop and the visuospatial sketchpad. This has 
since been updated and a fourth component introduced to the model: an episodic 
buffer (Baddeley, 2000; Repovs & Baddeley, 2006). This provides a model of 
working memory as a limited capacity store providing an interface between 
perception, long term memory and action.  
 
The phonological loop subsection of this working memory model is a short lived 
store for information presented acoustically, and coding mechanism for that 
information by repeated rehearsal sub-vocally. Subjects with problems in short term 
phonological memory tend to have lesions in the left temporo-parietal area 
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(Warrington et al., 1971; Vallar et al., 1997), suggesting this may be the anatomical 
base for the phonological loop, an idea backed up by functional neuroimaging 
studies suggesting the phonological loop is based in the left pre-frontal and parietal 
regions (Cabeza & Nyberg, 2000).  
 
The visuospatial sketchpad is an equivalent store and processing mechanism for 
visual information. It provides a capacity to hold and manipulate visuospatial 
information, and it is thought that it might be possible to separate the visuospatial 
sketchpad into visual and spatial memory components (Repovs & Baddeley, 2006). 
Lesions particularly in the right hemisphere can lead to deficits in visuospatial 
working memory (Hanley et al., 1991), and in functional neuroimaging studies, 
bilateral parietal activation is generally associated with spatial working memory 
(Smith et al., 1996; Cabeza & Nyberg, 2000).  
 
The central executive mechanism acts as a control system, overseeing the two 
subsystems and managing and directing attentional processes (Repovs & Baddeley, 
2006). This is the least researched component of the original working memory 
model, as well as the least understood (Repovs & Baddeley, 2006). Executive 
functioning has been linked to the frontal lobes in neuroimaging studies (Smith & 
Jonides, 1997).  
 
The idea of an episodic buffer has been added to the working memory model to 
explain some of the unexplained issues from the previous model. For example, it 
accounts for the advantage in recall for semantically linked words, provides an 
explanation for the links between working and long term memory, and explains 
how the two slave-systems (phonological loop and visuo-spatial sketchpad) interact 
and information from them binds together (Repovs & Baddeley, 2006). It is 
proposed to integrate information from both the working memory systems and 
long term memory, and represents a separate storage system using a multi-modal 
code (Repovs & Baddeley, 2006). 
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3.2 Long term memory and consolidation 
 
Long term memory is information maintained over a significant period of time. This 
period of time is debatable but generally thought to be of the order of minutes to 
hours rather than seconds. Alternatively, material in long term memory can be 
considered as the material that can be recollected following distraction (Squire, 
1986). It can be split according to the types of information stored into episodic 
memory (personal recollection of events in our lives) and semantic memory 
(knowledge of facts and concepts that are learnt, rather than experienced) (Tulving, 
1972). 
 
Memory is not fixed from the point of learning but over time continues to stabilise 
(Squire, 1986). The idea of consolidation has been around for over a century, since it 
was first proposed by Muller and Pilzecker ((Müller & Pilzecker, 1900) cited in 
(McGaugh, 2000)). Finding that newly learned information was disrupted by 
learning other information shortly after, they proposed that the processes that 
underlie the formation of new memories are fragile and consolidate over time. This 
hypothesis was supported by Duncan‟s research in 1949 that showed rats given an 
electric shock to the head shortly after learning a maze had much poorer memory 
for the maze than those who had no electric shock. Rats having shocks at longer 
delays had progressively better memory for the maze, with rats with a shock 1 hour 
or more after learning had equal memory to controls. This demonstrated that there 
may be a period after learning where the material learnt is susceptible to disruption, 
for example by electro-convulsive shock, but the material becomes more stable over 
time (Duncan, 1949). 
 
Declarative memory relies on the hippocampus and medial temporal lobe 
structures for the encoding and short term retrieval of memories (Squire, 1992), but 
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over time retrieval is thought to become independent of the hippocampus (Kapur & 
Brooks, 1999). However, when and which memories become independent of the 
hippocampus is an issue of debate, as will be discussed.  
 
The standard model of consolidation suggests that the hippocampus has a time-
limited role, being vital for early storage and retrieval followed by a gradual 
reorganisation process whereby information is transferred to neocortical networks 
(Sutherland & McNaughton, 2000). A short-term consolidation process, lasting 
seconds to minutes, binds information into a memory trace, followed by a long-
term consolidation process to stabilise it (Nadel & Moscovitch, 1997). The exact 
mechanism by which this happens is unclear, but Squire suggests that an important 
concept is that „information in the medial temporal lobe directs consolidation by 
gradually changing the organisation of cortical representations, for example, 
strengthening connections between the cortical sites that participate in representing 
a memory‟ (Squire & Alvarez, 1995). Hippocampal synapses can change quickly, so 
the hippocampus acts as a short term temporary memory store, while neocortical 
synapses change slowly. If the hippocampal system repeatedly reactivates 
representations in the neocortex, strong interconnections between cortical sites 
form, able to support the memory independent of the hippocampus (Squire & 
Alvarez, 1995). According to this model, with a purely hippocampal lesion there 
would be temporally-limited retrograde amnesia, whereas more extensive damage 
to the temporal neocortex would result in more extensive retrograde amnesia 
(Squire & Alvarez, 1995). For example, a patient with hippocampal damage might 
have amnesia for a period of time before the damage, while the memories were still 
being consolidated, but have intact memory for events longer ago which had 
already been fully established in the neocortex independent of the hippocampus.  
 
The Multiple Memory Trace theory (MMT) is another suggestion, which involves 
the hippocampus having a lifetime role in the retrieval of episodic autobiographic 
memories (Nadel & Moscovitch, 1997; Nadel et al., 2000). This is that the 
hippocampus is always involved in retrieval and storage of episodic memories but 
semantic information is established in neocortex so can survive hippocampal 
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damage (Nadel et al., 2000). As memory is created, a code in the hippocampus binds 
information stored in other brain regions to create a memory of a specific episode or 
scene, so interaction between the hippocampus and the other brain regions 
involved is required indefinitely. However, semantic memories are thought to be 
dependent on the hippocampus while they are consolidated and can later become 
independent (Nadel et al., 2000), demonstrating a crucial distinction between 
episodic and semantic memories. 
 
The cellular mechanism by which consolidation occurs is thought to be LTP (long 
term potentiation) (Squire & Alvarez, 1995). This is a form of synaptic plasticity, 
which involves the persistent enhancement of signal transmission between two 
neurons by their repeated synchronous stimulation (Cooke & Bliss, 2006). This 
follows the principles of Hebb‟s Law, that „if a synapse is active when a post-
synaptic neuron is active, the synapse will be strengthened‟ (Hebb, 1949; Gazzaniga 
et al., 2009). Long term potentiation is thought to be a good model for memory 
because of its longevity, both processes require protein synthesis, and potentiation 
is input specific, so a single pathway can be potentiated without impacting other 
connections to that neuron, increasing the information coding capacity of the brain. 
Also, association means that a weak stimulus can combine with a strong stimulus, 
or other weak stimuli, to become potentiated, providing a mechanism for 
associating events or entities in our learning (Cooke & Bliss, 2006). 
 
Consolidation does not merely provide a strengthening of memory traces, but also 
the opportunity for the integration of new memories with existing knowledge 
networks, so that they are accessible for delayed retrieval (Diekelmann et al., 2009). 
It also appears to provide an opportunity for experience and emotion to modulate 
the strength of our memories, for example by the interaction of stress hormones like 
adrenaline and cortisol released in states of arousal (Gold & Van Buskirk, 1975; 
Sandi & Rose, 1994; Conrad et al., 1997; McGaugh, 2000).  
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Sleep is thought to be important in the process of consolidation, and it has been 
clearly demonstrated that sleep after learning improves declarative memory 
performance, even when the confounding effects of circadian rhythms and fatigue 
at recall testing were removed (Gais et al., 2006; Drosopoulos et al., 2007), by 
stabilising memory traces and providing increased resistance to interference during 
consolidation (Ellenbogen et al., 2006). However, there are also suggestions that 
sleep‟s role in consolidation might be more active, for instance by restructuring 
brain activity (Orban et al., 2006) and through hormonal changes during sleep (Born 
& Wagner, 2009). 
 
Another aspect of long term declarative memory is recognition memory, the ability 
to recognise something that has previously been encountered. This is a matching 
process, comparing the content of the environment with the content of a memory. 
Recognition is commonly split into two domains: recollection – remembering details 
about an experience, and familiarity – awareness that something has been 
encountered before but with no further knowledge about it (Eichenbaum et al., 
2007). Localising these separate processes to areas of the brain has been attempted, 
and it is thought that they rely on separate but interlinked structures. In functional 
neuroimaging studies (Yonelinas et al., 2005; Diana et al., 2007) it has been found 
that regions in the pre-frontal, parietal and medial temporal cortices interact to 
provide recognition memory. The hippocampus seems to be crucial for recollection 
but familiarity is more associated with the peri-rhinal cortex (Montaldi et al., 2006; 
Diana et al., 2007; Eichenbaum et al., 2007). Within the structures that support 
recognition there are some very specific areas that fulfil a very specific role, for 
example the „fusiform face area‟ in the fusiform gyrus of the inferior temporal lobe 
which is associated with face recognition, and damage to this area leads to 
prosopagnosia (failure to recognise faces)(Kanwisher, 2000). 
 
3.3 Assessing memory problems 
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When people have problems with their memories, it can present in a number of 
ways, depending on where in the process is affected and to what severity. Amnesia 
is the general term for the disruption of memory, from the Greek „amnesia‟ meaning 
forgetfulness. It can be typically described as retrograde or anterograde, depending 
on the clinical symptoms. Retrograde amnesia is the loss of memories prior to the 
event causing memory loss, whereas anterograde amnesia is the loss of ability to 
form new long term memories after the event (Gazzaniga et al., 2009) Affected 
individuals tend to suffer from one or the other or a mixed picture of symptoms 
(Russell & Nathan, 1946). Memory problems are a common complaint brought to 
health professionals, and there can be a wide range of causes from genetic 
disorders, to metabolic or neurological dysfunction, to psychological distress.  
 
The first step in assessing a person presenting with memory difficulties should 
always be a good clinical interview with personal (including developmental, 
educational, occupational and social history) along with a comprehensive medical 
history (Groth-Marnat, 2000). Assessment of memory includes questionnaires to 
assess subjective memory and neuropsychological assessment measures to assess 
objective memory performance (Brooks, 1999). These two types of memory 
assessment do not necessarily assess the same functions, as results have often been 
found to be weakly correlated, as will be discussed in Chapter 5. Goldstein and 
Polkey suggest that self-report questionnaires are more closely associated with 
behavioural measures of memory (Goldstein & Polkey, 1992).  
 
In the sphere of neuropsychological testing, there are a number of single tests and 
batteries for testing memory. The majority of tests available assess the learning and 
retention of new information (Cull & Goldstein, 1997). The Weschler Memory Scale 
(WMS) is one of the most commonly used instruments in adults and adolescents in 
the UK and USA (Weschler, 1997a). It is composed of ten subtests measuring 
different aspects of memory, providing scores for auditory immediate memory, 
visual immediate memory, auditory delayed, visual delayed, auditory recognition 
delayed, working memory and general memory (Weschler, 1997a). There are other 
measures to test aspects of memory, for example word list learning tests like the 
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Rey Auditory Verbal Learning Test (Schmidt, 1996) (assessing verbal immediate 
memory, learning, verbal delayed recall and verbal recognition) and visual memory 
measures like the Complex Figure test (Osterrieth, 1944) (assessing immediate and 
delayed visual recall)(Groth-Marnat, 2000).  
 
When assessing learning and memory, there can be many confounding effects. Age, 
intelligence and education all need to be considered in the interpretation of any 
memory scores. Most memory assessments, such as the WMS, have age-related 
norms so that age as a confounding factor is taken into account (Weschler, 1997a). 
The WMS-III is also co-normed with the Weschler Adult Intelligence Scale (WAIS) 
(Weschler, 1997b), so IQ-memory discrepancies can be interpreted as reliable or 
abnormal. Number of years in education can also influence the level of performance 
on learning and memory tasks, although it is not clear whether or not this is a factor 
separate to IQ (Rosselli & Ardila, 1991; Boone et al., 1993). Other things that need to 
be taken into consideration when considering interpretation of memory test results 
include anxiety, depression, current situation, stress and lack of sleep. For more 
detailed descriptions of memory tests, see Chapter 9. 
 
Memory can be a major problem for people with epilepsy. In the next chapter the 
relationships of memory problems with various causative factors in epilepsy will be 
studied in more depth. 
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Chapter 4 Objective memory problems in epilepsy and the factors 
involved 
 
 
4.1 Background 
 
Success in epilepsy treatment is generally considered to be good seizure control, for 
example in a large community-based study 41% of patients reported that seizure 
control was the most important aspect of their anti-epileptic medication (Fisher et 
al., 2000). The importance of seizure freedom is borne out by findings that in well-
controlled (unlike refractory) epilepsy patients‟ neuropsychological status and 
social functioning is similar to the general population (Aldenkamp, A. P. et al., 
2003), and seizure frequency has been found to correlate with health related quality 
of life scores (Baker et al., 1997). However, there are also many other aspects of 
having epilepsy that affect patients‟ lives, and it is increasingly seen that optimal 
management of epilepsy goes beyond controlling seizures (Sander, 2005). 
 
As well as lifestyle limitations including driving restrictions and employment 
difficulties, and social issues such as stigma and dependence on others, the 
cognitive effects of epilepsy are a major problem. Interictal memory problems in 
people with epilepsy have been observed for over 100 years (Gowers, 1881; 
Thompson, 1991). Interictal psychological functioning is crucial because this is the 
usual clinical state of the patient. Memory and cognitive problems have a significant 
impact on quality of life therefore they are an important issue (Giovagnoli & 
Avanzini, 2000). The effects of epilepsy on cognitive functioning have been much 
studied from a number of different approaches, from general intellectual abilities or 
global measures of cognitive function to specific tests of discrete neuropsychological 
functions such as memory assessment.  
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There are a number of factors involved in influencing cognitive outcome, with a 
variety of levels of evidence supporting them, including pathological abnormalities 
underlying the seizure disorder, seizure variables such as type and frequency, anti-
epileptic drug use and mood disturbance (see figure 4.1). Complex interactions 
between them make it difficult to determine their individual contributions to 
cognitive dysfunction. It is important to understand the causative factors behind 
cognitive problems in epilepsy, which involves both identifying risk factors and 
examining the progression of cognitive difficulties within patients. With a better 
understanding of the causes and progression of cognitive problems in epilepsy 
comes a better understanding of how to minimise or mitigate those impairments. 
For the purposes of this project, the relationships found in temporal lobe epilepsy 
will be particularly considered because that will be the population studied. 
 
Figure 4.1: Factors affecting cognitive functioning in people with epilepsy  
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4.2 Pathology of TLE 
 
Pathological abnormalities in TLE vary, from none in cryptogenic epilepsies to HS, 
gliomas, hamartomas, and vascular malformations in surgically treated patients 
(Wolf et al., 1993). HS is the commonest pathological finding in TLE, found in 
around 70% of cases of intractable TLE (Najm et al., 2006) and a key component of 
mesial TLE (Hermann et al., 1997). Histologically, classic HS is characterised by 
destruction of the pyramidal neurons of Ammon‟s horn, especially in the subfield 
„CA1‟, and also in „CA3‟ and „CA4‟, with relative sparing in subfield „CA2‟ (see 
figure 4.2). However, dual-pathology cases with other neocortical temporal lobe 
pathology as well as HS might show a more diffuse pattern of neuronal loss (Najm 
et al., 2006). Hippocampal abnormalities are typically unilateral, on the side of 
seizure onset, although can also be bilateral. Patients with right sided TLE may be 
more likely to have bilateral hippocampal atrophy (García-Fiñana et al., 2006). 
Around half of those with histological HS will also have dentate gyrus cell 
abnormalities, and the neuronal damage also often involves the parahippocampal 
gyrus, uncus and amygdala (Gloor, 1991).  
 
 
Figure 4.2: Hippocampal anatomy (Hesselink) 
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4.3 Do these pathological abnormalities correlate with cognitive functioning or 
memory? 
 
There are a number of pathological abnormalities that have been investigated in 
TLE and considered in relation to the neuropsychological functioning of the patient. 
These are the presence of specific lesions, the presence or extent of HS, or 
hippocampal volume as a continuous variable. 
 
4.3.1 Findings from pre-surgical patients 
 
Many studies assessing neuropsychological performance in relation to pathological 
abnormalities have been conducted on pre-surgical patients, so that the pathological 
abnormalities can be assessed on the resected tissue. This has the benefit of allowing 
for accurate identification of pathology, but at the same time limits the population 
studied to those with medically refractory epilepsy. Comparisons have been made 
using neuronal cell loss, cell densities in different parts of the hippocampus and 
also the number and architecture of granule cells of the dentate gyrus, as well as the 
presence of HS. 
 
It is generally proposed that the left hippocampus is more important for verbal 
memory and the right for non-verbal memory. Studies have shown that there is 
significant correlation between left HS or neuronal cell loss in the hippocampus and 
presurgical verbal memory impairment in patients with left temporal lobe foci 
(Sass, Spencer et al. 1990; Sass, Sass et al. 1992; Miller, Munoz et al. 1993; Rausch 
and Babb 1993; Saling, Berkovic et al. 1993; Pauli, Hildebrandt et al. 2006). This 
correlation is sometimes task specific, for instance it has been found that left HS is 
associated with impaired learning and recall of word pairs but not of a logical 
memory story (a story read to a patient thus recalled by them) (Rausch & Babb, 
1993; Saling et al., 1993), although this is not always the case (Miller et al., 1993). It 
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has been suggested that the recall of prose may be more associated with the lateral 
component of the left temporal lobe, as there was a relationship found between 
prose recall and lateral temporal lobe resection but not mesial temporal lobe 
resection (Ojemann & Dodrill, 1985). In this context, HS or neuron loss is most 
commonly associated with impaired delayed recall (Miller et al., 1993; Rausch & 
Babb, 1993; Saling et al., 1993) or percent retention measures, while generally not 
associated with general cognitive ability, language competency (Sass et al., 1992), 
attention, recognition memory or immediate memory (Miller et al., 1993). 
 
Findings of a relationship between HS and non-verbal memory are less consistent. 
Impaired delayed recall of a complex figure has been associated with HS, although 
this was found across left and right HS groups so is not demonstrative of a material 
specific deficit (Miller et al., 1993). It has been proposed that this lack of a clear 
relationship between right-sided pathology and visual memory may be due to the 
way people verbalise even non-verbal information for storage and recall. 
 
Studies have also tried to further clarify more precisely whereabouts neuron loss 
correlates with memory impairment. Rausch found that damage to neurons in 
either the anterior or posterior part of the left hippocampus was not sufficient to 
severely impair memory performance, extensive damage is required (Rausch, 1987). 
However, correlation has been found between percent retention of logical memory 
story and neuron loss in region „CA3‟ and the hilar region of the hippocampus in 
left TLE patients (Sass et al., 1992). The internal limb of the dentate gyrus has also 
been found to be particularly well correlated with measures of memory (Pauli et al., 
2006), as well as the degree of granule cell loss and abnormality of granule cell 
architecture in the dentate gyrus (Blümcke et al., 2009). 
 
Comparing patients with different types of left temporal lobe pathologies (HS, 
mesial tumour, lateral tumour), Helmstaedter and colleagues proposed that, due to 
surgical outcome data, patients with hippocampal pathologies were more likely to 
be impaired in delayed recall of a word list, while patients with lateral temporal 
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lobe lesions were expected to be worse at immediate recall and working memory. 
The „hippocampal effect‟ was found in patients with HS who were more impaired 
in delayed recall of a word list (than patients with lateral tumours and also mesial 
tumours), but no „lateral effect‟ (worse immediate and working memory with lateral 
lesions) (Helmstaedter et al., 1997).  
 
4.3.2 Findings from MRI investigations 
 
A unilaterally small hippocampus and increased T2-weighted signal seen on MRI 
have been shown to be effective at identifying HS (Jackson et al., 1990; Lencz et al., 
1992) and side of seizure onset (Jack Jr et al., 1990; García-Fiñana et al., 2006). This 
would suggest that, as well as by assessing patients‟ pathological abnormalities at 
surgery, quantitative MRI can also be used to assess temporal lobe or hippocampal 
damage in patients who don‟t need surgery. It also indicates that assessing the 
relationship between MRI abnormalities and neuropsychological status can give an 
idea of the relationship between pathological abnormalities and neuropsychological 
status. 
 
MRI volumetrics have identified atrophy in TLE patients in the hippocampus (Jack 
Jr et al., 1992; Quigg et al., 1997; Woermann et al., 1998; Tasch et al., 1999; Daley et al., 
2006; García-Fiñana et al., 2006; Oyegbile et al., 2006), mesial temporal structures 
such as amygdala (Kälviäinen et al., 1997; Martin et al., 1999), fornix (Kuzniecky et 
al., 1999; Martin et al., 1999), and entorhinal cortex (Bernasconi et al., 1999) as well as 
basal ganglia and thalamus (DeCarli et al., 1998; Tuchscherer et al., 2010). 
Extrahippocampal temporal regions (Moran et al., 2001) and extratemporal regions 
such as cerebellum (Ney et al., 1994; Specht et al., 1997; Bohnen et al., 1998; Sandok et 
al., 2000) have also been found to be abnormal in TLE. MRI volumetrics have also 
been used in TLE patients to assess the whole brain, finding a relatively diffuse 
pattern of cerebral volume loss (in frontal, parietal and temporal but not occipital 
lobes (Hermann et al., 2003)) or reduced total brain volume (Oyegbile et al., 2006), 
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with white matter reduced more than grey matter (Hermann et al., 2003; Oyegbile et 
al., 2006). 
 
The relationships of hippocampal and temporal lobe volumes to memory have been 
investigated. The volume of the left (dominant) hippocampus has been shown to be 
correlated with delayed recall or retention of verbal information, including a logical 
memory story (Lencz et al., 1992) and also verbal paired associates, with a weaker 
and less consistent correlation with immediate recall (Griffith et al., 2003). This is 
consistent with the post-surgical findings discussed demonstrating that 
hippocampal pathology correlated better with delayed than immediate recall 
(Miller et al., 1993; Rausch & Babb, 1993; Saling et al., 1993). Volume of the left 
temporal lobe has also been shown to correlate with verbal recall of a word list 
(Lencz et al., 1992). This is in conflict with the aforementioned pre-surgical findings, 
that patients with hippocampal pathology are more impaired at word list recall, 
whereas logical memory story recall might be more related to the lateral temporal 
lobe (Rausch & Babb, 1993; Saling et al., 1993). No reliable relationships have been 
found between right hippocampal volume and visual memory measures, a finding 
consistent with previous studies (Griffith et al., 2003). 
 
For people with epilepsy, abnormalities outside the temporal lobes also exist. 
Therefore it is unsurprising that cognitive abnormalities often extend beyond the 
field of memory. Neuropsychological impairment in patients has been found to 
correlate with total brain volume (Oyegbile et al., 2006). The reduction in white 
matter raises the idea of reduced cortical connectivity in TLE and this is a model for 
the diffuse cognitive dysfunction which is seen (Hermann et al., 2003). The cause of 
the widespread volume abnormalities is unclear, but it could be due to the effects of 
seizures or their treatment on brain growth and cognitive development, the 
progressive adverse effects of longstanding epilepsy on brain structure and 
function, or discrete cerebral insults antedating or related to the onset of the focal 
epilepsy. Animal studies might suggest that white matter is particularly vulnerable 
to seizure activity, particularly in immature rat brains (Dwyer & Wasterlain, 1982). 
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In summary, findings from both MRI studies and pre-surgical patients show a 
number of abnormalities in TLE that correlate with various cognitive measures, 
largely in the temporal lobe and hippocampus as well as more diffuse volume 
abnormalities. Left hippocampal volume or HS correlates with retention or delayed 
recall of verbal information. More diffuse white matter changes, total brain volume 
reduction and diffusely reduced cortical thickness correlate with more extensive 
cognitive and executive dysfunction. It would seem clear that pathological changes 
in epilepsy have a significant detrimental effect on neuropsychological functioning. 
 
4.4 Relationship of duration of epilepsy with neuropsychological functioning  
 
When considering the factors involved in cognitive problems in epilepsy, it is 
important to consider how the problems might progress over time, to identify 
cognitive trajectories in epilepsy and to try and further disentangle the relationships 
of causative factors. Alongside this goes investigation into cognitive impairments in 
newly diagnosed patients, which will be considered in a later chapter. 
 
Cognitive decline in patients with chronic epilepsy may be due to progression of a 
disease underpinning epilepsy, progression of epilepsy (via kindling or further 
epileptogenesis), injuries associated with epilepsy (head injuries, status epilepticus) 
and physiological or pathological aging (Helmstaedter, 2002). Duration of epilepsy 
is a factor in cognitive impairment encompassing these independent issues. It can 
be an easier variable to measure than many of these individually, and by finding 
out if duration of epilepsy has a relationship with neuropsychological functioning, 
it is possible to identify whether epilepsy has a course of progressive cognitive 
decline over and above that found in healthy control subjects. 
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Investigations into the effect of duration of epilepsy can be either cross-sectional, 
where duration is examined as a co-variant in cognition, or prospective longitudinal 
studies where cognitive change over time is examined. Cross sectional studies are 
more common as they are easier to undertake, but they are only able to provide an 
indirect evaluation of cognitive change over time and disentangling other factors 
from the analysis is problematic. For example, longer duration of epilepsy is heavily 
confounded by aging, which is independently associated with cognitive decline. In 
contrast, prospective longitudinal studies allow researchers to compare a patient‟s 
performance with themselves over time, and with a control group practice effects 
can be taken into account to allow assessment of the patients‟ cognitive trajectory 
compared to a healthy population. However, these tend to cover a period of up to 
10 years rather than assess the lifetime cognitive trajectory and the pattern of 
change is not clear – whether it is linear or there are „critical periods‟. Also, it is 
uncertain whether any changes are permanent in nature or merely transitory 
(Hermann, BP et al., 2006). 
 
Prospective longitudinal studies assessing patients‟ cognitive trajectories have 
yielded mixed results. Some have found worsening performance with time in 
patients with localisation-related epilepsy on delayed recall of verbal paired 
associates and a complex figure, compared to healthy controls (Andersson-Roswall 
et al., 2004). Others have identified a lack of practice effects in patients, whereby 
performance does not decline but is significantly worse when compared to a score 
predicted by healthy control results (Hermann, BP et al., 2006). Holmes and 
colleagues described no significant deterioration in patients over a 10-year period, 
but there were no controls so practice effects were not accounted for (Holmes et al., 
1998). Hermann and colleagues also identified adverse cognitive outcomes in a 
subset of 20-25% of patients. Those with baseline volumetric abnormalities on MRI, 
low baseline full-scale IQ (demonstrating increased cognitive vulnerability with 
lower intellectual capacity) and to a lesser extent longer duration of epilepsy and 
higher age were most vulnerable to these adverse cognitive outcomes (Hermann, 
BP et al., 2006). 
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Other studies have not found relative progressive cognitive decline in patients with 
epilepsy. For example, Helmstaedter and colleagues demonstrated with age 
regression that, although TLE patients perform cognitively worse than controls and 
decline over time, this decline is at a similar rate to that in a normal population but 
starting from a lower point (Helmstaedter & Elger, 1999; Helmstaedter & Elger, 
2009). Rather than the steep increase in learning and memory performance seen in 
controls in adolescence until their early twenties, patients demonstrated little 
increase in performance and began to decline earlier. These findings suggest that 
cognitive impairment is a developmental problem, rather than a degenerative 
process of accelerated deterioration related to ongoing disease. However, Jokeit 
points out that the measure of intelligence used in these studies is one to assess 
premorbid functioning, so not really representative of intellectual functioning 
(Jokeit et al., 2000). 
 
Another interesting finding concerns cerebral reserve – the idea that subjects with 
higher education, greater occupational attainment, or increased participation in 
mindful activities may benefit from increased plasticity or neuro-protection that 
may serve to delay or attenuate disease effects (Stern, 2002). Some studies have 
suggested that duration of epilepsy is linked to neuropsychological impairment, but 
it is a relationship mediated by years of education (a common measure of cerebral 
reserve) (Oyegbile et al., 2004; Pai & Tsai, 2005), proposing that a patient with less 
education might have a more rapidly progressive cognitive decline .  
 
If there is a progressive cognitive decline in epilepsy patients steeper than that 
found in a normal population, it leads to the question of whether or not seizures 
may be related to cognitive performance. 
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4.5 Relationship of seizures and discharges to cognitive impairment 
 
In an animal model, even brief seizures have been shown to worsen emotional and 
spatial memory (Majak & Pitkänen, 2004). However, the evidence that these effects 
are also present in humans is less clear, perhaps due to the difficulties disentangling 
confounding factors.  
 
In a study assessing partial epilepsy patients‟ memory during video-EEG telemetry, 
where information was presented at the start of telemetry and recalled 48 hours 
later, there was no significant correlation between number or timing of seizures and 
memory performance – although most seizures were not generalised (Bergin et al., 
1995). This suggests that isolated seizures do not cause increased forgetting of 
recently learned material. The effects of seizures over a longer period, either with 
cross-sectional or longitudinal studies, have also been investigated. 
 
Some of these studies have demonstrated no impact of total lifetime number of 
seizures (Kramer et al., 2006) or EEG abnormalities (Scott et al., 1967) on cognition in 
epilepsy. Others have demonstrated strong correlations between total spike activity 
in depth electrodes and intelligence and other neuropsychological measures 
(Rausch et al., 1978) in a group of patients with refractory temporal lobe epilepsy. 
However, Rausch and colleagues warned against interpreting this as a cause and 
effect relationship, suggesting that whilst it could show that an active epileptic site 
is disruptive of function, it could also be the case that interictal spike discharges 
could be a manifestation of underlying pathology.  
 
Reviews within this area of the literature have demonstrated mixed results. Dodrill 
considered longitudinal cognitive investigations in patients with epilepsy, finding 
support overall for a „mild‟ connection between seizures and cognitive change 
(Dodrill, 2004). This was supported by findings including significant relationships 
between increased number of seizures and decreased scores on tests of various 
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abilities (Rodin, 1968; Dodrill & Wilensky, 1990; Dodrill, 2002), changes in 
intellectual functioning corresponding to changes in seizure frequency (Seidenberg 
et al., 1981), declines in diffuse areas of cognitive functioning but most consistently 
memory, and controls performing better over time than patients. However, several 
studies reviewed found it difficult to connect seizure frequency with loss of 
abilities. In a further, more select review, Vingerhoets considers some of the studies 
reviewed by Dodrill (those longitudinal studies with data on seizure types and 
frequency) and one additional study (Vingerhoets, 2006). From these, the conclusion 
is drawn that overall patients with chronic pharmacoresistant epilepsy show a mild 
decline in cognitive function, particularly memory, compared to matched controls 
over a time period, but this is not generally well associated with seizure-related 
factors. 
 
Cognitive decline related to seizure activity has also been considered in specific 
groups of patients. For example, Mantoan et al studied memory in relation to 
interictal epileptiform discharges and neuronal loss (detected by proton MR 
spectroscopy) in a group of patients with TLE and HS (Mantoan et al., 2009). 
Interictal epileptiform discharges (IEDs) were found to correlate with impaired 
immediate and delayed verbal recall in left HS, and bilateral IEDs correlated with 
poor verbal learning in right HS. Interictal discharges and neuronal metabolism 
were shown to be related to verbal memory function in the mesial temporal lobes.  
 
4.6 Is neuronal loss accelerated by seizures? 
 
It can be demonstrated reasonably consistently that pathological abnormalities have 
an effect on at least certain types of memory in patients with TLE. So, if seizures do 
cause cognitive problems with the progression of epilepsy, is the mechanism 
acceleration of neuronal loss? In a study of MRI total brain abnormalities in TLE, the 
impact of clinical seizure variables, eg duration of epilepsy, on cognition is 
mediated by its relation with grey matter and CSF volume abnormalities. This 
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suggests that clinical seizure variables may affect cognition via their impact on 
brain volume (Oyegbile et al., 2006). 
 
A kindling model of TLE in rats would suggest that repeated seizures might cause 
selective loss of neurons in the hippocampus (Cavazos & Sutula, 1990; Cavazos et 
al., 1994). However, using the pilocarpine model of initiating seizures no 
progressive neuronal loss was demonstrated in rats having recurrent seizures (Zhao 
et al., 1994), so even in rats without all the confounding factors it is difficult to know 
if seizures cause neuron loss. One way to examine this is to consider the 
relationships of seizure variables (such as frequency, type and duration of epilepsy) 
to pathology, using cross-sectional or prospective longitudinal studies. 
 
HS is one pathology in TLE that has been much investigated, and whether HS is the 
cause or effect of epilepsy is a longstanding and highly debated question. It has 
been shown in some cases to develop following status epilepticus (Nohria et al., 
1994; Wieshmann et al., 1997), head injury (Bigler et al., 1997), and demonstrated 
following prolonged febrile convulsions (Jackson et al., 1998; Shinnar, 1998; Sloviter, 
1999; Schulz & Ebner, 2001). However, although there is a relationship between HS 
and prolonged febrile seizures, it is debated whether the febrile seizures cause the 
HS or the febrile seizures occur because the hippocampus was already damaged 
(Cendes, 2005). Complex febrile seizures may also have an impact on global brain 
development, as findings suggest patients who have experienced complex febrile 
seizures have lower total cerebral volumes than those who have not (Theodore et al., 
2003). It has been suggested that the risk of neuronal damage from febrile 
convulsions is dependent on genetic susceptibility combined with environmental 
interaction (Sutula & Pitkanen, 2001).  
 
Cross sectional studies have found factors predicting or correlating with MRI 
hippocampal volumes (or atrophy) including: duration of epilepsy, 
neurodevelopmental insult (early recurrent seizures, initial precipitating injury), 
history of febrile seizures, early (<5 years) onset (Salmenperä et al., 1998; 
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Salmenperä et al., 2001) and total lifetime number of generalised tonic-clonic 
seizures (Kalviainen et al., 1998; Tasch et al., 1999; Fuerst et al., 2001; Seidenberg et 
al., 2005) but not consistently frequency of partial seizures. In contrast, mean 
hippocampal and amygdaloid volumes in people with a seizure onset less than 1 
year previously did not differ from controls (Salmenperä et al., 2001). These findings 
would suggest a combination of progressive and neurodevelopmental effects on 
brain volume.  
 
Longitudinal studies in epilepsy patients assessing progression of cerebral damage 
have found mixed results. Liu et al felt that brain volume reduction in epilepsy was 
the cumulative effect of initial precipitating injury and age-related atrophy, rather 
than seizure frequency and duration of epilepsy, as these were found to have no 
significant effect on cerebral volume reduction (Liu et al., 2005). Patients with TLE 
had reduced hippocampal volumes at baseline compared to other epilepsies and 
controls, but similar volume reduction over 3.5 years. Contrary to this, other 
longitudinal studies over a similar time period (3.4 years, 3.5 years) have found that 
in TLE (mild or intractable) there was a strong correlation between frequency of 
partial seizures (Fuerst et al., 2003) or generalised seizures (Briellmann et al., 2002) 
and hippocampal volume loss ipsilateral to seizure onset (Briellmann et al., 2002; 
Fuerst et al., 2003). Patients becoming seizure free in one of these studies showed no 
hippocampal volume loss, but due to numbers this should be interpreted with 
caution (Fuerst et al., 2003).  
 
Overall, results are very mixed and inconclusive, but there are suggestions that 
pathological abnormalities in TLE are, at least in some cases, correlated with 
duration of epilepsy or number of seizures and thus a progressive disorder. 
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4.7 Does the age of onset of epilepsy affect cognitive prognosis? 
 
Age of onset is a variable often interlinked with duration of epilepsy, as a patient 
with an earlier age of onset will likely have a longer duration of epilepsy 
throughout their lifetime. However, these two variables have different effects on 
neuropsychological functioning, as an earlier age of onset will mean seizures 
affecting a less developed brain which can cause different outcomes. Early age at 
onset of epilepsy is not a risk for cognitive impairment per se, for example a benign 
myoclonic epilepsy will start early in life but have little cognitive impact, but in a 
specific population such as TLE patients an early age of onset is often associated 
with a worse prognosis (van Rijckevorsel, 2006). 
 
Unlike in adults, where there is a reasonably stable cognitive substrate that is the 
target of adverse epilepsy factors, in children there is a dynamic pattern of cognitive 
and brain development (Hermann et al., 2008). There is some evidence suggesting 
that recurrent seizures in a developing brain are associated with adverse effects on 
both brain structure and function (Hermann, B et al., 2002). The immature brain is 
more prone to seizures than the mature brain, which is borne out by animal studies 
(Michelson & Lothman, 1991), alongside the clinical observation that the incidence 
of seizures is highest during the first decade of life and many childhood seizure 
disorders remit (Holmes, 1997). This is thought to be due to variation in the balance 
of excitation and inhibition (Holmes, 1997). It seems from animal models that 
seizures in a developing brain cause less neuronal damage and cell loss than in an 
adult brain (Lado et al., 2000; Marsh et al., 2006). However, early seizures can cause 
changes in the function of neurotransmitter systems and intrinsic neuronal 
properties, and thus have an adverse effect on brain development and function in 
the long term, which could lead to cognitive or behavioural problems (Wasterlain et 
al., 1999; Marsh et al., 2006). 
 
Onset of epilepsy early in life has been postulated to account for more generalised 
intellectual impairment in addition to memory problems in TLE due to the possible 
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interference in neurodevelopment, whereas later onset may be associated with more 
specific impairments related to the site of the discharges or pathophysiology. For 
example, in those with no pathological lesions or only HS, verbal memory has been 
shown to be reduced in patients with both early (before age 15) and late onset 
whereas IQ was significantly more impaired in those with early onset epilepsy 
(Kaaden & Helmstaedter, 2009). In those with more pathology than just HS, IQ was 
equally poor in early and late onset groups, and worse than verbal memory 
function. This suggests verbal memory loss is perhaps a good indicator of mesial 
temporal lobe function, whereas IQ, verbal and figural learning performance reflect 
more extra-temporal or „whole-brain‟ functions. Age of onset seems to have more of 
an impact on these „whole-brain‟ functions, suggesting disruption during 
development interferes with global functioning as well as localised functions 
(Kaaden & Helmstaedter, 2009). 
 
Similarly, in a cross sectional study childhood onset (up to 14) TLE was associated 
with worse verbal, performance, and full-scale IQ and verbal and non-verbal 
memory measures than late onset and controls (Hermann, B et al., 2002). These 
findings of worse performance across a range of functions with early onset epilepsy 
are corroborated by findings in patients with generalised epilepsy (O'Leary et al., 
1981; O'Leary et al., 1983). Childhood onset TLE has also been associated with 
widespread reduced cerebral volume in all lobes, i.e. extratemporal volume loss. So, 
early onset TLE is associated with generalised adverse neurodevelopmental impact, 
in terms of both structural changes and cognitive impairments.  
 
Considering duration of epilepsy and progression of impairment, patients with 
early onset have been found to be at risk of declining performance relative to 
chronicity of epilepsy when compared to those with later onset (Hermann, BP et al., 
2002). This generalised cognitive vulnerability, or increased risk of further cognitive 
decline, may be due to a lack of cerebral reserve (see earlier section on „duration of 
epilepsy‟). The concept of cerebral reserve is thought to help understand the risk of 
age-related decline when people have suffered an early brain insult. 
    46 
 
In contrast to the concept that childhood onset epilepsy might cause cognitive 
impairment due to poor cerebral reserve, there are also suggestions that an early 
age of onset of epilepsy may mean that cortical reorganisation can occur due to 
cerebral plasticity, when there is a non-diffuse neuropathology like HS. This would 
mean protection of particular functions such as memory in the presence of HS 
(Seidenberg et al., 1997). Furthermore, the study suggested that in an early onset 
epilepsy (before 5 years) with a single focal lesion, cerebral reorganisation of 
function may occur, allowing for preservation of memory even following surgery. 
However, these conclusions were based on a number of assumptions and 
extrapolations, and only relevant to a small population. 
 
Helmstaedter and colleagues‟ findings discussed earlier suggesting that cognitive 
impairment in epilepsy is not due to a progressive process but rather impaired 
neurodevelopment followed by normal aging processes from a lower level are also 
important in this discussion (Helmstaedter & Elger, 1999; Helmstaedter & Elger, 
2009). This is the theory that „normal senescence brings patients to mnesic disability 
at a younger age‟ p439 (Helmstaedter, 2002), with early age of onset representing a 
developmental hindrance factor (Kaaden & Helmstaedter, 2009). 
 
To further investigate the effects of neurological insults on the developing brain, 
Dikmen et al compared the neuropsychological performance of patients with early 
onset seizures (before five years), early onset brain damage without seizures, late 
onset (age 17-50) seizures and late onset brain damage without seizures (Dikmen et 
al., 1975). Those with early onset seizures performed significantly worse across most 
measures than all of the other groups, while those with early onset brain damage 
did not differ in performance from those with later insults. This emphasises the 
importance of early onset of cerebral damage on neuropsychological performance 
across pathologies. 
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Early onset of epilepsy impacts on cognitive functioning not only due to its effect on 
the structure and function of neurons, but also through education and social 
processes. Children with epilepsy generally have poorer academic performance 
than would be expected at school (Williams, 2003; Bishop & Slevin, 2004). This may 
be partly due to neurodevelopmental effects of seizures and AEDs, but also 
depends on personality of the child, social variables, family adjustment and school 
environment (Seidenberg & Berent, 1992; Williams, 2003; Bishop & Slevin, 2004). For 
example, stigma may cause lower expectations in parents and teachers, which could 
affect the child‟s effort, self-belief and academic performance (Williams, 2003). 
 
In summary, it seems that an early age of onset of TLE is associated with poor 
performance in neuropsychological tasks. This is characterised by a more 
generalised pattern of impairment than later onset seizures, probably due to 
interference with neurodevelopment by either an insult causing the epilepsy, 
epileptogenesis, or the seizures themselves, alongside the impact of family, school 
and social environment on educational performance.  
 
4.8 Anti-epileptic medication – the effects on cognition and memory 
 
Anti-epileptic drugs (AEDs) exert their effect by producing changes in the excitation 
levels in the central nervous system, and as these changes are global it is 
unsurprising that it is thought that some, if not all, AEDs have an effect on 
cognition and behaviour (Ortinski & Meador, 2004). The cognitive effects of 
antiepileptic medication first became a focus of interest in the 1970s (Ideström et al., 
1972; Dodrill & Troupin, 1977), probably stimulated by the growing number of 
treatment options available at that time (Aldenkamp, Albert P. et al., 2003). 
However, it is suggested that the adverse cognitive and behavioural effects of AEDs 
are more subtle than once thought and have been over-estimated (Kwan & Brodie, 
2001), as patients established on target doses with no active seizure disorder have 
been shown to not cognitively deteriorate over a 5-year period (Dodrill & Wilensky, 
1992). 
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Significant problems arise in designing a methodologically sound study that can 
identify cognitive impairment caused by AEDs whilst avoiding confounding 
factors, so while there has been much research, few studies are useful for drawing 
reliable conclusions (Vermeulen & Aldenkamp, 1995; Cochrane et al., 1998). 
Randomised clinical trials with monotherapy in patients with newly diagnosed 
epilepsy are the best procedure for assessing the cognitive effects of AEDs 
(Aldenkamp, 2001), as randomisation removes selection bias when allocating 
treatments so is the least biased method (Cochrane et al., 1998). Studies using add-
on or polytherapy designs make the identification of the responsible treatment 
factors more complex as drug therapy is usually not standardised. Combinations of 
AEDs may interact with or potentiate one another, which would affect the 
conclusions that can be drawn. Also, as polytherapy is used in refractory patients 
ongoing seizure effects are likely to confound the results (Vermeulen & Aldenkamp, 
1995). However, as many patients require polytherapy for seizure control, the 
results can be clinically relevant, reflecting issues faced in real life. Studies using 
healthy controls are often limited by brief exposure periods and a different cerebral 
substrate that the drugs are acting on, but can provide some useful indications for 
future research. 
 
Another problem with studies into the cognitive effects of AEDs is individual 
variance – medications that work well for some may not work at all for others, or 
those that cause no side effects at a large dose in one patient may cause toxicity in 
another at a lower dose. These unconventional patients may appear as outliers and 
affect the mean so by grouping all patients together, an effect may become non-
significant (Devinsky, 1995).  
 
Finally, the wide variety of neuropsychological tests used across different studies 
also makes it difficult to undertake reasonable meta-analysis and draw any reliable 
conclusions from previous research. 
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A meta-analysis of reports of the cognitive side effects of the commonly used „older‟ 
AEDs (Phenobarbital (PB), phenytoin (PHT), carbamazepine (CBZ) and sodium 
valproate (VPA)) found that all of the medications, even those considered 
cognitively safe, demonstrated some cognitive side effects compared to no 
treatment (Vermeulen & Aldenkamp, 1995). The „milder‟ drugs CBZ, VPA and PHT 
were associated with a mild, general psychomotor slowing. PB had significantly 
worse effects, with only minor differences between the others when a usual 
therapeutic dose was considered. Polytherapy was also shown to be more 
cognitively detrimental than monotherapy with any drugs; even if the two drugs 
used individually have mild effects, when given together interactions make them 
more harmful.  
 
A further study has compared the cognitive effects of CBZ and VPA using both 
healthy volunteers and also a group of newly diagnosed untreated epilepsy patients 
as control groups (Shehata et al., 2009). Both treated and untreated patients 
performed worse than healthy controls in a number of cognitive tests (including 
verbal reasoning, memory for objects, memory for beads, and non-verbal short term 
memory) and behavioural functions (including depression, aggression and 
neurosis). Treated patients had worse scores in memory for digits forward and 
backward and verbal short term memory, but not to a significant level. Within the 
treatment groups, dose of AED was significantly associated with neurosis and 
aggression but no cognitive measures, and duration of treatment associated with 
object, bead and non-verbal short term memory as well as depression, psychosis 
and aggression. In comparison of the different drug groups, VPA was associated 
with significantly higher levels of aggression and neurosis. No other differences 
between drug groups were found. 
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Figure 4.3: Delayed recall performance of a story in healthy volunteer studies on various 
AEDs (Motamedi & Meador, 2004)- reproduced with permission 
  
CBZ = carbamazepine; PHT= phenytoin; GBP = gabapentin; LTG = lamotrigine 
 
 
Assessing memory performance specifically is limited in most studies, and it is 
difficult to assess independently because of the effects of slowed mental processing 
and attention on memory tasks. In healthy volunteer studies, Meador et al 
demonstrated a 15% reduction in delayed recall of a paragraph in those taking PHT 
and CBZ compared to non-drug controls (see figure 4.3) (Motamedi & Meador, 
2004). Examining memory processes in more detail in refractory TLE patients 
treated with CBZ, PHT and PB, it was found that serum AED level was significantly 
related to verbal and non-verbal retention but not encoding (Jokeit et al., 2005). This 
suggests that high levels of CBZ, PHT, and PB have a particular effect on memory, 
but not attention or mental speed, as encoding was unaffected. Interestingly Jokeit 
et al also found high carbamazepine serum levels to be associated with reduced 
activation of the medial temporal lobes (using fMRI) in memory retrieval. 
 
Research has also been undertaken into the cognitive and behavioural effects of the 
newer AEDs. The effects of lamotrigine (LTG) and levetiracetam (LEV) will 
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particularly be focused on here, as these are the two most commonly prescribed in 
the population that will be studied in this project.  
 
In healthy volunteer studies comparing the cognitive effects of LTG with CBZ 
(Meador et al., 2001) and TPM (Meador et al., 2005), participants on LTG performed 
significantly better than those on CBZ and TPM on variables spanning objective 
cognitive and subjective behavioural measures. Also, compared to the non-drug 
group participants on LTG were impaired on significantly fewer measures than 
those taking both CBZ and TPM. The most susceptible domains to impairment by 
AEDs are sustained attention, processing speed, tasks requiring attention like recall 
of a paragraph and, with some drugs (CBZ and TPM) verbal fluency. On a specific 
memory measure in these studies, delayed recall of a paragraph, compared to the 
non-drug average participants taking LTG and gabapentin (GBP) performed no 
worse but those taking CBZ, PHT and TPM recalled 10-20% less than non-drug 
groups (Hermann et al., 2010). 
 
In patient studies, the cognitive profile of LTG has been assessed as monotherapy in 
newly diagnosed patients, and more frequently as add-on therapy (Smith et al., 
1993; Marciani et al., 1998; Gillham et al., 2000). Comparing LTG with CBZ in newly 
diagnosed patients, it was suggested that LTG had a comparatively favourable 
effect on long term cognitive function (Gillham et al., 2000). LTG compared to 
placebo as an add-on in a double blind crossover trial in a group of partial seizure 
patients found LTG to have no adverse cognitive effects compared to placebo and 
increases on a subjective measure of happiness (Smith et al., 1993). LTG has also 
been shown to reduce spontaneous epileptiform discharges on EEG (Binnie et al., 
1986; Marciani et al., 1996), which may help to explain its favourable cognitive 
profile. 
 
LEV has relatively little cognitive data available, a small sample study suggested it 
had no cognitive effects but this only included ten patients (Neyens et al., 1995).  A 
randomised, crossover, double blinded trial of healthy volunteers comparing its 
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cognitive profile to CBZ found those taking LEV to perform better than those on 
CBZ on 44% of variables, and compared to the non-drug average LEV impaired 
participants on significantly fewer measures (Meador et al., 2007). LEV has also been 
shown to improve attention and verbal fluency (Piazzini et al., 2006) and have a 
sustained positive impact on attention and both long and short term memory (Zhou 
et al., 2008) as an add-on therapy in patients with partial seizures, independent of 
seizure reduction. The mechanism for this is unclear, although LEV is derived from 
piracetam, a drug that has also been shown to improve learning, memory and 
attention (Genton & Van Vleymen, 2000). As little evidence is yet available on the 
cognitive safety of LEV these results should be interpreted with caution, although 
the possible positive cognitive effects are somewhat supported by improvements 
shown in Mini-Mental State Exam (MMSE) scores (a very crude test)  after 12 
months of LEV therapy (Wu et al., 2009) and improvements in subjective cognitive 
functioning assessments (Cramer et al., 2000). 
 
There is some evidence that „older‟ AEDs in particular may have a negative effect 
on cognition, especially when used as part of a polytherapy regime or in high doses. 
Studies have suggested that PB is the AED with the most detrimental effect on 
cognition (Vermeulen & Aldenkamp, 1995). On the other hand, there is no 
convincing evidence that LTG or LEV impair neuropsychological functioning, and 
indeed there are some studies suggesting LEV may exert beneficial effects on 
cognition. 
 
4.9 Mood 
 
Depression is a common comorbid mood disorder associated with epilepsy, with a 
significantly higher prevalence than that in a matched population of healthy 
controls or even patients with other chronic diseases (Perini et al., 1996; Marsh & 
Rao, 2002; Kanner, 2003; Baker, 2006). Prevalence varies depending on assessment 
and definition of depression, but has been quoted as being between 20 and 60% in 
patients with recurrent seizures and between 10 and 20% in those with controlled 
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epilepsy, demonstrating the importance of seizure control for mood (Hecimovic et 
al., 2003; Kanner, 2003). Depressive symptoms can manifest as major depressive 
disorder, atypical depression, dysthymia or a dysthymic-like disorder with 
intermittent symptoms (Miller et al., 2008). Anxiety is also more common in patients 
with epilepsy than in the general population (Marsh & Rao, 2002; Beyenburg et al., 
2005; Mensah et al., 2007). Depressed mood and anxiety are important factors for 
quality of life in epilepsy, having been shown, in some studies, to have more of an 
impact than seizure control in patients with epilepsy (Boylan et al., 2004; Johnson et 
al., 2004). 
 
The cause of higher rates of depression in patients with epilepsy is thought to be 
multifactorial – including the psychological impact of epilepsy and its associated 
challenges, the endocrine or metabolic effects of seizures, and a possible common 
underlying pathology (ie the relationship between the two conditions is 
bidirectional (Hesdorffer et al., 2000; Kanner, 2008)) (Miller et al., 2008). It has also 
been proposed that particular epileptic foci might lead to higher rates of depression 
and anxiety (Hixson & Kirsch, 2009). TLE seems associated with higher rates of 
depression than epilepsy generally (Perini et al., 1996; Quiske et al., 2000), 
particularly left TLE (Harden & Goldstein, 2002). Higher rates of anxiety have also 
been found in left TLE patients than right TLE patients and controls (Andelman et 
al., 2001). There are also links between some AEDs (notably LEV) and behavioural 
disturbance and mood disorders, particularly in patients with a past history of 
psychiatric disturbance (Hixson & Kirsch, 2009). 
 
Depression itself has been demonstrated to be reliably associated with objective 
memory impairment (Burt et al., 1995). Suggested reasons for this include mood 
congruency effects (that learning of negative information is best and learning of 
positive information impaired), that reduced motivation or energy means patients 
have impoverished output, or that there is impaired ability to use effortful memory 
strategies because of poor attention or motivation. So, a higher rate of depression in 
patients with epilepsy might be thought to correlate with memory impairments. 
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Examining this possibility, Elixhauser et al found a weak but significant correlation 
between memory performance scores and 3 subsections of mood scoring (tension / 
anxiety, confusion / bewilderment and anger / hostility) in patients with any type 
of epilepsy (Elixhauser et al., 1999). However, mood correlated better with 
perceived cognitive function scores on a quality of life measure, which is a 
relationship that will be discussed further in the next chapter. 
 
In examining the relationship between mood and objective memory in TLE, 
Helmstaedter et al found depressed mood to correlate with some objective memory 
performance measures, particularly in patients with left TLE with lateral temporal 
lobe lesions, i.e. those with more depression performed worse. There was no 
significant correlation between lateralisation and localisation of the lesion with 
mood, despite correlation between laterality and localisation of lesion with memory 
performance measures (Helmstaedter et al., 2004). The finding that site and side of 
lesion affects the association between mood and memory in TLE patients, supports 
findings that the association between mood and memory is stronger in left TLE 
(Paradiso et al., 2001). 
 
Depression and anxiety are not the only psychological disturbances found in 
patients with epilepsy – for example TLE patients have been found to be affected 
across nearly all emotional-behavioural domains including somatisation, 
depression, anxiety, obsessive compulsive traits, hostility and psychoticism 
(Hermann et al., 2000a). Higher levels of depression and anxiety have been 
associated with various factors including increasing duration of epilepsy (Hermann 
et al., 2000b), patient perceived seizure severity (Smith et al., 1991), number of 
complex partial seizures (Grabowska-Grzyb et al., 2006), increased frequency of 
seizures (Jacoby et al., 1996) and mesial temporal sclerosis (Quiske et al., 2000). 
However, using the Minnesota Multiphasic Personality Inventory (MMPI) (Butcher 
et al., 1989) as a measure of psychopathology, poor neuropsychological functioning 
has been shown not to be related to psychopathology in TLE (Moehle et al., 1984). 
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Whatever the relationship between objective memory performance and mood 
disorders, depression is also known to affect subjective reporting of memory due to 
a catastrophising bias (Baker et al., 2009). This, along with other factors involved in 
subjective memory reporting in epilepsy, will be discussed in the next chapter. 
 
4.10 Summary 
 
The relationships of various factors to memory performance in TLE have been 
considered, and the only thing that is clear is that this is a multifactorial problem 
from which it is not simple to extricate answers.  
 
Pathological lesions seem to be associated with worse memory performance, 
particularly problems in delayed verbal memory when the lesion is on the left. 
Clinical seizure variables like type and frequency of seizures and duration of 
epilepsy have a less perceptible relationship with memory functions, although an 
early age of onset seems to be particularly associated with a risk of impairment of 
generalised cognitive functions. Other factors like AED use and mood disorders 
may have some independent effect on cognition but likely any neuropsychological 
problems are due to the interaction of many of these factors. 
    56 
Chapter 5  Subjective memory problems in epilepsy 
 
 
5.1 Background 
 
Investigating the relationships between different factors and objective cognitive 
problems found in neuropsychological testing of patients with epilepsy allows us to 
consider the causes of identified memory deficits. However, whether or not 
objective problems correlate with subjective complaints is another question entirely. 
Therefore, in this chapter subjective reports of memory problems in epilepsy 
patients will be considered along with their relationship to objective problems. 
 
There are a number of cognitive problems that people with epilepsy recognise (see 
table 5.1), and cognitive problems which are also reported by relatives and 
caregivers (see figure 5.1). 
 
 Table 5.1: Common reports of cognitive impairments in people with epilepsy (Baker et al., 
2009) 
 
  
 
Specifically, people with epilepsy generally perceive their memory performance to 
be worse than controls (Vermeulen et al., 1993). In a survey of 760 patients, 54% of 
Forgetting the way around familiar places 
Impaired ability to do mental arithmetic 
Forgetting names of familiar people 
Difficulty retaining a telephone number 
Difficulty paying attention to a speech or news broadcast 
Difficulty understanding something you have heard or read 
Difficulty learning something new 
Slowness of thought 
Difficulty following instructions 
Impaired eye-hand co-ordination 
Sleepiness / tiredness 
Lethargy / sluggishness 
Forgetting anniversaries, appointments and dates 
Epilepsy and Cognitive Function Survey, International Bureau for Epilepsy (2004) 
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patients (compared to 23% of controls) described their memory as a moderate to 
severe nuisance in daily functioning (Thompson & Corcoran, 1992). These were not 
only individuals with intractable epilepsy but included those with controlled 
seizures, suggesting that memory complaints are not confined to patients with 
refractory epilepsy. Within this questionnaire, the frequency of a list of memory 
problems was described, showing that the most commonly reported problem 
among patients with epilepsy was the „tip of the tongue‟ phenomenon, reported as 
occurring at least daily in 43% of patients (see table 5.2).  
 
Figure 5.1: Common problems for children and teenagers with epilepsy reported by their 
caregivers (Baker et al., 2008) 
  
 
 
 
Table 5.2: The top 5 memory problems in each group (% reporting problem at least 
daily)(Thompson & Corcoran, 1992) 
Epilepsy Non-epilepsy 
1. Tip of the tongue (43%) 
2. Going back to check (39%) 
3. Forgetting where you’ve put things (33%) 
4. Forgetting names (31%) 
5. Forgetting you were told something 
(30%) 
Going back to check (20.5%) 
Forgetting where you’ve put things (18.5%) 
Forgetting names (14%) 
Tip of the tongue (14%) 
Rambling on (11%) 
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5.2 Epilepsy specific factors affecting subjective memory 
 
There are a number of epilepsy related factors that might be thought to affect 
subjective memory, including epilepsy duration, age of onset, frequency of seizures, 
seizure type and medication. However, subjective memory does not seem to be 
dependent on  many of these factors including type of seizures (Giovagnoli et al., 
1997; Piazzini et al., 2001; Salas-Puig et al., 2009), lateralisation of epilepsy (Hendriks 
et al., 2002), frequency of seizures (Giovagnoli et al., 1997; Au et al., 2006; Salas-Puig 
et al., 2009) or age of onset (Giovagnoli et al., 1997; Au et al., 2006). One study finds 
duration of epilepsy to correlate weakly but significantly with complaints 
(Hendriks et al., 2002), while this is contradicted elsewhere (Giovagnoli et al., 1997; 
Piazzini et al., 2001; Au et al., 2006). However, frequency of seizures has been shown 
to correlate strongly with anxiety and depression levels, which link to memory 
complaints (Piazzini et al., 2001).  
 
Around 50% of a large international study of over 5000 patients with epilepsy 
reported problems with memory as a side effect of medication (Baker et al., 1997). 
This included 47% of those on CBZ monotherapy reporting memory difficulties, 
48% on PHT, 37% on VPA and 30% on PB. However, Baker and colleagues note that 
other factors than AED use might also explain these concerns but it is not possible 
for them to disentangle these. A large community-based cross-sectional study in the 
Netherlands of patients with epilepsy taking medication (around 80% on 
monotherapy) has also found over 60% had cognitive complaints that they related 
to use of AEDs, predominantly memory problems and concentration difficulties 
(Carpay et al., 2005). Results regarding the relative impact of medication on memory 
complaints is mixed – some have found no medication effect (no difference between 
complaints in relation to number of medications or dosing) (Hendriks et al., 2002; 
Au et al., 2006), whereas elsewhere polytherapy has been shown to be associated 
with poorer subjective memory (Giovagnoli et al., 1997; Salas-Puig et al., 2009). 
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5.3 Relationship of complaints to performance 
 
Perception of cognitive functioning is shown to be an important factor in quality of 
life, but weak or insignificant correlations have been demonstrated between 
subjective and objective cognitive functioning (Vermeulen et al., 1993; Giovagnoli et 
al., 1997; Elixhauser et al., 1999; Piazzini et al., 2001; Baños et al., 2004; Au et al., 2006; 
Maarika et al., 2009), and the reasons behind this are much discussed. Many 
epilepsy patients referred with memory complaints perform at average or higher 
than average levels on neuropsychological testing (Thompson & Corcoran, 1992). 
These discrepancies have been demonstrated in various populations as well as in 
patients with epilepsy, including populations as varied as the elderly, stroke 
patients, and menopausal women (Kahn et al., 1975; Lincoln & Tinson, 1989; Weber 
& Mapstone, 2009), so it cannot solely be a problem related to epilepsy factors. 
Complaints that cannot be explained cause problems for both patients and 
clinicians (Vermeulen et al., 1993), so it is important to understand other factors that 
could be causing this discrepancy so that they can be addressed.  
 
The relationship between patients‟ perceptions of their memory and their 
performance is far from simple. If subjective memory does not correlate with 
objective performance, there are a number of possible explanations:  
i) that there is an impairment but it is not identified by neuropsychological 
tests, ie a methodological problem,  
ii) that the perception of memory problems reflects another problem such as a 
another cognitive deficit, or  
iii) that there is a problem with meta-memory, self-monitoring of one‟s memory 
performance which could be affected by mood disorders or epilepsy 
itself. 
 
 
i) Methodological problems 
    60 
In a review of the topic of correlation between subjective and objective memory 
measures in people with epilepsy, Hall and colleagues found a number of 
methodological issues present in most of the studies that makes it difficult to 
compare results across studies and draw firm conclusions as to the nature of the 
relationship, which will be discussed below (Hall et al., 2009). However, although 
inconsistent results are found, it seems that overall there is a lack of correlation, 
based on studies comparing subjective and objective memory in corresponding 
domains (Baños et al., 2004) and those finding a correlation in controls but not in 
patients with epilepsy (Piazzini et al., 2001). So, discrepant objective and subjective 
scores cannot be wholly attributed to methodological flaws (Hall et al., 2009), but 
there are a number which will be discussed in more detail. 
 
Sampling methods may affect the results of studies comparing objective and 
subjective memory problems (Hall et al., 2009). The majority of studies reviewed by 
Hall and colleagues had recruited patients from hospital or specialist tertiary clinics, 
or included pre-surgical patients. These are likely to be the most difficult to control 
cases of epilepsy, mostly refractory to medication, so the results from these studies 
may be difficult to generalise to a wider population of people with epilepsy, as 
around 70% are well controlled by medication. Also, some studies recruited 
participants as those referred to neuropsychology as having memory complaints, 
reducing the generalisability of results. On the other hand, these refractory patients 
are the population of patients who are most likely to have complaints about 
memory so they are the most relevant for finding out what factors are involved. 
 
It is thought that some memory tests or even some tasks within memory tests are 
more relevant to everyday memory failures than others (Vermeulen et al., 1993), for 
example story or word list tasks may test functions used more regularly than a 
visual memory test (Sunderland et al., 1983). The nature of everyday memory 
failures has been suggested not to be adequately assessed by conventional cognitive 
tests (Piazzini et al., 2001). As the tests used are generally designed to screen for 
brain damage or help identify localisation and lateralisation of a lesion, their 
ecological validity in real-life situations can be questioned. It has been commented 
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that the Weschler Memory Scale (WMS) fails to assess the same memory skills that 
are required in „everyday‟ situations (Hall et al., 2009). The Rivermead Behavioural 
Memory Test (RBMT) is thought to be a more ecologically valid test but studies 
using this measure still show only slight correlation with memory complaints 
(Elixhauser et al., 1999). A „Memory in Reality‟ test has also been used to try and 
improve ecological validity but this also had few correlations with memory 
complaints (Helmstaedter et al., 1998), and only in participants without memory 
impairment.  
 
The delay included in standard memory tests to measure long term memory 
function is generally 30 minutes, which may not be long enough to detect 
consolidation problems. Accelerated long term forgetting (ALF) is the idea that 
affected patients have normal memory over a short period but a problem with slow 
consolidation that means they forget things more quickly over days to weeks than 
other people. This would not be identified by standard memory tests and is thus 
another possible explanation for the discrepancy between subjective and objective 
assessment that will be discussed in detail in the next chapter. 
 
Another problem is with interpreting memory complaints, in that a person might 
feel they have a good memory for some things (eg faces) but poor memory for 
others (eg directions) and by using a single combined score on a unitary scale these 
variations will be hidden. It has been suggested that some complaints do correlate 
with aspects of performance, but using a single complaint index can hide this 
correlation (Vermeulen et al., 1993). Some studies have split subjective 
questionnaires into subscales such as: absentmindedness, memory for semantic 
structures, retrieval, rote memory and childhood memory (Vermeulen et al., 1993; 
Hendriks et al., 2002). Epilepsy patients have been found to have particular 
complaints in retrieval, memory for semantic structures and absentmindedness, 
suggesting their biggest problems compared to controls reflect absentminded 
behaviour and memory for complex meaningful information (Hendriks et al., 2002). 
However, while studies employing a single overall measure to assess subjective 
memory complaints often find no correlation with performance (Blake et al., 2000; 
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Andelman et al., 2004), studies using more detailed subjective assessment covering 
separate memory domains and also other relevant cognitive functions have also 
identified no correlation with objective memory performance (Baños et al., 2004). 
 
The level of cognitive demands in daily life have also been proposed as a potential 
modifying factor for memory complaints, as it would seem to follow that more 
demands in daily life would lead to a higher rate of memory failures (Gleissner et 
al., 1998). However, it was found that those with more objective impairment 
generally had lower cognitive demands (probably due to their memory deficits) and 
experienced a perception of greater impairment, so the idea of cognitive demands 
as a variable interfering with subjective-objective correlations is unlikely. 
 
As responding to a questionnaire asking about memory failures is in itself a 
memory task, subjects with better memories might remember a larger proportion of 
their memory failures whereas those with significant memory problems might 
forget them (Vermeulen et al., 1993). This was evident in a study using both 
retrospective and prospective rating of memory, where the prospective ratings 
showed that both patients and controls had underestimated the frequency of 
memory failures in the retrospective questionnaire (Thompson & Corcoran, 1992). 
Those who had most underestimated their memory failures were those who 
reported fewer failures on retrospective questioning, suggesting that those with 
more memory failures might be the least likely to report them. In some studies the 
opinions of relatives and friends of the patients‟ memory problems are also 
assessed, to investigate whether they are better correlated with objective 
performance. However, these findings have been inconsistent, one study finding 
patients to be more accurate with relatives underestimating memory problems 
(Helmstaedter & Elger, 2000) and one finding relatives to be more accurate 
(McGlone, 1994). 
 
In controls, correlations have been found between memory complaints and 
performance where there is none in patients (Piazzini et al., 2001), which would 
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suggest that the lack of correlation in patients is not merely due to methodological 
flaws in study design. It is clear that there are a number of potential methodological 
flaws but if there are still correlations between controls‟ complaints and 
performance then it would follow that there are other epilepsy or disease related 
factors influencing the relationship as well. 
 
ii) Other cognitive problems causing memory complaints 
Complaints of poor memory may also be due to other problems, for example 
patients may interpret cognitive problems such as visuo-spatial difficulties, 
attention and concentration problems or language difficulties as a memory problem 
(Hall et al., 2009). Batteries incorporating testing of various domains allow for this 
possibility to be excluded. It has been observed that mild language difficulties are 
present in patients with TLE complaining of memory difficulties (Mayeux et al., 
1980), and Helmstaedter and colleagues found language functions (including verbal 
fluency, vocabulary and confrontation naming) to predict nearly 30% of variation in 
memory complaints, verbal fluency being the strongest predictive factor in 
subjective memory scores (Helmstaedter & Elger, 2000). This suggests that language 
performance is important for subjective reporting of memory difficulties, and may 
explain some of the discrepancy, but there must be other factors involved as well. 
There have been studies demonstrating that attention and concentration deficits, in 
contrast, demonstrate little or no correlation with memory complaints (Vermeulen 
et al., 1993; Piazzini et al., 2001; Baños et al., 2004). 
 
iii) Interference with self-monitoring of memory 
It may be that epilepsy itself interferes with self-perception of memory (McGlone & 
Wands, 1991), or that other factors like mood and psychological factors could 
interfere with memory perception. As well as the well-documented relationship 
between mood and objective memory discussed in the previous chapter, mood can 
also have a significant impact on subjective memory reporting. In many of the 
studies examining the relationship between complaints and performance, it is noted 
that patients with epilepsy have significantly higher levels of anxiety and 
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depression than the controls (Giovagnoli et al., 1997; Piazzini et al., 2001; Andelman 
et al., 2004), and a number of studies have examined the relationship of anxiety and 
depression to memory complaints.  
 
When the correlation between mood and subjective memory is compared to that 
between objective and subjective memory, mood (or anxiety and depression) is 
found to correlate better than any objective memory measures with complaints 
(Giovagnoli et al., 1997; Elixhauser et al., 1999; Piazzini et al., 2001; Au et al., 2006; 
Maarika et al., 2009). When regression is used to calculate the influence of various 
factors on subjective complaints, psychosocial or emotional factors account for up to 
58% of variance, and a greater proportion of variance than any objective 
neuropsychological measures (Piazzini et al., 2001; Baños et al., 2004; Au et al., 2006; 
Butler et al., 2009). This impact of mood on the relationship between cognitive 
complaints and performance has also been demonstrated in other chronic 
conditions, such as multiple sclerosis (Maor et al., 2001) and following head injuries 
(Lannoo et al., 1998). There is evidence for a stronger relationship between memory 
complaints and depression and anxiety, than there is between memory complaints 
and objective memory performance, but there are other factors that are also 
important, and the relationship is still neither simple nor clear. 
 
Neuroticism has also been suggested to influence memory complaints – it has been 
shown to explain around 20% of variance in memory complaints (Vermeulen et al., 
1993) and correlate significantly but not overwhelmingly with cognitive complaints 
(Hendriks et al., 2002). Neuroticism may predispose some individuals to attach 
significance to commonplace forgetting – misinterpreting it as deteriorating 
memory function, as it has been suggested that there is an inverse relationship 
between neuroticism generally and subjective cognitive complaining, not just in 
people with epilepsy (Cañizares et al., 2000). 
 
Chronic disease rather than epilepsy-specific factors might account for some of the 
variance, due to limitation of activities and social and economic stresses leading to 
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negative self-evaluation, which could lead patients to overestimate memory 
problems (Vermeulen et al., 1993). The ways in which people represent and respond 
to their experiences with chronic illness can be quite different depending on their 
knowledge, their coping mechanisms and their health outcomes, and the Common 
Sense Model (CSM) of illness representation can be used to investigate people‟s 
adjustment to chronic conditions (Leventhal et al., 1998). If we can better understand 
the ways people view and respond to epilepsy it might allow for better 
understanding of the formation of beliefs about memory difficulties. 
 
The CSM suggests that people derive their personal representation of their illness 
from both internal and external information (ie their own perception of personal 
experiences and also information from significant others), and it may be conscious 
or unconscious, have more than one level or aspect, and change over time with 
adapting circumstances and experience (Leventhal et al., 1998). Coping strategies 
are employed and their effectiveness evaluated by feeding back through experience 
to affect the illness representation. It has been shown that certain coping strategies, 
particularly avoidance and emotionally-focussed strategies, are associated with 
perceiving a disease as highly symptomatic with serious consequences (Hagger & 
Orbell, 2003). So, theoretically, difficulty coping with epilepsy and the use of these 
mechanisms could mean patients perceiving their disease as highly symptomatic 
and overstating memory difficulties. There may also be an element of attentional 
bias, whereby once a person knows they have a condition they are particularly alert 
to anything associated with that condition (Hall et al., 2009). 
 
It seems that mood and other psychosocial factors might have quite an important 
impact on subjective memory reporting, and seem to explain some of the 
discrepancy between objective performance scores and subjective complaints. 
However, these issues do not explain all of the variance so the discrepancy is likely 
to be due to a number of factors interacting with one another. If these discrepancies 
between performance and complaints are true discrepancies as it appears, it is 
important that objective functioning, subjective functioning and mood are all 
assessed separately, as the constructs are related but independent, and all are 
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different aspects of a patient‟s functioning and important for their quality of life and 
the impact of disease (Elixhauser et al., 1999). 
 
One of the possible reasons for a failure of neuropsychological assessment to 
identify actual memory deficits is accelerated long term forgetting, which will be 
discussed further in the next chapter. 
 
    67 
Chapter 6  Accelerated long term forgetting 
 
 
6.1 Background 
 
As discussed in the previous chapter, objective measures of memory performance 
often do not correlate with subjective memory complaints in patients with epilepsy, 
and as unexplained complaints are a worry for both patients and clinicians, it is 
important to try to explain these discrepancies. As discussed, it is likely that there 
are a number of contributing factors that influence reporting of memory problems, 
such as mood and psychological wellbeing, but it has also been proposed that there 
is actual memory impairment that is not identified by standard neuropsychological 
tests. One possible reason for this is that the standard length of delay tested is too 
short, and there may be a problem, termed „accelerated long term forgetting‟ (ALF) 
with retention or consolidation of memories over days to weeks while memory over 
a delay of 30 minutes is unimpaired. 
 
Accelerated long term forgetting shows a different pattern from the typical amnesic 
syndrome, when patients would characteristically demonstrate impaired recall and 
recognition of information presented within seconds, so long as rehearsal is avoided 
by distraction. This initial impairment does not increase after the first few minutes 
(Isaac & Mayes, 1999). In contrast, patients studied with ALF demonstrate 
unimpaired memory at initial testing and after a 30 minute delay, with forgetting 
accelerating after this time. 
 
A number of case reports first emerged of epilepsy patients with this interesting 
pattern of memory impairment, in those with various aetiologies of epilepsy 
including closed head injuries and paraneoplastic limbic encephalitis, tending to be 
quite severe individual cases (Kapur et al., 1996; Kapur et al., 1997; O'Connor et al., 
1997; Mayes et al., 2003). A number of group studies have since been undertaken 
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(Bell, 2006) 25 patients with cryptogenic TLE  
25 healthy controls ‘loosely’ matched 
for age, education, sex and 
handedness 
 
Verbal (story) recall and 
recognition 
Logical memory story subtest -
WMS-III 
 
30 minutes, 2 weeks Patients performed generally worse than 
controls at all measures but no evidence of 
accelerated forgetting 
Reference Participants Measures for long term 
memory assessment 
Time delay Findings  
(Butler et al., 2009) General: 41 pts with TEA identified 
by TIME project 
20 healthy controls matched by age 
and education 
ALF: Long term forgetting tested in 
subgroup of 22 patients and 20 
controls 
Verbal (story and word list) and 
non-verbal recall 
average z score across  
-15 words from Rey Auditory 
Verbal Learning Task,  
-Rivermead Behavioural Memory 
Test, 
-7 designs from Graham-Kendall 
Memory for Designs test 
 
30 minutes, 1 week, 3 
weeks  
Combined z-score showed ALF in patients 
Long term forgetting had no relation to 
volume of medial temporal structures or 
standard measures of anterograde memory 
 
(Butler et al., 2007) General: 50 patients with TEA (TIME 
study) overall 
ALF: subset of 24 TEA patients (with 
normal performance on standard 
memory tests and no cognitive 
deficit) and 24 pair-wise matched 
(age and education) controls 
 
Verbal (word list) and non-verbal 
recall 
15 words from Rey Auditory 
verbal learning task 
7 visual designs from Graham 
Kendall memory for designs test 
 
30 minutes, 1 week, 3 
weeks  
Verbal: Patients’ recall worse at 30 mins and 
declined significantly more by 1 week than 
controls. Little further change by 3 weeks 
Non-verbal: No difference between patients 
and controls at 30 minutes, patients 
significantly worse at 1 and 3 wks 
 
(Davidson et al., 
2007) 
21 children with IGE aged 8-16  
21 healthy controls matched for age 
and IQ 
Verbal (story) recall and 
recognition and non-verbal recall 
Childrens’ Memory Scale – stories 
and dot locations subtests 
 
30 minutes, 7 days Verbal: Patients poorer at initial learning, but 
no significant group difference at 30 minutes, 
patient group significantly worse at 1 week at 
recall (no difference at recognition) 
Non-verbal: No significant differences, but 
trend to patients being worse at initial trials 
needed and recall at 1 week 
 
Table 6.1: Summary of studies assessing long term forgetting in patients with epilepsy 
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(Mameniskiene et 
al., 2006) 
70 patients with TLE  
59 healthy controls age matched 
(patients had less education) 
Verbal (story and word list) and 
non-verbal recall 
Rey Auditory Verbal Learning Test 
(RAVLT) (Lithuanian equivalent) 
Immediate and delayed recall of 
short verbal logical story (VLS) 
Rey-Osterrleith complex figure 
test  
 
30 minutes, 4 weeks Patients scored significantly worse on all short 
and long term measures with higher  
percentage forgotten over 4 weeks 
Those who had seizures between visits 
performed worse at second visit despite 
similar immediate and delayed results.  
 
(Bell et al., 2005) 42 patients with TLE and lateralised 
seizure onset 
49 healthy controls matched to age, 
education and gender (but with 
higher IQ than patients) 
 
Verbal (word list) and non-verbal 
recall 
12 word list - Selective reminding 
test procedure  
12 geometric figures – Selective 
reminding test procedure 
 
30 minutes, 24 hours Verbal: Both R and L TLE patients significantly 
worse than controls, but no difference 
between groups in rate of loss between tests 
Non-verbal: R and L TLE patients significantly 
worse than controls, but no difference 
between groups in rate of loss between tests 
(Manes et al., 2005) 7 patients with TEA  
7 healthy controls matched to age 
and estimated premorbid IQ (NART) 
 
Verbal (story) and non-verbal 
recall and recognition 
Logical memory story recall and 
recognition  
Visual reproduction of designs: 
recall and recognition  
 
30 minutes, 6 weeks 
 
 
Verbal: No significant difference between 
groups at 30 minutes, with significant drop in 
both groups by 6 weeks but significantly 
worse in patients 
Non-verbal: No evidence of accelerated 
forgetting 
 
(Blake et al., 2000) 23 patients with partial epilepsies  
19 healthy controls matched to age, 
education and IQ  
Verbal (story) recall and 
recognition 
1 of 2 stories from Adult Memory 
and Information Processing 
Battery  
 
30 minutes, 8 weeks No difference between groups in initial 
learning or recall at 30 minutes, patients 
significantly poorer on recall and recognition 
of story at 8 weeks 
 
(Giovagnoli et al., 
1995) 
28 patients with cryptogenic TLE 25 
healthy controls ‘loosely’ matched to 
age, socioeconomic level and 
profession  
Non-verbal recall 
10 abstract designs - Selective 
Reminding test procedure 
1 hour, 1, 3, 6, 13 days  No significant difference between groups at 
delayed recall scores 
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(Martin et al., 1991) 21 TLE patients post unilateral 
anterior temporal lobectomy (n=6) 
or candidates for surgery (n=15) 
21 healthy controls matched to 
education but not age or IQ 
 
Verbal (word list) recall and 
recognition 
12 word list - Selective Reminding 
Test procedure 
30 minutes, 24 hours No difference between groups initially or at 30 
minutes, patient group had significantly 
poorer recall over 24 hours. No difference in 
recognition 
(Wilkinson et al., 
under review) 
27 pre-surgical TLE patients with 
hippocampal abnormality  
(n=15 left-sided abnormality,  
n=12 right-sided abnormality) 
22 healthy controls matched to age, 
gender and IQ (NART) 
Verbal (story) and non-verbal 
recall 
Adjusted version of logical 
memory story from WMS-III 
Rey-Osterreith complex figure 
test 
1 hr, 6 wks Verbal: At 1 hour, L sided patients significantly 
poorer recall, after 6 weeks both patient 
groups significantly poorer than controls 
Non-verbal: At 1 hour R sided patients 
significantly poorer recall, at 6 weeks both 
patient groups significantly poorer than 
controls 
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over a range of intervals, some providing more evidence than others for ALF. These 
are summarised in Table 6.1 and a brief description of each will be given to give an 
idea of the level of information currently available. 
 
6.2 Papers with evidence of ALF 
 
Martin et al (Martin et al., 1991) tested 21 patients with temporal lobe epilepsy, 
either pre (n=15) or post (n=6) surgery, compared to 21 controls with tension 
headaches.  A Selective Reminding Test of 12 unrelated words was used to assess 
verbal recall and recognition at 30 minute and 24 hour delays, whereby a word list 
was learnt over 12 trials until two consecutive trials were correct, with only the 
words forgotten being prompted each time. This method of selective reminding is 
aimed to avoid the idea of „over-learning‟ (Bell 2005) when all of the material is 
repeatedly presented.  There was found to be no difference between the patients 
and controls in performance on the final trial or in recall at 30 minutes. A group by 
time interaction was found after 24 hours, showing significantly poorer free recall 
performance among patients at 24 hours. There were no group differences found in 
recognition performance over time. The controls had significantly higher mean IQ 
than patients, which could have skewed the results in their favour, so results were 
analysed with IQ as a co-variate which showed that there was still a significant 
group by time interaction not explained by IQ. However, the small group size needs 
to be taken into account when interpreting results as it could mean the study is 
underpowered. 
  
A cohort of 23 patients with partial epilepsies and 19 education and IQ matched 
healthy controls were studied with no significant differences on standard memory 
neuropsychological assessment (Blake et al., 2000). Participants were asked to learn 
one of two stories from the Adult Memory and Information Processing Battery over 
a maximum of ten trials until 90-100% correct (Coughlan & Hollows, 1985). They 
were tested on recall at 30 minutes and recall and recognition at eight weeks. There 
were no differences between patient and control groups at number of trials needed, 
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performance in first three trials, or recall at 30 minutes. Both groups showed 
significantly poorer recall at eight weeks, with patient group significantly worse 
than controls at both recall (p=0.014) and recognition (p=0.047). Within these 
results, left hemisphere patients were also significantly poorer than both controls 
and right hemisphere patients on eight week recall, with no significant difference 
between right hemisphere patients and controls. So accelerated forgetting of verbal 
information was demonstrated in patients with left hemisphere localisation related 
epilepsy. 
 
Accelerated forgetting has been investigated alongside autobiographical amnesia in 
the syndrome of transient epileptic amnesia. A group of seven right handed 
patients with TEA in remission were studied, alongside seven healthy right handed 
controls matched for age and estimated premorbid IQ (Manes et al., 2005). 
Accelerated forgetting was assessed with both an orally presented logical story and 
reproduction of four designs, with recall tested immediately, at 30 minutes and at 
six weeks and recognition tested at 30 minutes and six weeks for both tests. The 
results for logical memory showed no difference between groups immediately or at 
30 minutes in recall or recognition. Both groups showed significant change over six 
weeks in recall, with the TEA group performing highly significantly worse 
(p<0.001) confirming accelerated forgetting of verbal information. Although the 
majority of the patients reached floor level by six weeks, because the control group 
were well spread with none at floor or ceiling it can be considered as a valid result 
demonstrating accelerated forgetting. Recognition scores showed no deterioration 
over six weeks in the control group but significant forgetting in the patient group. 
The results for visual reproduction show no data for recall at six weeks because all 
patients reached floor level, but a significant difference between groups‟ recall at 30 
minutes. Recognition was near perfect in both groups, with some deterioration over 
six weeks in patients but no significant difference between the groups. Thus, the 
visual reproduction part of the assessment did not provide very useful results as 
recall was too near floor and recognition too near ceiling levels, despite the positive 
results in the verbal component. 
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The largest study so far into accelerated forgetting (Mameniskiene et al., 2006) 
looked further into the relationship between long term forgetting and seizure 
frequency. A cohort of 70 patients with TLE was recruited alongside 59 controls 
matched to age and gender (although controls had longer mean time in education, 
more students and less unemployment). Long term forgetting was assessed with a 
word list (equivalent to the Rey Auditory Verbal Learning task) learned over five 
attempts, verbal logical story and Rey-Osterreith complex figure. Recall was tested 
at 30 minutes and after four weeks. Patients were worse than controls on all recall 
measures (immediately, after 30 minutes and after four weeks) apart from complex 
figure copying, with significantly increased forgetting rates over the four week 
delay. Comparing the effect of seizures, those experiencing seizures during the four 
week delay showed significantly increased rates of forgetting of the verbal logical 
story compared to patients who had no seizures. Those with seizures involving 
impaired consciousness showed increased forgetting rates across all measures 
compared to those with no impairment of consciousness. Also patients with four or 
more seizures showed an increased rate of forgetting of the logical story compared 
to those with less than four seizures. Abnormal interictal EEG was also associated 
with increased forgetting on all measures. These results not only seem to confirm 
increased rates of forgetting in patients with TLE but also go further in discussion of 
a mechanism. However, caution should be advised when labelling this increased 
forgetting as the previously described accelerated long term forgetting, because the 
patients not only showed forgetting of a larger proportion of the information but 
also impairment at the initial recall and first delayed recall of information. This 
shows that they did not have intact initial memory, so the faster rate of forgetting 
could merely be demonstrative of a more general memory impairment rather than 
specifically accelerated forgetting. Due to the large numbers and controlling for age 
and gender, as well as the consideration of seizures, this study is one of the most 
robust. 
 
Whether the phenomenon of accelerated forgetting might also be present in 
children with idiopathic generalised epilepsy has also been studied (Davidson et al., 
2007), by testing 21 children with IGE aged 8-16 and 21 control subjects matched to 
age and IQ. Assessment involved use of the Stories and Dot locations subtests of the 
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Children‟s Memory Scale (Cohen, 1997) to assess verbal and visuospatial memory, 
learning to 90% and 83% accuracy respectively over up to ten trials, with delayed 
recall and recognition tested after 30 minutes and one week. There were no 
significant differences found at 30 minutes but the patient group scored 
significantly worse than controls after one week in story recall, although there was 
no group difference on recognition. On visual recall, there was a trend towards a 
difference after one week, and no difference after 30 minutes, but no significant 
difference and no difference on recognition. These results are suggestive of 
accelerated forgetting, especially of verbal material, on recall after a one week delay 
in children with IGE, suggesting that it is not only patients with temporal lobe 
epilepsy that suffer from this problem. This also has implications for children‟s 
learning and intellectual development. 
 
Butler et al studied patients with transient epileptic amnesia and some of the 
neuropsychological features associated with the condition, including accelerated 
forgetting (Butler et al., 2007). A group of 24 patients were studied with TEA who 
performed normally on standard anterograde memory tests, 12 of whom had 
subjective complaints of accelerated forgetting, and 24 controls matched to age and 
education. A word list from Rey Auditory Verbal Learning Task was presented over 
five to 15 trials until 90% accuracy was reached at free recall (Schmidt, 1996). Recall 
was subsequently tested at delays of 30 minutes, one week and three weeks. The 
same process was undertaken with seven designs from the Graham-Kendall 
memory for designs test (Graham & Kendall, 1968). On the verbal test, there was no 
difference in number of trials taken to reach the criterion, but a small but significant 
difference in 30 minute recall, worse in patients. After one week patients 
experienced significantly accelerated forgetting with little further change up to 
three weeks. On the designs tests, there was no difference in number of trials or 
recall at 30 minutes, but patients‟ performances declined significantly faster over 
three weeks. Notably, when the patient group was split, those with a subjective 
complaint demonstrated significant accelerated forgetting of both words and 
designs, while those with no complaint were no different to controls, despite there 
being no difference between the patient groups on any other neuropsychological 
measure.  
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Butler et al again looked at accelerated forgetting as one of the types of memory 
problem found in patients with transient epileptic amnesia, with a subset of patients 
who were also involved in the 2007 study (Butler et al., 2009). Accelerated forgetting 
was tested in a group of 22 patients with TEA and 20 control subjects. A 15 word list 
(from Rey Auditory Verbal Learning Task), seven designs from Graham-Kendall 
memory for designs test and a short prose passage (from Rivermead Behavioural 
Memory Test) were presented over five to 15 trials until recall was 90%. Recall was 
then tested on all three measures, at 30 minutes, one week and three weeks. Long 
term forgetting was calculated as a composite measure across the three tests. There 
was found to be significant accelerated forgetting using the composite measure in 
the patient group compared to controls. This did not correlate with hippocampal 
volumes, seizure variables or any anterograde standard memory measures. 
Accelerated forgetting has been demonstrated to occur in at least a proportion of 
patients with TEA. 
 
Pre-operative temporal lobe epilepsy patients with hippocampal atrophy have been 
studied to assess accelerated forgetting over a six week period, matching 
participants‟ performance on initial recall to assess rate of forgetting more 
accurately (Wilkinson et al., under review). A group of 27 patients and 22 healthy 
controls matched for age, gender and IQ were investigated. Participants were read a 
short verbal story up to five times until 75% was remembered at free recall. They 
were also shown and asked to copy a Rey-Osterreith complex figure, with no 
learning criterion. Recall for both items was tested at one hour and six weeks. There 
was significant group by delay interaction for both tasks, with patients 
demonstrating significantly faster forgetting of both verbal and non-verbal material 
over the six week delay. Patients with left hippocampal atrophy had significantly 
faster forgetting of the verbal test over one hour, and both groups of patients had 
faster forgetting over the six week time delay. In visual testing, patients with right 
hippocampal atrophy performed worse at one hour, but not significantly so. Both 
patient groups showed faster forgetting than controls over the six week delay. 
These results demonstrated a material specific effect of lateralisation of 
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hippocampal sclerosis over a short delay, but increased forgetting over the longer 
period was not associated with pathology. Participants were otherwise well 
matched to controls to avoid condounders, suggesting this is an interesting finding.  
 
6.3 Papers not showing evidence of ALF 
 
Giovagnoli and colleagues (Giovagnoli et al., 1995) assessed 28 patients with 
temporal lobe epilepsy with no detected lesion on CT or MRI and 25 healthy 
controls from clinical staff partly matched to age, profession and socioeconomic 
group. A selective reminding test was administered consisting of ten abstract 
designs, repeated over 18 trials until two consecutive correct trials with recall tested 
at one hour and one, three, six, and 13 days. On initial testing right TLE patients 
were significantly worse than both controls and left TLE patients on all measures, 
with no difference between left TLE patients and controls. All subjects got 
significantly worse over the trials from day one onwards, but there was no group by 
time interaction, and no evidence of accelerated forgetting. Compared to the left 
TLE group and controls, the right TLE group had significantly less schooling, were 
slightly older, and performed less well at Raven Coloured Progressive Matrices 
which estimates abstract reasoning. These discrepancies may bias the results and 
explain why right TLE patients performed worse. 
 
Bell et al (Bell et al., 2005) tried to collect data to assess the possible benefits from an 
extra long term memory assessment, assessing patients on both an individual and 
group level. They studied 42 patients with temporal lobe epilepsy (20 with right 
TLE, 22 with left TLE) and 49 controls matched to age, education and gender 
(although controls had significantly higher IQ). Assessment was auditory (12 item 
word list) and visual (12 geometric figures) using the selective reminding procedure 
up to a maximum of 6 trials, with free recall measured after sixth trial, at 30 minutes 
and after 24 hours. Participants were judged to have memory impairment with a 
score of more than one standard deviation below the control mean. Verbal results 
showed left TLE patients to be significantly worse than controls on immediate, 30 
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minute and 24 hour recall, with no difference in the rate of information lost at either 
delay. There was also no difference in the percentage of patients and controls with 
isolated memory impairment at 24 hours. Similar results were found in the visual 
assessment. This study has demonstrated no evidence of accelerated forgetting, 
suggesting that if it is a real phenomenon found in TLE as previous studies suggest, 
it is not found consistently in all TLE patients. 
 
Bell also investigated forgetting over a longer delay of two weeks in 25 patients 
with TLE (6 post-surgical) and 25 controls matched to age, gender and years of 
education (but with a significantly higher IQ) (Bell, 2006). Participants were tested 
with the logical memory subtest of the WMS-III (Weschler, 1997a), two stories 
presented orally to them, and free recall was tested immediately, after 30 minutes 
and after two weeks. If there was no recall a standard cue was used. Yes/no 
recognition questions were also asked at 30 minutes and two weeks. Again, the 
patients were analysed as a group and individually, and memory impairment was 
judged to be a score greater than one standard deviation below the control mean. 
The TLE patient group was found to perform worse than controls on immediate, 30 
minute and two week delayed recall, but there was no evidence of disproportionate 
forgetting. Patients were also significantly poorer at both 30 minute and two week 
recognition but with no disproportionate rate of forgetting. Individually, more of 
the patients had impaired retention at the 30 minute delay, but not at the two week 
delay, and fewer showed isolated impaired retention at two week delay. Bell again 
failed to find evidence of accelerated forgetting in temporal lobe epilepsy patients. 
56% of the patients had also been included in the previous study, and been shown 
not to exhibit accelerated forgetting over 24 hours. Also, there was no mention of 
whether or not the participants had subjective memory complaints, which have 
been shown to correlate with accelerated forgetting (Butler et al., 2007). 
 
6.4 Problems with designs 
 
One of the problems with both of Bell‟s studies is that the patients and controls had 
significantly different initial recall rates. This can cause a problem for a number of 
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reasons, including scaling, as the higher performing group, the controls, had a 
larger amount of information after initial recall that they could forget. Long term 
consolidation therefore could be affected by a participant‟s rate of learning, 
attention and encoding ability. If more information is encoded into memory, this 
could lead to a greater amount of information available for forgetting. If the controls 
forget the same amount as patients, it will appear that forgetting rates are equal but 
in fact the controls will have forgotten a smaller proportion of the initial 
information. This can lead to an underestimation of the worse performing group‟s 
forgetting, as they had much less to forget. Because of this possibility, it may be 
more effective to ensure that patient and control groups are matched on their levels 
of initial recall.  
 
Many of the other studies got around this problem by having a specific learning 
criterion both groups must reach (eg (Wilkinson et al., under review)), although in 
some cases (Giovagnoli et al., 1995; Bell et al., 2005) this did not work as the patient 
group failed to reach criterion in the specified number of trials. Mameniskiene and 
colleagues bypassed the problem of groups not matching at initial recall by 
investigating the percentage of information initially remembered that was forgotten 
rather than merely the amount of information forgotten (Mameniskiene et al., 2006).  
 
Another problem with the patient group having a poorer memory than controls at 
the initial testing or short delay is that it is difficult to discover the mechanism for 
any problems or increased forgetting rates over the longer delay. If the groups are 
shown to be different in their memory for items at the initial testing session and the 
short delay, this shows a general memory impairment. If the memory at a short 
delay is abnormal then the amount of information retained over a longer period will 
be affected, as impaired encoding and initial retrieval of the information could 
cause problems over a longer delay, as well as consolidation problems. This means 
that poorer recall over a long delay could be interpreted as „ALF‟ when it is merely 
a manifestation of a more global memory impairment. 
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Some of the studies (Martin et al., 1991; Bell, 2006) mentioned above included post-
operative temporal lobe epilepsy patients. These patients, having had at least a 
significant portion of one of their hippocampi removed, will likely have some 
memory problems that may be different from those with intact hippocampi and 
thus could confound the results.    
It has been demonstrated that there are two recall mechanisms present in free recall 
(Glanzer & Cunitz, 1966). The primacy effect is achieved through rote learning 
fixing items in the long term memory and the recency effect is due to short term 
memory. If immediate recall is tested of, for example, a word list, without any 
distraction between presentation of the list and recall, then some of the immediate 
recall will be due to short term memory. This creates a problem when comparing 
immediate and 30 minute recall, as any decay cannot be differentiated between loss 
from long term memory or failure to convert short term to long term memory. 
Because of this, it may be seen to be more useful to perform a short distraction task 
in between presentation and initial recall to ensure that any recall is due to long 
term memory and not due to short term memory and the recency effect. 
 
6.5 Testing procedures and populations 
 
The types of test used to assess different domains of very long term memory vary 
between the studies examined, so the tests used for each domain will be considered 
and the results obtained from them, as well as what this could mean. 
 
Verbal recall and recognition were tested by two main groups of tests: stories and 
word lists. Stories were used in 7 studies (Blake et al., 2000; Manes et al., 2005; Bell, 
2006; Mameniskiene et al., 2006; Davidson et al., 2007; Butler et al., 2009; Wilkinson et 
al., under review), with three testing recognition as well as recall. The story used 
most commonly was one of the logical memory stories in WMS-III, or a modified 
version of it. Also used were the story subtest of the Children‟s Memory Scale, 
stories from the Adult Memory and Information Processing Battery and a prose 
passage from the Rivermead Behavioural Memory Test. Only one of the studies 
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testing verbal recall of a story (Bell, 2006) failed to demonstrate accelerated 
forgetting in patients, using the WMS logical memory story. In those testing 
recognition memory of stories, one found accelerated forgetting over a period of 8 
weeks (Blake et al., 2000) while two found no difference between groups over one 
and two week intervals (Bell, 2006; Davidson et al., 2007). 
 
A word list was used to assess verbal recall in five studies (Martin et al., 1991; Bell et 
al., 2005; Mameniskiene et al., 2006; Butler et al., 2007; Butler et al., 2009) as well as 
verbal recognition in one (Martin et al., 1991). 15 words from the Rey Auditory 
Verbal Learning Task or an equivalent were used in three of these, and 12 words 
from the Selective Reminding Test in the other two studies. Again, accelerated 
forgetting was demonstrated in patients for verbal recall in all studies bar one (Bell 
et al., 2005), but was not found in verbal recognition (although this was only 
examined in one study). Stories and word lists both seem to show similar evidence 
of verbal long term forgetting. 
 
Non-verbal recall and recognition were tested in eight studies (Giovagnoli et al., 
1995; Bell et al., 2005; Manes et al., 2005; Mameniskiene et al., 2006; Butler et al., 2007; 
Davidson et al., 2007; Butler et al., 2009; Wilkinson et al., under review) using a 
variety of tests. The Rey-Osterreith Complex Figure test was used in two, Graham 
Kendall Memory for Designs test in two, visual selective reminding test in two and 
also dot locations subtest from Children‟s Memory Scale and visual reproduction of 
designs subtest of WMS-III. Four found significant accelerated forgetting in patients 
(Mameniskiene et al., 2006; Butler et al., 2007; Butler et al., 2009; Wilkinson et al., 
under review)– mostly using Rey-Osterreith complex figure, one found a trend 
towards accelerated forgetting (Davidson et al., 2007) and three found no evidence.  
 
Thus, accelerated forgetting has been demonstrated in both verbal and non-verbal 
recall, with more evidence in verbal recall, across both story and word list testing. 
So it would seem to follow that testing for ALF would need to look at both verbal 
and non-verbal recall, as there is no strong evidence for one being more affected 
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than the other. Which is more affected is likely to be predicted by the laterality of 
the epilepsy as well, for example verbal memory would be more affected by 
epileptic foci in the left temporal lobe, as demonstrated by Blake et al (Blake et al., 
2000). 
 
The length of time delay used in the studies varies from 24 hours to eight weeks. In 
general, verbal accelerated forgetting seems to be more apparent earlier, from 24 
hours (Martin et al., 1991), apart from in Bell‟s studies where it is not present at all. 
Non-verbal accelerated forgetting seems to be slightly more delayed, eg in Butler‟s 
study with one and three week test points, a trend for ALF is shown in non-verbal 
recall after one week and significant levels after three weeks, whereas significant 
ALF is shown in verbal recall after one week (Butler et al., 2007). Davidson et al, 
testing after one week, also only showed a trend towards ALF in non-verbal recall 
compared to significant ALF in verbal recall (Davidson et al., 2007). There are no 
studies testing over less than three weeks that demonstrate significant non-verbal 
ALF. Considering this, if non-verbal ALF is to be tested I would propose that the 
time delay would need to be at least three weeks from initial testing to a final 
delayed recall test. 
 
Looking at the populations of patients studied, it is clear that there is evidence for 
accelerated long term forgetting in TEA in particular. Patients with TLE or partial 
epilepsies more generally have also been examined with slightly more mixed 
results, four studies showing accelerated forgetting over delays from 24 hours to 
eight weeks and three studies (two of which study largely the same population) 
finding no evidence for ALF. There is also a suggestion that the phenomenon might 
occur in children with idiopathic generalised epilepsy. Mameniskiene‟s study has 
also compared results within TLE patients between seizure types, finding those 
with simple partial seizures to have significantly less accelerated forgetting than 
those with complex partial and secondary generalised seizures during the study 
period (Mameniskiene et al., 2006) 
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6.6 Proposed mechanisms of accelerated forgetting 
 
The mechanism that underlies accelerated forgetting is not fully understood, and it 
is not yet clear how it fits in with previously held theories. As previously discussed, 
the process of remembering can be split into a number of stages: perception, 
encoding, consolidation, storage and retrieval. Squire and Alvarez described two 
processes of long term consolidation – a fast and a slow process, with the fast 
process based in the medial temporal lobe structures including the hippocampus, 
where synapses can change quickly and slow consolidation occurring as the medial 
temporal lobe repeated co-activates the neocortex, where synapses change slowly, 
until connections form within it (Squire & Alvarez, 1995). 
 
It has been proposed that accelerated forgetting is due to a problem with long term 
(slow) consolidation of memories, and that findings of accelerated forgetting 
demonstrate that memories have an extended period of vulnerability. This is most 
likely an extended period of consolidation, compatible with Squire‟s proposal, and 
mesial temporal lobe insult disrupts some crucial aspects of the consolidation 
process (Blake et al., 2000). It is also suggested that the findings are consistent with 
the idea that there are two consolidation systems, fast and slow, as the patients 
showed normal memory at shorter delays, indicating an intact fast consolidation 
system, with only a deficit on longer delays (Blake et al., 2000).  
 
It is claimed that the subjects‟ initial normal performance in the same study shows 
that their results cannot be explained by a deficit in retrieval or encoding. However, 
this is disputed by Davidson et al, who found accelerated forgetting of word recall 
but intact recognition, and claim that the normal word recognition scores suggest 
that ALF must be a problem with retrieval rather than poor retention (Davidson et 
al., 2007). They propose that it is not a consolidation defect unless consolidation is 
redefined in broader terms as „the process of stabilization of the memory trace and 
its maturation into a form suitable for later retrieval‟. The idea that ALF is a 
retrieval problem is not backed up by other studies assessing recognition, as even 
those who found normal recognition deny that this demonstrates a retrieval 
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problem, claiming words can be stored poorly in degraded form (Martin et al., 
1991). 
 
Whatever type of memory deficit accelerated forgetting is, the pathophysiology of 
the process is still unclear. As discussed in Chapter 4, there are a number of possible 
factors that interact to cause memory difficulties in patients with epilepsy. Seizure 
activity is widely proposed as a possible mechanism of disrupting consolidation, 
partially due to reports of patients having fewer memory problems once their 
seizures are controlled on anti-convulsants (eg(O'Connor et al., 1997)). 
Mameniskiene et al‟s results supported this view, demonstrating an increase in 
accelerated forgetting in patients who had seizures during the study, particularly 
complex partial or generalised seizures. They also demonstrated a correlation 
between subclinical epileptiform activity and increased forgetting (Mameniskiene et 
al., 2006). Wilkinson et al also found a significant correlation between seizure 
activity and 6 week forgetting rate (Wilkinson et al., under review). Jokeit et al 
studied forgetting during video-telemetry and found that memory performance for 
new material was related to the occurrence of seizures in the left temporal lobe 
(Jokeit et al., 2001). 
 
However, other studies have failed to find the same correlations. Overt seizure 
frequency has been found to not be related to long term memory performance 
(Blake et al., 2000; Butler et al., 2009), and significant accelerated forgetting has been 
found while none of the patients involved had a seizure during the study period 
(Manes et al., 2005; Butler et al., 2007). It is proposed that these patients with no 
overt seizures could still have subclinical epileptiform activity, disrupting the 
activation of neocortical cell assemblies, and thus interrupting slow consolidation 
(Blake et al., 2000). Butler suggests that, in TEA, because of the relationship between 
TEA attacks and waking from sleep, there could be subclinical epileptiform activity 
occurring during sleep which may disrupt sleep-dependent memory consolidation 
(Butler et al., 2007). 
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Another possible proposed mechanism is a structural abnormality, which may be 
causing both the epilepsy and the accelerated forgetting. It is thought that ALF may 
be a mild form of the amnesic syndrome caused by subtle damage to the medial 
temporal lobes (Butler & Zeman, 2008), as many of the initial case studies that 
emerged demonstrating ALF reported structural lesions in the medial temporal 
lobe. However, no correlation was found between hippocampal atrophy and ALF, 
although this could be due to insensitive techniques (Butler et al., 2009). Wilkinson, 
studying patients with hippocampal abnormalities, found that performance at one 
hour was associated with hippocampal pathology but not performance at 6 weeks, 
again suggesting that there is more than one mechanism of memory problem in 
epilepsy (Wilkinson et al., under review). Indeed, the general absence of 
hippocampal damage is particularly noted to explain why fast consolidation is 
intact in certain studies (Blake et al., 2000). An alternative structural cause of ALF 
has also been proposed – a high rate of ischaemic risk factors was noted among 
patients with TEA (Manes et al., 2005), and three had non-specific vascular changes 
on MRI. It is purported that it may be worth investigating a link between mild 
cerebrovascular disease and accelerated forgetting. 
 
Anti-convulsant medications tend to have some cognitive side effects, and have 
been suggested as a possible mechanism for accelerated forgetting. Jokeit et al 
found high serum levels of anticonvulsants to be associated with poor recall over a 
30 minute delay (Jokeit et al., 2005). However, particularly relating to TEA, most of 
the patients had memory complaints before they were started on treatment, and 
some report improvement in their memory since initiation of treatment (Butler & 
Zeman, 2008). Also, in cases of TEA, the doses of anticonvulsant used are generally 
very low and thus unlikely to cause the types of side effects Jokeit studied. So at 
least in cases of TEA, AEDs are unlikely, although not impossible, to be the cause of 
accelerated forgetting. 
 
Psychological problems can cause memory issues. However, four of the studies 
demonstrating accelerated forgetting also assessed mood with the Hospital Anxiety 
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and Depression Scale and found it not to correlate with forgetting rate (Blake et al., 
2000; Butler et al., 2007; Butler et al., 2009; Wilkinson et al., under review). 
 
 
6.7 Summary 
 
 
In summary, ALF has been demonstrated inconsistently in a variety of populations 
including TEA, TLE and other partial epilepsies and children with IGE. There are a 
number of methodological pitfalls to studying long term forgetting, such as how to 
ensure results over a delay interval that can be comparable, and which domains to 
test over what time period. The mechanisms causing ALF are as confused as those 
involved in any memory impairment in epilepsy, but there is a suggestion that 
seizures or interictal discharges may have an important role by disrupting long 
term consolidation, alongside possibly pathological changes and AEDs. 
 
 
 
ALF has been demonstrated in a variety of groups of patients, but always in those 
with refractory epilepsy, and even some post-surgical patients. A group it has not 
been examined in is those recently diagnosed with epilepsy, where some cognitive 
deficits are demonstrable, as will be discussed in the following chapter. 
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Chapter 7  Cognitive problems in newly diagnosed epilepsy 
 
 
7.1 Background 
 
Cognitive research undertaken in newly diagnosed or recent onset epilepsy 
minimises the confounding variables of duration of epilepsy, lifetime number of 
seizures and AEDs and allows for clarification of the relationship of various factors 
to patients‟ problems. When considered alongside other research, it can also give an 
idea of cognitive progression through epilepsy. To assess the current level of 
evidence regarding cognition in recently diagnosed epilepsy, a systematic review of 
the literature has been undertaken. Studies looking at patients with a diagnosis of 
epilepsy for less than 12 months, comparing patients to controls (or normative data) 
and using objective neuropsychological assessment were included. Studies 
examining childhood-onset epilepsy were excluded as different cognitive problems 
may be caused by the effects of seizures and underlying lesions on 
neurodevelopment, as discussed in Chapter 4. Studies reviewed are summarised in 
Table 7.1. 
 
The results demonstrated by these studies were mixed, with some offering clear 
evidence of cognitive impairments in newly diagnosed patients, some 
demonstrating no difference between patients and controls, and some providing an 
unclear picture of possible or varied impairment. There are a number of problems 
with studying cognitive performance in a population of „newly diagnosed‟ patients 
with epilepsy, which can lead to difficulty drawing conclusions from the data, 
which will be considered in this review. 
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Study Patients Controls Domains assessed Results Methodological issues 
(see key below) 
(Kalviainen et 
al., 1992) 
74 newly diagnosed  
untreated patients 
with single (46) or 
several (28) 
unprovoked seizures 
39 healthy 
subjects  
General intellectual 
functioning  
Verbal ability  
Verbal learning and memory 
Attention and flexibility of 
mental processing  
Simple psychomotor speed 
No differences single vs several seizures. 
Pts worse than controls on memory (imm 
and delayed recall and delayed recognition 
of word list) and attention. 
30% of patients’ scores indicate subtle 
memory and attention dysfunction (>1SD). 
b, e  
(Helmstaedter 
et al., 1993) 
16 newly diagnosed  
untreated patients 
with complex partial 
(CPS) or primary 
generalised seizures 
(PGS) 
19 healthy 
subjects 
Attention  
Visuoperceptual speed 
Verbal fluency  
Memory  
 
CPS patients sig worse than controls on 
sustained attention, verbal learning ability, 
visual retention.  
PGS in between CPS and controls. 
Patients with structural lesion on imaging 
poorer than controls and pts without lesion. 
a, c, e, f, g  
(Pulliainen & 
Jokelainen, 
1994) 
43 newly diagnosed 
untreated  patients  
21 healthy 
subjects  
General Intellectual 
functioning  
Motor speed and coordination  
Visual motor speed  
Attention and concentration  
Memory and learning  
Mood state 
Patients worse than controls on some motor 
speed measures and symbol digit task, 
otherwise no diff. 
Patients more depression and helplessness 
than controls 
 
a, b, c, d, e  
(Äikiä et al., 
1995) 
56 newly diagnosed  
untreated  patients 
with cryptogenic 
partial epilepsy  
 
48 healthy 
subjects  
General intellectual 
functioning   
Verbal memory – story and list 
learning 
 
 
No difference between controls and pts at 
story recall. 
Pts worse on delayed recall of word list (no 
difference learning, immediate recall or 
recognition).  
More pts impaired (>1SD) at delayed recall 
and % retention of word lists (52% pts v 15% 
controls) 
c, e  
Table 7.1: Summary of studies examining cognition in newly diagnosed epilepsy 
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(Kalviainen et 
al., 1995) 
100 newly diagnosed 
untreated patients 
with 2 unprovoked 
seizures or 1 seizure 
and distinct EEG 
 
59 patients 
with single 
seizure, no 
relapse over 
next year and 
no AED 
General intellectual 
functioning  
Verbal fluency  
Verbal memory – story and list 
learning 
Attention and flexibility 
No differences between groups 
 
b, d, e, h 
 
(Gigli et al., 
1996) 
8 newly referred, 
previously 
untreated,  patients 
with clinical and/or 
EEG evidence of 
cryptogenic TLE  
9 healthy 
subjects  
Attention 
Psychomotor speed 
Verbal and visual memory 
 
No significant differences between pts vs 
controls, or Left vs Right TLE patients. 
 
a, c, e, f, g 
 
(Prevey et al., 
1998) 
201 newly diagnosed 
untreated or 
undertreated 
patients with 
secondary 
generalised seizures 
(SGS) (119), or 
complex partial 
seizures (CPS) (82)  
45 healthy 
subjects  
General intellectual 
functioning 
Verbal and visual memory 
Motor speed and integration 
Concentration and mental 
flexibility 
Emotional/personality factors 
 
Control subjects better than pts on 17 of 18 
measures, but not all significant.  
Patients sig worse on memory and motor 
speed / integration. 
SGS worse than CPS measures taxing 
concentration and flexibility 
 
c, d, e, g 
Previously diagnosed 
but undertreated 
patients included 
 
(Aikia et al., 
1999) 
89 newly diagnosed  
untreated patients 
with partial epilepsy 
48 healthy 
subjects 
General intellectual 
functioning  
Verbal immediate and delayed 
memory  - story and word list 
Pts worse at immediate and delayed recall of 
word list than controls 
c, d, e 
(Ogunrin et al., 
2000) 
60 newly diagnosed, 
previously untreated 
patients with 
epilepsy from Nigeria 
60 healthy 
subjects 
Short term memory  
Psychomotor speed 
Sustained attention 
Pts sig worse on all measures except 
response bias on vigilance test 
 
d, b, e 
 
    89 
(Pulliainen et 
al., 2000a) 
52 newly diagnosed 
untreated patients 
with partial (26), or 
generalised (26) 
epilepsy 
26 healthy 
subjects 
General intellectual 
functioning  
Motor function and co-
ordination 
Concentration, attention and 
mental flexibility 
Memory 
 
Patients sig worse on motor speed and co-
ordination and sustained attention, as well 
as delayed figural memory. No differences 
between patient groups. Within patients, 
those impaired have less education and are 
older, with a trend towards more seizures 
and more symptomatic aetiology 
a, e 
 et al., 
2001) 
39 newly diagnosed 
untreated patients 
with left TLE, 16 
patients with chronic 
(>10 yrs) left TLE  
(both groups remote 
symptomatic or 
cryptogenic) 
46 healthy 
subjects 
Verbal intellectual functioning  
Verbal memory  - story and list 
learning 
No differences on story recall. 
Both patient groups worse than controls at 
immediate and delayed recall and % 
retention of word list. Chronic pts most 
affected. 
Individual – 56% new pts impaired (>1SD) on 
delayed recall (vs 17% controls), moderate 
impairment associated with SGS not 
aetiology 
c, d, e, g 
(Aikia et al., 
2006) 
105 newly diagnosed 
untreated patients, 
having had at least 2 
partial seizures (+/- 
GTCS) in last 12 
months 
 
19 Patients 
with single 
seizure not 
requiring AED 
General intellectual 
functioning  
Memory  
Attention, concentration and 
mental flexibility 
Verbal fluency 
Psychomotor speed 
No sig differences between groups in scores d, e, g, h 
(Wesnes et al., 
2009) 
570 newly diagnosed 
untreated patients 
across 21 countries 
Data from 
Cognitive Drug 
Research 
(CDR) system 
normative 
database 
Psychomotor speed,  
Vigilance 
Memory 
Attention and concentration 
Mental flexibility 
 
Pts with epilepsy impaired compared to 
normative database on power of attention 
and visual recognition tasks. Impairments 
more marked with increasing age. 
a, b, c, d, e, g 
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Drawbacks in design: (if not mentioned in report, classed as negative) 
a) Controls not well matched to patients (ie not matched to age and education) 
b) Seizure type not taken into account, either during selection or analysis 
c) Seizure frequency or total number of seizures not taken into account 
d) Presence of pathology not taken into account 
e) Mood not taken into account 
f) Small sample size 
g) Inadequate exclusion criteria for participants (need at least: alcohol/drug misuse, learning difficulties, progressive neurological disease, 
major psychiatric disease) 
h) Control group not neurologically normal
(Taylor et al., 
2010) 
155  newly 
diagnosed untreated 
patients with 
epilepsy  
87 healthy 
subjects  
Psychomotor speed  
Memory 
Information processing 
Mental flexibility  
Mood 
In raw scores, patients worse than controls 
on 10/16 measures. 
Adjusted for age, sex and education: pts 
worse on psychomotor speed, verbal and 
visual memory. 
Between seizure types: generalised worse on 
motor speed 
No influence of seizure history 
Mood not correlated with scores 
a, g 
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7.2 Drawbacks of the research 
 
Potential confounding factors 
There are a number of potential confounding factors present in many studies on this 
topic, which can temper the interpretation of results and make their findings less 
clear than they may seem. These include clinical, demographic or seizure related 
patient factors that could impact on cognitive functioning, and also factors 
concerned with the matching of controls. 
 
i) Matched controls 
The control groups in these studies are very important, because it is their 
performance that is used as a standard with which to compare the patient groups 
and state whether or not they are impaired. Therefore, it is important that controls 
are as well matched to patients as possible, as regards variables that could affect 
cognitive functioning other than seizures or epilepsy. All of the studies have 
patients and controls matched for age, which can clearly affect cognitive 
functioning. Another demographic variable that is generally quoted is gender, and 
the majority of the studies have matched the gender of patients to controls although 
there are two that have not (Pulliainen & Jokelainen, 1994; Gigli et al., 1996).  
 
Years of education, or level of education, is often used as a variable to try to predict 
intellectual ability, as years of education has been shown to correlate with IQ (eg 
r=0.70 (Matarazzo, 1972)) and is identifiable without testing so easier to use when 
recruiting matched controls. A number of the studies have controls matched to 
education level, however there are some where the controls have significantly 
higher levels of education (Helmstaedter et al., 1993; Pulliainen & Jokelainen, 1994; 
Pulliainen et al., 2000a; Taylor et al., 2010) and some where level of education is not 
mentioned (Gigli et al., 1996; Aikia et al., 2006). Where there are unequal levels of 
education between the groups this could explain any cognitive differences, rather 
than any epileptic activity, so a difference might be found between patients with 
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epilepsy and healthy controls where there would be no true difference if the groups 
were well matched (ie a type I error). 
 
In some instances IQ, or verbal IQ, is used as a measure to match patients and 
controls while assessing other cognitive functions for comparative impairment. This 
allows for close matching so that individual functions can be examined in more 
detail, however if epilepsy is thought to impair general intellectual functioning a 
reduced IQ would be expected compared to controls otherwise matched.  
 
Another issue with controls is whether or not they are neurologically normal. They 
will tend to be recruited using the same exclusion criteria as patients (see below) but 
in some studies controls are patients who have had a single seizure (Kalviainen et 
al., 1995; Aikia et al., 2006). If the effects of frequency or number of seizures is the 
focus of investigation, or the effects of AEDs, this is understandable, but patients 
having had a single seizure may have an underlying epileptogenic process so 
cannot be considered neurologically normal. If it is an underlying epileptogenic 
process that causes impairment then they could be affected by that and a finding of 
no difference with patients having had two or more seizures may be a type II error 
and misleading. 
 
ii) Patient factors 
There are a number of variables within patient groups that could affect cognitive 
functioning and not be noted or controlled for in these studies, which could 
therefore affect results giving either type I or type II errors. 
 
The exclusion criteria for patients (and controls) involved in these studies is 
important, as other problems such as severe psychiatric disturbance, alcohol or 
drug abuse or ongoing neurological disease could also affect cognitive functioning 
and the results of neuropsychological assessments. Not all the reports clearly state 
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the exclusion criteria used for each study, but those excluded include individuals 
with major psychiatric issues, mental retardation or learning difficulties, alcohol or 
drug abuse, progressive neurological disease, any previous neurological disease 
that could affect cognition, other major medical illnesses, or acute symptomatic 
seizures. When the exclusion criteria are strict, this suggests that other likely causes 
of cognitive impairment apart from epilepsy or seizures have been minimised, but 
when there are inadequate exclusion criteria there could be other factors interfering 
with cognitive functioning. 
 
There are other seizure-related clinical variables that could affect cognitive 
functioning between patients, such as seizure type, previous seizure activity and 
pathology. The type of epilepsy, whether it is primary generalised or localisation-
related, could have an impact on cognitive functioning. If studies have a mixed 
cohort of patients, or unspecified epilepsy types, there could be a pattern of 
impairment in one group but not the other which would be misleading if all the 
patients are analysed together. Some of the studies have only studied localisation 
related epilepsy (Äikiä et al., 1995; Gigli et al., 1996; Prevey et al., 1998; Aikia et al., 
1999; Aikia et al., 2001; Aikia et al., 2006) and some have assessed cohorts of partial 
and generalised patients separately (Helmstaedter et al., 1993; Pulliainen et al., 
2000a; Taylor et al., 2010). However, some have assessed patients having any type of 
seizure together (Kalviainen et al., 1992; Pulliainen & Jokelainen, 1994; Kalviainen et 
al., 1995; Ogunrin et al., 2000; Wesnes et al., 2009) which could reduce the specificity 
of the results, and the likelihood of finding a true significant impairment. 
 
When epilepsy is localisation related, there are other factors which come into play. 
Whether or not there is a lesion, or any pathological abnormalities on imaging can 
have a significant impact on cognition, as discussed in Chapter 4. In some studies 
the presence of abnormalities on imaging is used as an exclusion criterion 
(Kalviainen et al., 1992; Äikiä et al., 1995; Gigli et al., 1996; Taylor et al., 2010) to try 
and avoid this as a confounding factor, or pathology is taken into account during 
analysis (Helmstaedter et al., 1993; Pulliainen et al., 2000a), but others include 
patients with both cryptogenic and symptomatic epilepsy in one group (Pulliainen 
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& Jokelainen, 1994; Kalviainen et al., 1995; Prevey et al., 1998; Aikia et al., 1999; Aikia 
et al., 2001; Aikia et al., 2006), while others do not comment on any imaging findings 
(Ogunrin et al., 2000; Wesnes et al., 2009). Where these studies are trying to 
investigate the effect of seizures and epilepsy on cognition rather than any 
particular structural lesions, any pathological abnormalities become confounding 
factors that can affect the way the results are interpreted. On the other hand, if the 
aim of the study was to identify cognitive problems associated with epileptogenic 
pathology it would be important to ensure the location and type of lesion was 
consistent between patients.  
 
Where localisation related epilepsy is examined, the probable location and laterality 
of seizure focus could affect the type of cognitive problem, for example a left 
temporal lobe focus could be associated with verbal memory deficits. In the 
majority of studies, even when only partial seizure patients are studied, this is not 
mentioned or controlled for with any extra analysis. There are three studies 
assessing a more specific population of TLE patients (Helmstaedter et al., 1993; Gigli 
et al., 1996; Aikia et al., 2001). The problem with only assessing a more specific 
population is that, while the results may be more accurate for that population, they 
are less generalisable to a population of patients with epilepsy in general. 
 
When deciding whether factors are confounding variables, it is important to keep in 
mind the specific aims of each study. If the aim is to identify whether or not there 
are any signs of cognitive impairment after minimal amounts of seizure activity, 
then it is incredibly difficult to identify suitable participants. Those having partial 
seizures particularly may have years of simple or complex partial seizures without 
realising what they are and present for medical attention following a generalised 
seizure, and even if patients have only generalised seizures they could have 
multiple seizures before one is witnessed or it is clear that they are seizures. Once a 
patient presents, a diagnosis of epilepsy would not generally be made until at least 
two seizures have occurred, so a „newly diagnosed‟ patient will have had at least 
two seizures, likely more, as well as interictal epileptiform discharges. The total 
number of seizures, or previous seizure activity, is used in some studies during 
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analysis to see if it has an effect on any cognitive impairment found (Kalviainen et 
al., 1992; Pulliainen et al., 2000a; Taylor et al., 2010), but generally is not used in 
analysis and ignored as a potential confounder. 
 
As has been discussed, mood and psychosocial factors are also important factors in 
both subjective and objective cognitive functioning. Only three of the studies 
reviewed here use a measure to assess the participants‟ mood status (Pulliainen & 
Jokelainen, 1994; Prevey et al., 1998), and only one of these analyses the relationship 
between mood and cognition (Taylor et al., 2010). This is another potential 
methodological flaw, as if there was mood disturbance causing cognitive problems 
(and feelings of depression have been shown to be more common in newly 
diagnosed epilepsy patients than controls (Pulliainen et al., 2000b)) and mood was 
not assessed, the cognitive problems could be attributed to epilepsy. 
 
AED use is another potential confounding factor in cognitive studies in epilepsy 
patients, but in these studies all of the participants have been assessed before the 
start of AED treatment, so that is one major factor avoided and ruled out by the 
study designs. 
 
Limitations in study design 
The gold-standard study design for minimising bias is a randomised controlled 
trial, but that would not be appropriate to address the questions asked in these 
studies, as an observational study is needed. Ideally, a prospective study carrying 
out neuropsychological assessment with people before their first seizure and 
following any seizures would allow for investigation of the cognitive effects of 
seizures and the early stages of epileptogenesis. However, as this would require 
seeing a huge number of healthy people to catch enough having seizures to draw 
conclusions it is an unrealistic aim, and retrospective studies of patients recruited 
from presentation are far more manageable. Longitudinal studies are able to give 
information about the progression of cognitive functioning from diagnosis, which 
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would seem to be more useful than a snapshot from a cross-sectional study. A 
number of the reports reviewed are part of a longitudinal study, for instance 
assessing the effects of various AEDs, but only the baseline scores have been 
considered for the purposes of this review. 
One of the major issues in any clinical research is the number of participants 
involved, and the statistical power that provides for reporting findings. It is likely 
that if cognitive impairment is present from diagnosis in some patients with 
epilepsy, it will only be in a subset of patients (Kalviainen et al., 1992) and will vary 
person to person. This means that in small studies differences may appear non-
significant if only a few patients are impaired, or likewise be exaggerated if a 
sample contains many such patients, so the results need to be considered in the 
context of the study. 
 
The selection of participants for research can often be a situation for introducing 
bias, as it is important that the sample included in the study is representative of the 
population that the results will be generalised to. However when newly diagnosed 
patients are concerned, the vast majority will be diagnosed at clinics by a 
neurologist, regardless of the type or severity of their condition (in contrast to 
chronic patients when neurologists may only see those who have uncontrolled 
seizures), so selection bias in patients is not a major issue. The selection and 
recruitment of controls is not generally discussed in any detail, but merely quoted 
as „volunteers‟. There is a possibility that people who are likely to volunteer for a 
cognitive functioning study might either be those who are particularly worried 
about their cognitive functioning or those who are confident in their functioning 
and are eager to test themselves, so may not be a representative sample of the 
population. It is unclear how this can be minimised whilst acting ethically and not 
coercing people into participating. 
 
Lastly, one of the major problems with reviewing this research is that different 
cognitive processes were examined across the studies, including memory and 
learning, attention and concentration, motor speed and co-ordination, 
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visuoperceptual speed, verbal fluency, reaction times, intellectual functioning and 
mental flexibility. These cognitive functions are diverse and not necessarily 
interrelated, so it is difficult to compare and draw conclusions when research has 
tested different processes. Even within these general functions there is much 
diversity, for example within memory there are many different types of memory, 
thought to rely on different areas of the brain. Therefore it is difficult to directly 
compare results relating to different processes, and this was further compounded 
by the variety of testing methods used for each process.  
 
7.3 Papers identifying impairments in newly diagnosed patients 
 
A number of studies have demonstrated cognitive impairments in patients newly 
diagnosed with epilepsy, which will be considered first. The drawbacks of these 
studies are noted in table 7.1, but the findings will be discussed below. These 
studies assessed a range of populations of seizure patients, some more specific than 
others. Patients diagnosed with any or an unspecified type of epilepsy were 
assessed in three of the studies, only patients with partial onset epilepsy were 
assessed in three of the studies, patients with partial epilepsy were compared to 
those with primary generalised epilepsy in three of the studies and in one study 
patients had had any sort of unprovoked seizure, with or without a diagnosis of 
epilepsy. 
 
A sub-set of those patients having had any unprovoked seizure were found to have 
cognitive impairment compared to controls when memory and attention were 
assessed in patients with a single or several unprovoked seizures before starting 
anti-epileptic drug (AED) therapy, and compared to healthy controls (Kalviainen et 
al., 1992). Subtle memory or attention dysfunction was found in the scores of a sub-
set of patients (around 30%). Patients in general performed worse than controls at 
immediate and delayed recall of a word list, delayed recognition of a word list, and 
some of the attentional measures. Poor memory performance was correlated with 
poor attention, suggesting that the attention impairment demonstrated could lead 
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to memory problems. Within the patients, there were no differences in any of the 
neuropsychological measures tested between those having a single or several 
seizures. 
 
Some studies have assessed patients newly diagnosed with any type of epilepsy. 
Pullainen et al found newly diagnosed patients with epilepsy performed worse than 
controls on some motor speed tasks and a visual motor speed task, quite a limited 
range of impairment considering the extensive testing (Pulliainen & Jokelainen, 
1994). A Nigerian population of newly diagnosed untreated epilepsy patients were 
found to have slower reaction times than controls, poorer attention, and perform 
worse at both verbal and visual memory than controls.(Ogunrin et al., 2000). Any 
correlation between attention and memory was not discussed, but attention deficits 
could affect memory performance, as demonstrated previously (Kalviainen et al., 
1992), and the type of memory tested was immediate memory which might be 
worst affected by attention problems. This generalised pattern of impairment is the 
most diffuse and extensive demonstrated yet, perhaps reflecting the wide range of 
patients studied. Newly diagnosed patients have also been found to be impaired on 
attention and visual recognition tasks, with impairments becoming more marked 
with increasing age in a large international study (Wesnes et al., 2009). The problem 
with this trial was that no controls were assessed, so patients‟ results could only be 
compared to a normative database. This means that only their performance on 
certain tasks can be judged, so impairments could easily be missed. These studies 
on any type of epilepsy patient show a mixed range of impairments, perhaps due to 
the mixed cohort. 
 
Some studies have focused on slightly more specific groups of patients, such as 
those with partial onset epilepsy. Newly diagnosed cryptogenic partial epilepsy 
patients have been found to be significantly poorer at delayed recall of a word list 
(Äikiä et al., 1995), with no differences on recall of a story, or immediate recall of a 
word list. This seems to show a specific impairment in delayed recall of unrelated 
verbal material. Newly diagnosed partial epilepsy patients generally have also been 
shown to be impaired at both immediate and delayed recall of a word list, but not a 
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story(Aikia et al., 1999). Interestingly, patients who would later become refractory to 
treatment performed worse overall than those who would be controlled by 
treatment, suggesting that memory impairment at diagnosis is a potential predictor 
of seizure outcome. As these studies were done on a relatively specific population, 
it could be that they have been able to identify in more detail a specific deficit. This 
finding is also backed up by another study showing newly diagnosed or untreated 
partial epilepsy patients perform worse than controls at a motor speed task and 
immediate and delayed verbal memory (for a word list), with patients having 
secondary generalised seizures performing worse than those without on some of 
the most taxing measures of concentration and flexibility (Prevey et al., 1998). This 
demonstrates impairment in verbal memory in patients generally with additional 
impairments in executive functions in those with generalised seizures, suggesting 
generalised seizures may have an impact on interictal executive function. These 
studies focusing on partial-onset seizure patients all seem to suggest a similar 
deficit in verbal memory of a word list, particularly delayed recall. 
 
Other studies have compared groups with different types of seizure onset. Patients 
with complex partial seizures have been found to perform significantly worse than 
controls on measures of sustained attention, verbal learning ability and visual 
retention, while patients with primary generalised seizures performed in between 
the controls and those with complex partial seizures (Helmstaedter et al., 1993). 
Again, a correlation between attention and memory was not mentioned but 
impaired attention could have impacted on memory scores. In this study, patients 
with a structural lesion on imaging were found to perform worse across nearly all 
domains than patients without a lesion. Newly diagnosed patients with no 
structural lesions have been found to perform significantly worse (following 
adjustment for age and education) than controls at finger tapping, motor speed, 
figure recognition, immediate and delayed recall of a word list and immediate recall 
of a story (Taylor et al., 2010). Analysis to identify differences between epilepsy 
types found that those with primary generalised epilepsy performed worse than 
those with partial epilepsy at motor speed. In another study, when those with 
newly diagnosed partial and generalised seizures were investigated, patients did 
not differ in cognitive or motor measures according to seizure onset, but performed 
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generally worse than controls in visual motor tasks, mental flexibility and delayed 
visual memory (Pulliainen et al., 2000a). Risk factors for impairment within the 
patient groups were also investigated, finding that abnormal imaging findings, 
higher age, lower level of education and higher total number of seizures correlates 
with worse concentration and memory performance. 
 
In summary of the studies with positive findings, a wide range of cognitive deficits 
have been demonstrated in patients newly diagnosed with a variety of epilepsy 
types. Studies assessing patients newly diagnosed with any epilepsy type have 
results varying from impairments solely in motor speed to global cognitive 
impairment. These disparate results may reflect the differences in testing 
procedures, or the wide variety of patient populations studied, but it is fair to say 
that some form of cognitive impairment has been demonstrated in each case. With 
such a wide population to assess, it is unsurprising that there is such variance 
between results. 
 
Research assessing more distinct populations was able to identify more specific 
impairments. Studies assessing partial seizure patients identified impairments 
particularly in delayed, but also immediate verbal memory. None of these studies 
commented on the localisation of the epilepsy but the most common type of partial 
epilepsy is temporal lobe epilepsy, which has a clear association with memory 
deficits. When comparing patients with partial to generalised onset seizures, no 
significant differences were found, apart from one finding of slower motor speed in 
generalised seizure patients. When comparing those with complex partial seizures 
and those with secondary generalisation it was shown that the latter had more 
problems with concentration and mental flexibility. One consistent finding has been 
that patients with a structural lesion or abnormal imaging have worse cognitive 
performance (although the domains affected likely depend upon the location of the 
lesion). 
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7.4 Papers failing to identify impairments in newly diagnosed patients 
 
There are some studies which have failed to identify any cognitive impairment in 
newly diagnosed patients. When patients having had 2 unprovoked seizures or 1 
seizure and an abnormal EEG were assessed, there were found to be no significant 
difference in intellectual functioning, verbal fluency, verbal immediate and delayed 
memory for a word list and a story, or attention and flexibility when compared to 
controls who had a single seizure with no relapse over the next year (Kalviainen et 
al., 1995). Newly diagnosed partial epilepsy patients were also found to be not 
different in intellectual functioning, verbal memory of a word list and story, visual 
memory, attention, mental speed, verbal fluency or reaction times from a control 
group having had a single seizure (Aikia et al., 2006). However, in both of these 
studies the controls had also had a seizure, so as discussed previously they are not 
neurologically normal so the results need to be interpreted with caution. 
 
Gigli et al also found no significant difference between confirmed cryptogenic TLE 
patients and healthy controls, assessing verbal memory, attention, reaction time and 
recognition of words and dots (Gigli et al., 1996). The baseline results showed no 
significant difference between patients and controls on any measure, or between 
right and left TLE patients. However, due to the small sample size it is difficult to 
draw firm conclusions from this. Also, the volunteer controls were matched to the 
patients by age but no other measures, so many other factors could have influenced 
their performance on the tests. 
 
7.5 Discussion  
 
Despite the difficulties with confounding factors and study design, there are some 
conclusions that can be drawn from the reports presented. The weight of the 
evidence, as it stands, supports the idea that at least a proportion of patients with 
epilepsy have some form of cognitive impairment from diagnosis. The evidence is 
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neither overwhelming nor universal and often mixed as to the nature of the deficit, 
but there are a few clear points which are reinforced between studies. Firstly, partial 
epilepsies in particular seem to be likely to be associated with a verbal memory 
deficit, most commonly in delayed recall of a word list. This could suggest a 
problem with encoding from short to long term memory, with retrieval, or with 
consolidation. Secondly, patients who experience generalised seizures might be 
more likely to have difficulties with executive functions such as concentration, 
mental processing and motor speed. Thirdly, the presence of a structural lesion 
seems to be associated with greater cognitive impairment, although in studies 
examining only those without structural lesions (eg (Taylor et al., 2010)) deficits 
were still evident. 
 
As cognitive problems have been identified from diagnosis in adult patients before 
the start of anti-epileptic treatment, there are implications for the understanding of 
cognitive problems in epilepsy. As mentioned previously, a number of factors are 
considered important regarding the development of cognitive impairments in 
epilepsy, including anti-epileptic medications, underlying aetiology, repeated 
seizure activity and psychosocial issues. The findings of problems before the use of 
anti-epileptic medications means that these cannot be entirely blamed for cognitive 
problems, even if they have some effect later. Smith et al has also found attention 
and motor speed deficits in unmedicated patients with epilepsy (Smith et al., 1986). 
The findings regarding structural lesions demonstrate the impact that aetiology and 
pathology can have on cognitive function, although as impairments were also found 
without these it is clear that this cannot be the only factor. When seizure activity is 
considered, the finding of no impairments in patients compared to controls when 
controls had had a seizure may suggest that the seizure activity may be an 
important factor in cognitive impairment. Also, the findings of cognitive problems 
in adult-onset epilepsy show that problems are not purely related to the 
interruption of neurodevelopment when epilepsy begins in childhood. 
 
As impairments seem to be present in patients without structural abnormalities, this 
suggests that underlying epileptogenesis could also have a role in cognitive 
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dysfunction (Hermann, B et al., 2006). Epileptogenesis can be defined as „the 
alteration of a normal neuronal network into a hyperexcitable network in which 
recurrent, spontaneous seizures occur‟ (Badawy et al., 2009a). This can involve 
multiple mechanisms, including abnormality of neuronal structure and 
organisation, ion channel dysfunction and disturbances in network function. 
Alterations such as axonal sprouting, network reorganisation, or changes in 
neurotransmitters can lead to the predisposition to have recurrent seizures (Badawy 
et al., 2009a; Badawy et al., 2009b), and these changes could also potentially 
contribute to cognitive dysfunction. 
 
Another factor not really addressed so far is the possible impact of psychological 
wellbeing on cognitive functioning. As discussed, whilst some of the studies used 
some form of mood assessment as part of their protocol (Pulliainen & Jokelainen, 
1994; Prevey et al., 1998; Taylor et al., 2010) the majority did not relate them to 
neuropsychological performance. Patients have been found, between the studies, to 
have more depression, helplessness, tension and confusion and less vigour than 
controls. Both mood and a perceived loss of control has been demonstrated to 
correlate with subjective cognitive complaints after a first seizure (Velissaris et al., 
2009), although not with attention or processing speed. Mood is generally thought 
to correlate better with subjective than objective cognitive complaints (as discussed 
in Chapter 5), demonstrated here by a lack of correlation between mood scores and 
results on neuropsychological tests in the studies reviewed. A study analysing the 
results from a group of patients and controls assessed in one of the reviewed 
reports (Pulliainen et al., 2000a) has also looked at the relationship between 
depressive or other negative mood states and cognitive functioning in newly 
diagnosed patients (Pulliainen et al., 2000b). It was found that just one motor speed 
measure was correlated with depression and negative mood, so despite a higher 
rate of depression, bewilderment and lack of vigour than controls newly diagnosed 
patients cognitive problems cannot be explained by psychological factors. 
 
The results from these studies are interesting for the understanding of cognitive 
impairments in epilepsy, but the evidence is neither universal nor overwhelming, 
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and there are a number of confounding factors and methodological flaws that are 
difficult to limit. More research is needed in this field, preferably with consistent 
use of testing procedures for comparisons. Future research could focus on specific 
groups of patients, as this is more likely to bring focussed clear results, when 
compared to well matched healthy controls. 
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Chapter 8  Study aims and objectives 
 
 
8.1 Aims 
 
The aim of this research is to investigate memory functioning in newly diagnosed 
patients with localisation related epilepsy, particularly looking at long term 
forgetting: 
 To identify if there is any evidence of accelerated forgetting in newly 
diagnosed patients with localisation related epilepsy 
 To identify differences between rates of forgetting in recall and recognition 
 To identify differences in rates of forgetting between verbal and visual 
memory 
 To identify any correlation between subjective memory complaints, objective 
memory performance (both initial and over a long delay) and mood 
 To examine the relationship between seizure related variables and 
neuropsychological performance 
By identifying these differences in forgetting rates we hope to be able to gain further 
insight into the mechanisms of previously unidentified memory problems in 
epilepsy. This study will be unique as we will be assessing newly diagnosed 
patients, so we will be able to give an idea as to whether ALF might be present from 
early in the course of epilepsy, or whether it develops over time, which again will 
help to identify the mechanisms involved. 
 
8.2 Hypotheses 
 
With the aim above in mind, the following hypotheses have been developed: 
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1. Accelerated forgetting of a) verbal recall, b) verbal recognition, c) visual 
recall and d) visual recognition will be present in at least a subset of patients 
with newly diagnosed localisation related epilepsy compared to controls 
2. Initial forgetting rates will be correlated with standard memory test scores, 
but long-term forgetting rates will not 
3. Patients newly diagnosed with localisation related epilepsy will have higher 
rates of subjective memory complaints than controls 
4. Long term forgetting rates will be a better predictor of subjective memory 
complaints than standard neuropsychological tests  
5. Patients newly diagnosed with localisation related epilepsy will have higher 
rates of anxiety and depression than controls 
6. Measures of depression and anxiety will be a better predictor of subjective 
memory complaints than standard neuropsychological tests  
7. Seizure / epilepsy related factors 
 Patients with secondary generalised seizures will have worse 
neuropsychological performance and higher rates of long term 
forgetting than those having complex or simple partial seizures and 
controls 
 Patients with a greater total number of seizures will have worse 
neuropsychological performance and higher rates of long term 
forgetting than those having fewer seizures 
 Patients with an abnormality found on MRI will have worse 
neuropsychological performance and higher rates of long term 
forgetting than those with no abnormality 
 Patients having a seizure during the delay between initial assessment 
and follow up will have worse rates of forgetting than those not 
having a seizure during the delay 
 
    107 
Chapter 9   Methods 
 
 
9.1 Design 
 
In order to fulfil these aims, a quantitative cohort study will be conducted, studying 
two populations: patients with recently diagnosed localisation related epilepsy and 
matched healthy controls. The control group was needed as the assessments used 
are not standardised, and it was necessary to show that poor performance was due 
to true impairment rather than test difficulty. The control group were matched to 
patients by age, gender and years of education on an individual basis, as close as 
was feasible, as these are variables that might otherwise affect their performance on 
the memory test and cause a type 1 error. 
 
9.2 Participants 
 
Participants were patients recently diagnosed (in the last 6 months) with 
localisation related epilepsy from clinics at the Walton Centre, Liverpool and 
controls. The initial intention was to investigate only patients recently diagnosed 
with temporal lobe epilepsy, but as there have been significant time constraints on 
this study and there were not enough patients being diagnosed with temporal lobe 
epilepsy, it was decided that the inclusion criteria would be widened to patients 
diagnosed with any localisation related epilepsy to try and gather a more useful 
sample size. Diagnosis was based on the clinical judgement of a consultant 
neurologist specialising in epilepsy. Clinical information alongside results from 
EEGs and imaging were gathered where possible, so that this information could be 
used in the analysis of results. 
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Participants were aged 16 to 80, as the neuropsychological tests in this research 
include normative data encompassing this age range. They had English as a first 
language, and full scale IQ of greater than 70 (as measured by WASI – see below), 
so that learning disability or language issues did not confound the 
neuropsychological evaluation. Exclusion criteria were: 
 
 A history of drug or alcohol abuse (more than 50 units of alcohol per week 
regularly at any point in the last five years, or drug abuse)  
 Any major psychiatric disorders (psychiatric diagnoses requiring 
medication)  
 A history of moderate or severe brain injury – this might be defined as 
Glasgow Coma Scale (GCS) of 12 or less (Marion, 1999), but for the purposes 
of this study classification was based on the reports of patients and families, 
who do not know GCS. Other measures of severity include length of coma 
or duration of post-traumatic amnesia (Sherer et al., 2008). In this study, a 
head injury associated with either a period of unconsciousness longer than 
15 minutes or post traumatic amnesia for six hours or more was classed as 
moderate or severe (DWP, 2010). 
 Progressive or degenerative neurological condition 
 Previous neurosurgery 
 
These exclusion criteria were necessary to, as far as possible, avoid confounding 
factors that could affect participants‟ cognitive functioning other than seizure or 
epilepsy variables. 
 
For the patient subgroup, information was also accessed on seizure type, total 
number of seizures, time since first seizure, seizure frequency and current 
medication, alongside any information about abnormalities on imaging or EEG 
reports where possible. Control participants had the same inclusion and exclusion 
criteria as patients, apart from the diagnosis of epilepsy. 
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9.3 Sample size 
 
The primary outcome measure for this study was the proportion of forgetting of the 
verbal logical memory story between 30 minute recall and three week recall. A 
sample size calculation was undertaken based on results found by Wilkinson et al, 
as a similar outcome measure was used in this study, a proportional forgetting rate 
of a logical memory story in patients with temporal lobe epilepsy (Wilkinson et al., 
under review). To achieve power of 80%, and significance level of 0.05, a sample 
size of 21 in each group would be needed to recognise a difference of 0.15 with 
standard deviation of 0.19 (this sample size calculation was done by Dr Stephen 
Lane, Statistician at University of Liverpool). This is a smaller difference than that 
found in Wilkinson‟s study (0.27), but this study was investigating newly diagnosed 
patients so the difference might be expected to be smaller. A difference of 0.15 
might be thought to be a minimum clinically significant difference. Therefore, the 
aim was to recruit a sample size of 21 in each participant group, 42 participants in 
total. 
 
The sample size of the study was limited by the number of people diagnosed with 
localisation related epilepsy during the study period, and as a result it was 
recognised that the study might be underpowered. However, smaller group sizes 
are more acceptable in neuropsychological studies due to the nature of testing very 
specific populations, and many of the studies into this field so far have had small 
group sizes (Blake et al. (2000) n = 23, in Martin et al. (1991) n = 21 and in Bell 
(2006), n = 25). 
 
9.4 Ethical Approval  
 
Ethical approval was obtained from the North West Research Ethics Committee in 
January 2010 (ref: 09/H1001/98). Amendments to the Participant Information Sheet 
and Consent Form were made following the researcher‟s practical experience to 
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provide more accurate information about the assessments, which were approved as 
minor amendments by the Ethics Committee in April 2010. Research governance 
approval was obtained from the Walton Centre NHS Foundation Trust R&D 
Committee. All participants gave written informed consent for their participation in 
the research.   
 
9.5 Recruitment 
 
At the start of the study clinic letters were reviewed from all fast track and new 
patient epilepsy clinics at the Walton Centre in the previous six months to identify 
any potentially suitable patients who had been diagnosed with localisation related 
epilepsy within this time. These patients were then invited to join the study by a 
written invitation letter (see appendix 1), alongside an information sheet explaining 
the purpose, process and possible risks and benefits of the study (see appendix 2), 
and also seen on their next visit to clinic if it was during the recruitment period to 
follow up the invitation.  
 
The author also went through the notes and referral letters for patients who would 
be attending all epilepsy clinics at the Walton Centre each week (including both 
new patient and follow-up consultant clinics and nurse-led clinics) to try and 
identify any potentially suitable patient participants, either recently diagnosed or 
with first or second seizures who might be diagnosed at clinic. If any were 
identified the author sat in on the clinic to see whether they were actually suitable 
and, if so, speak to them about the research and invite them to join the study. The 
author also sat in on all fast track clinics in case a patient was suitable. This 
approach allowed the author to meet many of the patient participants at their initial 
diagnosis and assess them soon after. However, one of the drawbacks in recruiting 
patients at diagnosis is that it is very difficult to know from referrals whether or not 
patients will be diagnosed until they are seen in an epilepsy clinic and a detailed 
history taken, so it was a time-intensive approach that required seeing many 
patients in order to recruit a few. On the other hand, the opportunity to sit in on 
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clinics regularly allowed the author to gain a better understanding of epilepsy 
generally and the wide range of difficulties and problems the disease, its course and 
its treatment causes. 
 
Once recruited, patient participants were asked if they knew anybody without 
epilepsy of a similar age and same gender as them who might be willing to 
participate as a control, and if so to give them an information sheet explaining the 
study so that they could contact the researcher if they wish to participate. Asking 
friends and relatives is a method for recruiting matched controls that has been used 
in a number of studies investigating accelerated forgetting (Blake et al., 2000; Bell et 
al., 2005; Bell, 2006; Butler et al., 2007; Butler et al., 2009). However, largely due to the 
time commitments involved in participating in the study, a number of the patients 
were unable to find people willing to act as controls, so an advert was posted on the 
intranet at the Walton Centre for staff members to volunteer as control participants 
to match to the remaining patients. For each patient, the author aimed to recruit a 
control of the same gender and level of education, and within five years of the same 
age, either through patients or the advert. 
 
9.6 Data Collection 
 
9.6.1 General 
Once the participant had been given all the information and agreed to be involved 
in the research, two assessments – a long (around three hour) first assessment and a 
brief (15 minute) follow-up three weeks later – were arranged  with the participant 
at times that were mutually convenient to the participant and the author. Verbal 
consent was taken when arranging these assessments and written consent for 
participation in the research was obtained at the start of the first assessment, so that 
there was time between arranging and carrying out the assessment for the 
participant to consider their decision and think of any questions they might have. 
The author personally conducted all of the assessments, to ensure consistency of 
assessment and avoid observer bias. Participants were offered the option of having 
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the assessments either in a room in the Clinical Trials Unit at the Walton Centre or 
as home visits. Having all the assessments in the Clinical Trials Unit would ensure 
consistency, and no distractions. On the other hand, a number of people found it 
difficult to get to the Walton Centre and were happier to participate if the 
assessments could be done as home visits. Where this was the case, lone worker 
policy was followed to ensure the safety of the author and it was ensured that there 
was a quiet space in the home with a table and chairs and distractions were 
minimised. 
 
9.6.2 First Assessment 
Table 9.1: Battery of tests administered at the initial assessment 
Test References Cognitive function tested 
Weschler Abbreviated Scale of 
Intelligence (WASI) 
(Weschler, 1999) 
 
General intellectual 
functioning 
Weschler Memory Scale, 3rd 
Edition (WMS-III) 
(Weschler, 1997a) 
 
General memory 
functioning 
Hospital Anxiety and Depression 
Scale (HADS) 
(Zigmond & Snaith, 
1983) 
 
Emotional well-being : 
anxiety and depression 
Memory Questionnaire 
 
(Thompson & Corcoran, 
1992) 
Subjective view of memory 
functioning 
Experimental 
tests 
Logical Memory 
Story A from WMS-
III  
 
 
Long term verbal learning 
and memory 
Visual Scenes Test  Long term visual learning 
and memory 
 
 
The first assessment took between two and a half and three and a quarter hours in 
all participants, varying depending on the speed at which tests were completed and 
how many breaks in between tests participants wanted. Breaks, tea, coffee or water 
were offered between tests within the assessment to ensure that the participant‟s 
performance was not affected by fatigue or boredom. After written consent had 
been obtained, each assessment began with a clinical history (including seizure 
history in patients), to get an idea of the participant‟s current health status and 
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discover any factors (such as alcohol, medication, or previous neurological history) 
that could impact on neuropsychological performance and confound the findings. 
 
Following the history taking, the tests administered at the initial assessment are 
listed above (table 9.1) with a brief description of each following:  
 
a) Weschler Abbreviated Scale of Intelligence (WASI) (Weschler, 1999) 
 
The WASI is an abbreviated version of the Weschler Adult Intelligence Scale- 3rd 
Edition (WAIS-III) (Weschler, 1997b), which is thoroughly validated, with 
normative data and scoring procedures provided in the accompanying manual. 
It consists of four of the subtests of the WAIS-III which can be used to produce 
three index scores of intellectual functioning: verbal (VIQ), performance (PIQ) 
and full-scale (FSIQ).  
 
Two subtests are combined for the verbal score: vocabulary and similarities (see 
table 9.2). The vocabulary subtest comprises asking the participant to define a 
series of words, for which they score zero, one or two depending on how well 
they are able to define each word. The similarities subtest comprises asking the 
participant to explain how two words are alike, and again scoring zero, one or 
two depending on how well they are able to verbalise the similarity. 
Table 9.2: Sample items for verbal subtests of WASI 
Subtest Sample item 
Vocabulary Tell me what PERFORM means 
Similarities In what way are NEAR and DISTANT alike? 
 
Two subtests are combined to give the performance score: block design and 
matrix reasoning. For the block design subtest, the participant is given a number 
of blocks which have some sides all red, some sides all white and some sides 
half red and half white. The time it takes them to copy various designs of 
increasing difficulty using the blocks is measured (see figure 9.1). The matrix 
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reasoning subtest comprises the participant being shown a series of incomplete 
patterns, with a set of five potential options to complete each pattern (see figure 
9.2). The scores from the four subtests are scaled according to age, then 
combined to give the verbal, performance and full scale (FSIQ = all four 
subtests) scores. 
 
Figure 9.1: Example design from WASI: block design subtest 
 
Figure 9.2: Example item from WASI: Matrix Reasoning subtest 
 
It was felt that a rating of intellectual functioning was needed as part of the 
assessment, both to assess differences between patients and controls and to 
identify any correlation between domains of intellectual functioning, memory, 
and long term forgetting. The WASI provides a shortened but thorough method 
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of assessing verbal and performance skills which has been extensively normed 
and validated, so factors such as age are taken into account. 
 
b) Weschler Memory Scale – 3rd Edition (WMS-III) (Weschler, 1997a) 
 
Table 9.3: WMS-III primary indices and the subtests used 
Primary Index Subtests included Description of function tested 
Auditory Immediate Logical Memory I 
Verbal Paired Associates I 
 
Ability to recall information 
immediately after oral 
presentation 
Visual Immediate Faces I 
Family Pictures I 
 
Ability to recall information 
immediately after visual 
presentation 
Immediate memory Logical Memory I 
Faces I 
Verbal Paired Associates I 
Family Pictures I 
Ability to recall both visual and 
auditory information immediately 
after presentation 
Auditory delayed Logical Memory II 
Verbal Paired Associated II 
 
Ability to recall information 
presented orally after a 25-35 
minute delay 
Visual delayed Faces II 
Family Pictures II 
 
Ability to recall information 
presented visually after a 25-35 
minute delay 
Auditory recognition 
delayed 
Logical Memory II recognition 
VPA II recognition 
 
Ability to recognise orally 
presented information after a 25-
35 minutes delay 
General memory Logical Memory II 
Faces II 
Verbal Paired Associates II 
Family Pictures II 
Auditory Recognition Delayed 
total score 
Ability to recall and recognise 
orally and visually presented 
information after a delay 
 
 
 
Working memory Letter-Number Sequencing 
Spatial Span 
Ability to remember and 
manipulate both orally and 
visually presented information in 
short term memory storage 
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The WMS-III provides a general assessment of memory functioning in 
adolescents and adults that has been heavily researched and validated, and co-
normed with the WAIS-III. There are 11 subtests, of which six are primary and 
five optional, which are combined to give eight primary index scores (see table 
9.3). Many of these subtests are administered in two conditions – to assess initial 
recall and delayed recall 25-35 minutes later. 
 
 Logical Memory – Two stories are orally presented to the participant 
(the second one is presented twice) and after each presentation the 
participant is asked to recall as much as they can of the story, as close to 
the same words as they can remember. They are asked to recall both 
stories again after a 25-35 minute delay filled with other subtests, and 
then asked some yes/no recognition questions about the content of each 
story. 
 Faces – a series of 24 photographs of faces are shown to the participant, 
and then another series of 48 photographs of faces (the same 24 plus 24 
new faces). For each face in the second series the participant is asked to 
say whether or not they have seen the face in the first series. After a 25-
35 minute delay they are shown another series of 48 faces (the original 
24 plus 24 different new faces) and again asked to say for each face 
whether or not it was in the first series. 
 Verbal Paired Associates – a list of eight pairs of unrelated words (such 
as badger – paper) are orally presented to the participant, and then they 
are given the first word of each pair and asked for the corresponding 
word. There are four trials of the list of word pairs, with them being 
presented in a different order (but the same pairs) each time. After a 25-
35 minute delay participants are again given the first word of each pair 
and asked for the corresponding word. Recognition of word pairs is also 
tested when participants are asked to report whether or not a word pair 
has been presented before when a list of 24 word pairs is read by the 
examiner. 
 Family Pictures - four pictures are presented each involving a number of 
family members carrying out activities. After presentation, participants 
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are asked who was in each scene, whereabouts they were and what they 
were doing. After a delay of 25-35 minutes participants are asked the 
same questions again, with no further presentation of the scenes. 
 Letter-Number Sequencing – A string of mixed letters and numbers is 
read by the examiner, and the participant has to reorganise the string 
into numbers first, in ascending order, and then letters in alphabetical 
order. For example, 5-B-4-L would become 4-5-B-L. The length of the 
string is gradually increased. 
 Spatial Span – a three dimensional block board is used. First the 
examiner points to a series of blocks and the participant has to touch the 
same blocks in the same order, with increasing numbers of blocks, then 
the examiner points to a string of blocks and the participant has to touch 
the blocks in reverse order. 
 
The WMS-III is extensively normed so that raw scores are adjusted for age 
before conversion to index scores, allowing a wide range of ages of participants 
to be assessed and their performances compared to what would be expected at 
their age. 
 
An assessment of general memory performance was needed for this study, 
partly to try and examine the discrepancy between subjective and objective 
memory functioning and whether it is due to failings in the objective 
assessment, and also to investigate any relationship between memory 
performance assessed traditionally with a 30 minute delay and long term 
forgetting. 
 
The WMS-III was chosen for this study as it is currently the most widely used 
general memory assessment in patients with epilepsy referred to 
neuropsychology services for memory assessment. The strength of the 
predictive value of the WMS scores for long term forgetting rates will 
demonstrate the efficiency of this measure as an assessment to identify memory 
problems in patients with epilepsy. For example, if there is little correlation 
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between WMS scores and long term forgetting, and accelerated forgetting was 
present in the patient group, it might be important to introduce additional 
memory assessment as part of any neuropsychological battery used in assessing 
patients with epilepsy. 
 
However, there are a number of drawbacks to using the WMS-III for detailed 
memory assessment. When considering the effectiveness of the WMS for 
lateralising temporal lobe epilepsy or lesions, a number of the subtests contain a 
mixture of verbal and non-verbal elements, rather than reflecting primarily the 
functions of one hemisphere or the other (Jones-Gotman et al., 2010). Also, 
although the subtests attempt to assess different domains of memory, the verbal 
and nonverbal tasks are dissimilar and thus cannot provide a direct comparison 
of the hemispheres. 
 
c) Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983)  
 
The Hospital Anxiety and Depression Scale is a well-established and reliable 
instrument for the screening of individuals with clinically significant anxiety 
and depression. It is a self-report questionnaire with seven items for each 
subscale (see table 9.4), which gives a score for anxiety and for depression which 
can be categorised into normal, mild, moderate or severe.  
 
Table 9.4: Example question and responses from each subscale of the HADS 
Scale Question Responses Score 
Anxiety I feel tense or ‘wound up’:  Most of the time 
 A lot of the time 
 Time to time 
 All the time 
 
3 
2 
1 
0 
Depression I still enjoy the things I used to 
enjoy: 
 Definitely as much 
 Not quite as much 
 Only a little 
 Hardly at all 
0 
1 
2 
3 
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A scale measuring anxiety and depression was needed as part of the assessment 
because it was felt to be important to investigate the emotional well-being of the 
participants so that it could be taken into account when looking at both the 
objective memory performance and the relationship between objective and 
subjective memory. The HADS was felt to be the most appropriate measure 
because it is a widely used and well validated measure and it is brief so 
avoiding lengthy interviews for the participant, when they already face a tiring 
assessment. 
 
d) Memory Questionnaire (Thompson & Corcoran, 1992) 
 
The Memory Questionnaire is a self-report instrument to assess an individual‟s 
view of their memory. Respondents are asked to rate the frequency of 
occurrence of 18 various everyday memory failings (see table 9.5 for an 
example), with a minimum total score of 18 and maximum of 108. There is also a 
general rating of how much of a nuisance the participant finds their memory to 
be, from „no nuisance at all‟ (zero points) to „a serious nuisance‟ (three points).  
 
Table 9.5: Sample item from Memory Questionnaire 
Sample question Responses Score 
How frequently do you... 
...Forget where you have put 
something, or lose things 
around the house? 
Not at all 1 
About once in the last 3 months 2 
About once a month 3 
About once a week 4 
About once a day 5 
More than once a day 6 
 
 
An instrument was required as part of this study to assess the participants‟ 
views of their own memory, so that the relationships between subjective 
memory, objective general memory performance and long term forgetting could 
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be examined. This questionnaire was devised for a research study investigating 
subjective cognitive functioning in patients with epilepsy (Thompson & 
Corcoran, 1992), and has been used in other studies examining long term 
forgetting rates (Butler et al., 2009), so it is designed for an appropriate 
population. Also, it comprises both a rating of frequency of individual problems 
and an overall nuisance rating, so there are a number of outcomes that can be 
analysed separately (such as the overall nuisance ratings, total scores for 
frequency of failings, which items are rated as more troublesome in which 
populations, and how frequently certain items are reported as a problem). 
 
e) Experimental- Logical Memory Story (see appendix 4) 
 
One of the logical memory stories from the WMS-III was administered again 
after the WMS assessment, but the administration was slightly adjusted. 
Performance at initial recall was assessed immediately, and the presentation and 
immediate assessment repeated until a learning criterion of 85% had been 
exceeded (28 or more out of 32, using a combination of the recall unit score and 
thematic unit score), up to a maximum of five trials. This allowed for matching 
of the groups at initial recall performance, so that the results from the delayed 
assessments could be compared with each other. A criterion of 85% was chosen 
as a suitable level because a 100% criterion could cause ceiling effects. The 
number of trials taken to reach the learning criterion was also noted, as this 
could be used as a measure of initial learning efficiency.  
 
Delayed recall and recognition were assessed 25-35 minutes after the last 
learning trial had been completed, in the same way that they would be assessed 
in the WMS-III.  
 
A logical memory story has been chosen to assess verbal long term forgetting as 
the aim is to sample memory in a way that is closer to the demands of everyday 
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life, so a text using meaningful prose can be thought to mimic what might be 
needed in everyday life rather than other verbal tests such as a word list or 
unrelated word pairs. It could be suggested that a story would be easier to 
rehearse than other potential verbal assessments and thus confound the results, 
but it was felt that as the participants were being asked to do so many different 
assessments at the initial visit it would be unlikely they would specifically 
rehearse this story and it was more important to use an ecologically valid test. 
 
f) Experimental- Visual Scenes Test (see appendix 5) 
 
Non-verbal delayed recall and recognition was also tested at both visits. The 
visual scenes test has been devised by Dr Nils Muhlert. It has been designed to 
test forgetting over long intervals, and is based on the „family pictures‟ subtest 
of the WMS-III (Weschler, 1997a), along with elements from the spatial memory 
test (Baxendale et al., 1998) and the complex pictures test (Mandler & Johnson, 
1976). Item recall, spatial recall and descriptive recall are assessed. The objects in 
the scenes were chosen so as not to be too closely semantically related to the 
scene (i.e. not too easy to guess). 
 
There are four scenes, each with items in each quadrant. First participants were 
told “You are going to be shown four pictures. In the corners of each of the 
pictures will be some objects. When I point to one of the corners I would like 
you to look at the objects in that corner. Later, I will ask you to remember what 
was in the pictures, so have a good look at each of the objects. Try to remember 
as many of the objects as possible.” 
 
Participants were then shown each picture in turn, with the examiner pointing 
to each corner of each picture for two seconds each. After the presentation of all 
of the scenes, the participant was asked to „take away three from one hundred, 
and carry on taking away three‟ out loud for 20 seconds. This distraction period 
allows the investigator to ensure that the recall performance for the scenes is 
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relying on long term rather than short term memory by excluding „recency‟ 
effects. Participants were then asked to recall items from the first scene, eg „can 
you tell me what was in the beach picture?‟ Spatial recall was then assessed by 
asking participants to point to the corner where the objects were that they 
recalled. Descriptive recall was assessed by asking the participant to identify 
two descriptors for each object they recall. Similar to the logical memory story, it 
was important to match participants‟ performance on this initial recall. 
Therefore, if participants did not reach a learning criterion of 75%, the entire 
exercise was repeated until they did, up to a maximum of five trials.  
 
As well as recall, recognition was also tested after a delay of 25-35 minutes. This 
was done with a series of four option forced choice questions, with the correct 
answer in a pseudorandomised position in the answers, with the question and 
four possible answers presented verbally. Two scenes were used for testing 
recall and two for recognition, as it was thought that the recognition memory 
questions may cue recall of the scenes.  
 
This test was chosen to assess long term non-verbal memory because it has been 
designed for this purpose. The nature of encoding and storing simple geometric 
forms is likely to be different from complex visual scenes, and a test of visual 
memory using complex pictures is felt to be more representative of the complex 
visual world we ordinarily encounter (Mandler & Johnson, 1976). It was felt that 
using a complex visual scenes test to assess long term visual memory would 
therefore be more ecologically valid than one using geometric designs or 
random shapes. 
 
9.6.3 Follow-up assessment 
 
At the initial assessment, the date and time for the follow-up assessment were 
confirmed, as close to three weeks (21 days) later as is possible. This assessment was 
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carried out in the same location as the initial assessment (whenever possible), i.e. 
either the Clinical Trials Unit or a home assessment, so that the participant had the 
same stimuli around them and the situation allowed them optimal recall conditions. 
At the initial assessment the participant was not told what was involved at the 
second assessment, merely that it would last around fifteen minutes and be a 
follow-up to see how they are doing. This was to try and avoid rehearsal of any 
learnt material during the delay period which could affect the reliability of the 
results. As they had been through so many different assessments, even if the 
participants did try to rehearse the material, the chances of them rehearsing the 
right subtests were small. 
 
At the follow-up visit, first the participant was asked if they had any questions 
about the previous session, as well as how they had been during the three week 
delay and if there had been any changes in medication. Patient participants were 
also asked if they had any seizures, and if so how many and to describe them so 
that they could be classified. 
 
Participants were also assessed on their delayed recall and recognition of both the 
logical memory story that was presented until a criterion was reached, and the 
visual scenes test. This involved the same procedure as for testing delayed recall 
and recognition after 25-35 minutes. The participant was first asked to remember as 
much of the story as they could, without any further presentation, and asked the 
recognition questions which are part of the WMS-III. For the visual scenes test, 
recall of the beach and stage scenes was assessed, and recognition questions with 
four multiple choice answers were asked for the park and street scenes, as at 25-35 
minutes. These delayed recall and recognition scores for verbal and visual 
information after a three week delay provided the basis for the long term forgetting 
scores. 
 
Participants were thanked for their participation, and offered feedback on their 
results from the standardised tests from the initial assessment, and permission was 
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requested from the patient participants for their results to be given to their 
neurologists. This will provide a baseline comparison if they require any further 
neuropsychological assessment in the future. Participants were also asked if they 
would like to be sent a summary of the general findings of the study once analysis 
was complete. 
 
9.7 Data entry and statistical analysis 
 
The assessments for patients and controls were all carried out by the author, to 
ensure consistency of presentation and collection of data. The assessments were 
scored according to criteria set out in the test manuals, and checked before being 
entered into an SPSS (Statistical Package for Social Sciences) version 17.0 database. 
Confidentiality was maintained by providing each participant with a unique 
identifying number, which was used in databases and record sheets, with no 
identifying information stored alongside the data collected. The author conducted 
all the statistical analysis, using SPSS version 17.0, using statistical textbooks for 
reference and guidance (Kirkwood & Strerne, 2003; Kremelberg, 2010). 
 
9.7.1 Demographic and Clinical Characteristics 
Demographic characteristics recorded and included in analysis were age, gender, 
handedness, and both years of education and level of education (highest level of 
education undertaken – school, college or university). The locations of the two 
assessments were also considered and the length of time between assessments. 
Differences between the characteristics of the two groups (patients and controls) 
were analysed. First, the spread of the data was considered for continuous variables 
(age, years of education, length of time between assessments) to see whether they 
met the assumption of normality. Distribution was assessed by visually inspecting 
histograms and considering the values for skewness in each test variable. None of 
these measures differed from the normal distribution so parametric tests were 
suitable to analyse them. The means and standard deviations were used as a 
measure of central tendency and spread, and independent t tests used to assess 
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differences between the means. For categorical variables Fisher‟s exact tests were 
used to assess difference in proportions between the groups, as the expected 
numbers in the cells were too small for Chi Square analysis. 
 
Clinical variables were described within the patient group. The distribution of data 
was considered and measures of central tendency were used to describe the data 
based on the spread. „Time since diagnosis‟ and „time since first seizure‟ were both 
negatively skewed variables, so medians and inter-quartile ranges were used to 
describe them. „Time since diagnosis‟ was skewed because the majority of patients 
were recruited as they were diagnosed in clinic but those recruited via letter or in 
first follow-up had been diagnosed up to six months before assessment. „Time since 
first seizure‟ was similarly negatively skewed as, while the majority had not had 
seizures for very long, there were a couple of patients who had had infrequent 
seizures for a number of years. When the distribution was normal, the mean and 
standard deviation was used as a measure of central tendency, and for categorical 
variables proportions were calculated. 
 
9.7.2 Baseline neuropsychological assessment 
Descriptive statistics were used to compare the performances of the patient and 
control groups in the intellectual functioning and memory assessments at the first 
visit. Again the spread of the data was considered and all scores from the WMS and 
the WASI fitted the normal distribution. Independent t tests were used to compare 
the means of the assessment results between groups. Intellectual functioning scores 
were correlated with years of education in each participant group separately. This 
was done using Pearson‟s R correlation coefficients as the scores fitted assumptions 
of normality. Intellectual functioning scores were also compared with WMS indices 
memory scores to assess the relationship between intellectual functioning and 
memory, using Pearson‟s R correlation coefficients. 
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9.7.3 Long term forgetting analyses 
9.7.3.1 Hypothesis 1 analyses – differences in forgetting rates in patients and controls 
As will be described in section 10.2.1a), the results of the long term forgetting tests 
were first considered according to age. Then, the distribution of the data was 
considered using histograms and the value for skewness, and any variables which 
did not fit assumptions of normality were described with non-parametric measures. 
In these variables, central tendency was described by median and inter-quartile 
range, and differences between groups examined with Mann Whitney U tests. In 
those variables which fitted assumptions of normality, means and standard 
deviations were used to describe central tendency and independent sample t tests 
used to compare differences between the group means. Where one group‟s data 
was skewed and the other normally distributed, non-parametric tests were used. 
 
For the analysis of forgetting over time in the two groups, undertaking a mixed 
factorial ANOVA with between subjects factor of group (patients vs controls) and 
within subjects factor of delay (immediate, 30 minutes, 3 weeks) was considered. 
However, the primary outcome variable was the rate of forgetting over the delay 
between 30 minutes and 3 weeks, so it was considered more appropriate to compare 
this rate using independent sample t tests between the two groups. Also, the sample 
size number was small, thus reducing the power of ANOVA analysis to detect a 
difference between the groups. 
 
Also, for each long term forgetting variable (three week verbal recall, three week 
visual recall, three week verbal recognition and three week visual recognition), the 
control group mean and standard deviation were used as an estimate of the 
population mean and standard deviation, and individual impairment was 
described as one standard deviation below the mean. The proportions impaired in 
each group were calculated, as well as the odds ratio of impairment with „newly 
diagnosed epilepsy‟ as the exposure factor. The difference between proportions 
impaired in the two groups was assessed using Fisher‟s exact test, as the numbers 
were too small for Chi Squared to be valid. 
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9.7.3.2 Hypothesis 2 analyses- correlations between WMS subtest scores and long term 
forgetting rates  
As the data from all of the long term forgetting measures, and that from the WMS 
subtests, was shown to fit assumptions of normality, it was possible to undertake 
correlation analyses using Pearson‟s R correlation coefficients to identify 
relationships between measures from the WMS and measures from the long term 
forgetting subtests, with verbal and visual subtests examined separately, in both 
patients and controls and in all participants together. Correlations within scores of 
the experimental tests were also examined, using Pearson‟s R correlation 
coefficients to identify relationships between the scores on various parts of the 
subtests. 
 
9.7.3.3 Hypothesis 3 analyses – subjective memory complaints in patients and controls 
Descriptive statistics were used to compare subjective memory complaints in 
patients and controls. As the overall MQ score data was normally distributed, an 
independent sample t test was used to compare the mean scores in the two groups. 
The nuisance rating could be categorical, or an ordinal variable, depending on how 
it was labelled. The proportions describing memory complaints as „no nuisance‟ or a 
„mild nuisance‟ were compared to those describing memory as a ‟moderate 
nuisance‟ or „severe nuisance‟, using Fisher‟s exact test. The categories had to be 
combined to create a 2x2 table so that the statistical test could be carried out. The 
most commonly reported problems were also described, or problems reported at 
least daily in each group. The proportions of participants rating each problem as 
happening „once a day‟ or „more than once a day‟ were calculated and the five most 
common noted. A Pearson‟s R correlation coefficient was calculated in each group 
for the relationship between memory complaint score and age, and a Spearman 
rank correlation coefficient (because the nuisance rating data was ordinal) was 
similarly calculated for the relationship between nuisance rating and age in each 
group. A Spearman rank correlation coefficient was also used to describe the 
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correlation between the two memory complaint scores (the total score and the 
nuisance score) as the nuisance scores are ordinal data. 
 
9.7.3.4 Hypothesis 4 analyses – comparisons of subjective and objective memory 
performance 
Pearson‟s R Correlation coefficients were calculated in each group for the 
relationships between various neuropsychological measures (intellectual 
functioning, WMS scores and long term forgetting scores) and memory complaint 
total scores, to compare subjective and objective memory performance. Spearman‟s 
rank correlation coefficients were also calculated in each group for the relationships 
between the same neuropsychological measures and memory nuisance rating. 
 
9.7.3.5 Hypothesis 5 analyses – anxiety and depression levels in patients and controls 
Distributions of the data were examined, and while anxiety scores were found to 
have a normal distribution, depression scores were negatively skewed. So, using 
descriptive statistics to compare results between the patient and control groups, an 
independent t test was used to compare mean anxiety scores and Mann Whitney U 
test to compare depression scores, with median and inter-quartile range as 
measures of central tendency and spread. The proportions of patients and controls 
in each category of anxiety and depression were compared using Fisher‟s exact 
tests. 
 
9.7.3.6 Hypothesis 6 analyses – relationship between psychological wellbeing and 
subjective memory function 
In each participant group, Pearson‟s R correlation coefficients were calculated for 
the relationships between anxiety and depression scores and memory complaint 
total score. Spearman rank correlation coefficients were calculated for the 
relationships between anxiety and depression scores and memory nuisance rating 
scores, and also between anxiety category and memory complaint total and 
nuisance scores. No correlations between subjective memory and depression 
    129 
category were examined as there was only one participant from each group not in 
the „normal‟ category for depression. The correlation coefficients calculated in this 
section could be compared to those calculated for hypothesis 4 to assess good 
predictors of subjective memory functioning. 
 
It was hoped that it might be possible to undertake multiple regression analysis to 
identify the important factors determining subjective memory rating, but there were 
not enough participants to make this valid. 
 
9.7.3.7 Hypothesis 7 analyses – relationships between long term forgetting and clinical 
variables 
To compare long term forgetting in those with different seizure types, the 
performance of participants who had had generalised seizures were compared with 
those who had not. Comparisons were made across psychological wellbeing scores 
and neuropsychological functioning scores, including full-scale IQ, WMS general 
memory and results from the long term forgetting tests. Distribution of measures 
was considered and where the distribution fitted assumptions of normality, means 
and standard deviations were compared using independent sample t tests. Where 
the distribution was skewed medians and inter-quartile ranges were used as 
measures of central tendency and spread and differences between groups examined 
with Mann Whitney U tests. Proportions were compared using Fisher‟s exact tests. 
 
Analysis was also undertaken to find a relationship of long term forgetting with 
number of seizures. For this, Pearson‟s R correlation coefficients were calculated for 
the relationships between both total lifetime generalised seizure number and 
duration of seizures and a range of neuropsychological variables, including those 
measuring long term forgetting. 
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It was not possible to undertake analysis of results based on pathology, as there 
were not enough patients with abnormalities on imaging to make any analysis 
valid. 
 
The mean long term forgetting scores (in verbal recall, verbal recognition, visual 
recall and visual recognition) of patients having had a seizure during the interval 
were compared with those not having a seizure using independent sample t tests. 
 
It was intended that multiple regression analysis would be undertaken on verbal 
long term forgetting and visual long term forgetting results separately, but there 
were not enough participants. 
 
9.7.3.8  Individual level analyses 
As discussed in section 9.7.3.1, participants were classified as „impaired‟ on long 
term forgetting scores if they had results more than one standard deviation below 
the control mean. This was used to define groups so that comparisons could be 
made in the differences in scores between those impaired and those not impaired. 
This was described separately in those impaired in three week verbal recall and 
those impaired in three week visual recall. A range of demographic, clinical and 
neuropsychological variables were compared between those impaired and not 
impaired, using independent sample t tests to compare means if the distribution 
was normal and non-parametric tests (Mann Whitney U) to compare performance 
in variables with a skewed distribution. Proportions were compared using Fisher‟s 
exact tests. 
 
During the statistical analysis, multiple comparisons and correlations were 
undertaken. It is noted that this increases the chance of type I errors, particularly 
using a significance level of 5%. A Bonferroni correction could have been used to 
reduce this risk of type I errors. However, a Bonferroni correction is conservative 
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and, particularly in studies such as this with a small sample size, increases the risk 
of type II errors and makes it difficult to detect „small‟ or „medium‟ effects 
(Nakagawa, 2004). Due to the large number of comparisons and correlations the use 
of a Bonferroni correction would have the result of no significant findings. As the 
aim was to look for patterns and potential trends that can be further explored in 
future research, it was decided that this correction would not be applied, but the 
results need to be interpreted with caution because of this. 
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Chapter 10  Results 
 
 
10.1 Baseline characteristics 
 
A total of 27 participants were assessed, between 16 and 77 years of age, including 
14 patients and 13 controls. The primary outcome measure for the study was three 
week forgetting of the story. As age cannot be taken into account due to the lack of 
standardised norms for scoring this test, and age might be expected to be related to 
forgetting, the three week forgetting data for all participants was first investigated 
according to age group. Both patient and control participants were categorised 
together according to decades, and mean three week verbal forgetting scores were 
considered for each decade (see Table 10.1 and Figure 10.1). 
Table 10.1: Mean 3 week verbal forgetting according to age 
Age n LMS 30-3 mean (SD)  
0-20 3 19.13 (17.49) Between groups 
one way ANOVA: 
F=2.98 (p=0.030*) 
21-30 8 27.65 (14.72) 
31-40 5 24.53 (11.02) 
41-50 2 30.76 (7.00) 
51-60 4 21.80 (14.69) 
61-70 2 19.65 (2.52) 
71-80 3 60.71 (21.65) 
*p<0.05, LMS 30-3 is % of story forgotten between 30 minutes and 3 weeks 
 
This demonstrates a clear deterioration in forgetting after the age of 70, and it was 
subsequently felt that including those over 70 might confound results and affect the 
reliability of any findings of differences between patients and controls. As there 
were only three participants over 70 it was not possible to examine them separately 
and consider their pattern of forgetting. Thus, for the analysis of the results 
including long term (three week) forgetting, the scores of those over 70 have been 
excluded to avoid this potential confounding effect.  
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Figure 10.1: Distribution of 3 week verbal forgetting scores according to age 
 
 
After the participants over 70 have been excluded so as to avoid the confounding 
effect of the three week forgetting results, 13 patients and 11 controls remain.  
 
Baseline demographic variables, clinical characteristics and baseline standard 
neuropsychological assessment results have also been examined in the cohort of 27 
participants prior to exclusion of the over 70s, so as to ensure there are no clear 
differences between the original sample and the final study group used for analysis. 
Details of these results can be found in appendix 6. 
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10.1.1 Demographics (see table 10.2) 
Differences between patient and control groups in age, gender, handedness and 
education (both years and level of education) were analysed. No significant 
differences were found in any demographic variable.  
 
Table 10.2: Participants’ demographic information 
 All Patients Controls Difference 
(95% CI) 
Significance 
(p value) 
Number of participants 
 
24 13 11   
Age/years  
Mean (SD) 
 
36.21 
(15.74) 
37.62 
(16.17) 
34.55 
(15.83) 
3.07 
(-16.68, 10.54) 
0.644 
Gender  M 13 
(54.2%) 
6 
(46.2%) 
7 
(63.6%) 
 0.444 
F 11 
(45.8%) 
 
7 
(53.8%) 
4 
(36.4%) 
Handedness  R 21 
(87.5%) 
11 
(84.6%) 
10 
(90.9%) 
 1.000 
L 3 
(12.5%) 
 
2 
(15.4%) 
1 
(9.1%) 
Education /years  
Mean (SD) 
13.58 
(2.83) 
 
13.00 
(2.48) 
14.27 
(3.17) 
-1.27 
(-1.12, 3.66) 
0.281 
Education 
/level  
school 9 
(37.5%) 
5 
(38.5%) 
4 
(36.4%) 
School vs 
higher 
education 
1.000 
college 6 
(25.0%) 
5 
(38.5%) 
1 
(9.1%) 
university 9 
37.5%) 
3 
(23.1%) 
6 
(54.5%) 
 
 
 
10.1.2  Procedure (see table 10.3) 
 
The procedure of assessment, i.e. where assessment took place and the time delay 
between the two assessments, could have an impact on results, so differences in 
these measures between groups have been considered. Differences in proportions of 
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patients and controls having their initial assessments at home or in the Clinical 
Trials Unit (CTU) were examined and found to be not significant (p=0.679). One 
patient had their follow up assessment in a different location to their initial 
assessment, this was because the date of her follow-up fell on a bank holiday and 
the CTU was not available, and it was felt to be more important to ensure 
consistency of time delay than of location. However, this change did not affect the 
difference in proportion of home and CTU visits between patients and controls, 
which remained not significant. Not every participant was able to have their follow-
up assessment exactly 21 days after their initial assessment, so the mean interval 
between assessments has also been examined, finding no significant difference in 
interval between patients and controls (p=0.654). 
 
Table 10.3: Procedural details of assessments in patients and controls 
Procedure All  
(n=24) 
Patients 
(n=13) 
Controls 
(n=11) 
Difference 
(95% CI) 
Significance 
(p value) 
Location of 
initial 
assessment  
CTU 8 
(33.3%) 
5 
(38.5%) 
3 
(27.3%) 
 0.679 
Home 16 
(66.7%) 
 
8 
(61.5%) 
8 
(72.7%) 
 
Location of 
follow up 
assessment 
CTU 7 
(29.2%) 
4 
(30.8%) 
3 
(27.3%) 
 1.000 
Home  17 
(70.8%) 
 
9 
(69.2%) 
8 
(72.7%) 
 
Interval 
between/days  
Mean (SD) 
21.00 
(0.89) 
20.92 
(0.64) 
21.09 
(1.14) 
-0.17 
(-0.93, 0.60) 
0.654 
CTU = Clinical Trials Unit 
 
10.1.3 Clinical Variables 
 
The clinical seizure variables of patients have been examined (see table 10.4). Over 
half of the patients assessed (53.8%) had had both partial and generalised seizures, 
while two (15.4%) had had simple and complex partial seizures only and four 
(30.8%) had had generalised seizures only at diagnosis, with a mean total lifetime 
    136 
number of two generalised seizures. The median time from diagnosis to the first 
assessment was four weeks, although the median time since the patients‟ first 
seizure was 18 months. This highlights the difficulty of trying to assess patients 
early in the course of epilepsy, as they will likely have a period of waiting between 
first seizure and diagnosis to see how things go.  
 
Table 10.4: Clinical variables in patients 
Patients N=13 
Seizure type Partial only 2 (15.4%) 
Partial and generalised 7 (53.8%) 
Secondary generalised only 4 (30.8%) 
 
Total number of generalised seizures 
Mean (SD) 
2.23 
(1.30) 
 
Time since diagnosis / weeks 
Median (IQR) 
4.00 
(1.75, 12.75) 
 
Time since first seizure / months 
Median (IQR) 
18.00 
(5.25, 66.00) 
 
Number of medications 
Median (IQR) 
1 
(1, 1) 
 
Age of onset 
Mean (SD) 
34.23 
(16.75) 
 
The mean age of onset of seizures was 34.23 years, although the distribution of age 
of onset in patients was bi-modal with a peak in the 20s and a smaller peak in the 
60s as might be expected considering the distribution of age of onset of epilepsy in 
the general population. 
 
Medication is expected to be a confounding factor in this study, and all but two of 
the patients were on one AED. Unfortunately, although lamotrigine was the most 
commonly taken medication (39%), patients were taking a range of AEDs (see figure 
10.2) so it will be difficult to allow for AED use in the analysis of experimental 
results.  
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Figure 10.2: AED being taken by patients 
AED in use
15%
23%
39%
8%
15%
none
CBZ
LTG
LEV
VPA
 
 
As the patients were largely recruited at diagnosis, many had not had investigations 
by the time they were assessed. During analysis any outstanding investigation 
results were chased up, but five (35.7%) of the patients did not undergo EEG 
recording, so results from these patients were unavailable. This was down to the 
decision of the clinician managing the patients. They were patients with a clear 
history of localisation related epilepsy in whom it was felt an EEG would not affect 
management. Obtainable results from patient investigations are shown in table 10.5. 
 
Table 10.5: Patient investigation results 
 Patients (n=13) Details 
MRI / CT Normal 11 (84.6%)  
Abnormal 2 (15.4%) 1 showing right hippocampal 
sclerosis, 1 showing DNET in 
right temporal lobe 
EEG Normal 7 (53.8%)  
Abnormal 1 (7.7%) Clear epileptic activity with left 
sided temporal focus 
Not done 5 (38.5%)  
Laterality Left 1 (7.7%) According to EEG 
Right 2 (15.4%) According to MRI abnormalities 
Unknown 10 (76.9%)  
DNET = Dysembryoplastic neuroepithelial tumour 
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Table 10.6: Localisation of epileptic focus in patients 
 Patients (n=13) 
TLE confirmed by investigations 3 (23.1%) 
TLE diagnosed clinically based on history 8 (61.5%) 
Secondary generalised seizures suggested clinically, 
origin unclear 
2 (15.4%) 
 
The investigation results can be considered alongside the clinicians’ clinical 
opinions based on the patients’ histories to give an idea of the localisation of 
epileptic foci in the patient group (see Table 10.6). All patients were considered by 
consultant epileptologists to have localisation related epilepsy, which in 11 (84.6%) 
could be localised to the temporal lobes (as documented in their notes). Although 
this was only confirmed by investigations in three patients, the others had histories 
suggestive of TLE, demonstrating that the majority of the patients had likely TLE. 
The remaining two patients had histories suggestive of secondary generalised 
seizures but of unclear origin, so they may have had TLE or may have had other 
localisation related epilepsies. 
 
10.1.4 Background intellectual functioning – WASI 
Table 10.7: Mean scores for VIQ, PIQ and FSIQ in patient and control groups 
 Overall 
(n=24) 
Patient 
(n=13) 
Control 
(n=11) 
Difference 
(95% CI) 
Significance 
(p value) 
VIQ 
Mean (SD) 
102.92 
(15.76) 
97.38 
(14.01) 
109.45 
(15.78) 
-12.07 
(-24.68, 0.54) 
0.060 
PIQ 
Mean (SD) 
111.58 
(13.07) 
104.38 
(10.45) 
120.09 
(10.71) 
-15.71 
(-24.68, -6.73) 
0.001** 
FSIQ 
Mean (SD) 
108.04 
(13.99) 
101.00 
(11.44) 
116.36 
(12.35) 
-15.36 
(-25.44, -5.29) 
0.005** 
*p<0.05, **p<0.01, ***p<0.001,  VIQ = Verbal IQ, PIQ = Performance IQ, FSIQ = Full scale IQ 
 
Results from the WASI can be used to give a score for VIQ, PIQ and FSIQ. Patients 
performed significantly worse than controls in PIQ and FSIQ (p=0.001, p=0.005 
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respectively) (see table 10.7), despite similar levels of education. When the 
relationship between education and intellectual functioning is examined, in all 
participants years of education are significantly correlated with VIQ and FSIQ 
scores (p<0.05) (see table 10.8). However, when the groups are split, years of 
education only significantly correlates with VIQ and FSIQ in controls, with no 
correlations between years of education and any intellectual functioning measure in 
patients. 
 
 
Table 10.8: Correlations between intellectual functioning scores and education 
All participants (n=24) Years of education 
VIQ 0.446 (p=0.029)* 
PIQ 0.259 (p=0.222) 
FSIQ 0.427 (p=0.037)* 
Patients (n=13)  
VIQ 0.144 (p=0.639) 
PIQ -0.276 (p=0.361) 
FSIQ -0.073 (p=0.812) 
Controls (n=11)  
VIQ 0.612 (p=0.045)* 
PIQ 0.551 (p=0.079) 
FSIQ 0.760 (p=0.007)** 
Values reported are Pearson’s R correlation coefficients and p values,  
*p<0.05, **p<0.01, ***p<0.001 
VIQ = Verbal IQ, PIQ = Performance IQ, FSIQ= Full Scale IQ 
 
10.1.5 Background memory scores – WMS 
 
The WMS provides scores on eight separate indices, as shown in table 10.9. Between 
patients and controls, there were no significant differences. 
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Table 10.9: Mean scores (SD) in WMS indices 
 All 
(n=24) 
Patients 
(n=13) 
Controls 
(n=11) 
Difference 
(95% CI) 
Significance 
(p value) 
Auditory Immediate 
Memory (AIM) 
 
107.63 
(15.62) 
104.00 
(13.45) 
111.91 
(17.51) 
-7.91 
(-21.02, 5.20) 
0.224 
 
Visual Immediate 
Memory (VIM)  
 
96.38 
(13.18) 
92.31 
(11.54) 
101.18 
(13.88) 
-8.87 
(-19.63, 1.88) 
0.101 
Immediate Memory 
(IM) 
 
102.71 
(14.71) 
98.15 
(13.04) 
108.09 
(15.31) 
-9.94 
(-21.93, 2.06) 
0.100 
Auditory Delayed 
Memory (ADM) 
 
106.50 
(14.02) 
105.08 
(11.67) 
108.18 
(16.83) 
-3.11 
(-15.21, 9.00) 
0.600 
Visual Delayed 
Memory (VDM) 
 
98.83 
(13.68) 
95.92 
(12.14) 
102.27 
(15.15) 
-6.35 
(-17.90, 5.20) 
0.266 
Auditory Recognition 
Delayed Memory 
(ARDM) 
 
112.71 
(10.73) 
110.00 
(10.80) 
115.91 
(10.20) 
-5.91 
(-14.86, 3.04) 
 
0.185 
General Memory 
(GM) 
 
106.17 
(13.85) 
103.31 
(11.99) 
109.55 
(15.67) 
-6.24 
(-17.95, 5.48) 
0.281 
Working Memory 
(WM) 
105.88 
(17.14) 
101.38 
(17.27) 
111.18 
(16.13) 
-9.80 
(-24.04, 4.44) 
0.168 
 
Background neuropsychological variables and differences between patients and 
controls are shown in figure 10.3. 
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Figure 10.3: Results from standard neuropsychological assessments in patients and controls 
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10.2 Long term forgetting results 
 
Consideration of the long term forgetting results of the study will be ordered 
according to the hypotheses outlined previously. 
 
10.2.1 Hypothesis 1: Accelerated forgetting of a) verbal recall, b) verbal recognition, c) 
visual recall and d) visual recognition will be present in at least a subset of 
patients with newly diagnosed localisation related epilepsy compared to controls 
 
10.2.1a) Verbal recall over 3 weeks  
 
Various parameters of the long-term verbal subtest, the logical memory story 
(LMS) have been examined, considering differences between patients and 
controls (see table 10.11).  
 
Number of trials is the number of presentations of the material given that it 
took for the participant to reach the criterion level required (85%) and thus 
provides a measure of initial learning efficiency. „LMS 0‟ is a measure of the 
participants‟ recall performance on the trial (as a percentage of the total 
possible score) when they reached the criterion level, and is used for calculating 
the amount of information forgotten at delays. „LMS 30‟ is a score for 
information recalled after a 30 minute delay (as a percentage of total possible 
score), and „LMS 3‟ is a similar measure for information recalled after a three 
week delay. 
 
„LMS 0-30‟ and „LMS 30-3‟ are the forgetting scores. „LMS 0-30‟ is the 
percentage of information which had initially been recalled when the 
participant reached criterion level which was not recalled after the 30 minute 
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delay, and thus suggests the amount of information forgotten between the 
initial learning and the 30 minute delay. It is calculated with this formula: 
 
 
 
 
Similarly, „LMS 30-3‟ is calculated as a percentage of information forgotten 
between 30 minutes and three weeks, using a similar formula: 
 
 
 
 
Table 10.10: Key to verbal long term forgetting variables 
Variable What it measures 
LMS 30 % recall of story at 30 minutes 
LMS 0-30 % of story forgotten between final trial and 30 minutes 
LMS 3 % recall of story at 3 weeks 
LMS 30-3 % of story forgotten between 30 minutes and 3 weeks 
LMSR 30 % recognition of story at 30 minutes 
LMSR 3 % recognition of story at 3 weeks 
LMSR 30-3 % difference in recognition between 30 minutes and 3 weeks 
 
By calculating these forgetting scores as a percentage of initial and 30 minute 
recall scores, a rate of forgetting is calculated which does not rely on the initial 
or 30 minute recall performance being perfectly matched. For example, a 
participant could have poor recall at 30 minutes due to an encoding problem 
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(say 50%) but retain a high proportion of that information over three weeks 
(say 80%). If only the recall scores were analysed, this would show 40% recall at 
three weeks, but by calculating the forgetting rates between the two intervals it 
is possible to better understand the pattern of memory impairment in this 
participant. 
 
 
The performance of patients and controls has been compared (see table 10.11). 
There is no significant difference in initial learning (as demonstrated by 
number of trials taken to reach criterion). Although recall performance at 30 
minutes was not significantly different between patients and controls, patients 
had forgotten a significantly higher percentage of the initially remembered 
material (p=0.024) (see figure 10.4). After the three week delay, patients‟ recall 
performance was significantly worse than controls (p=0.021), although the 
difference in the percentage of information forgotten between the 30 minute 
recall and the three week recall was not significant (p=0.077). 
 
 
Table 10.11: Performance of patients and controls in verbal recall 
*p<0.05 
LMS 30= % of story recalled at 30 minutes; LMS 0-30 = % of story forgotten between final trial 
and 30 minutes; LMS 3 = % of story recalled at 3 weeks; LMS 30-3 = % of story forgotten 
between 30 minutes and 3 weeks 
 
LMS All  
(n=24) 
Patients 
(n=13) 
Controls 
(n=11) 
Difference 
(95% CI) 
Significance 
(p value) 
Number of trials 
to criterion  
median (IQR)  
1 
(1, 2) 
1 
(1, 3) 
1 
(1, 2) 
 0.588 
Performance at 
criterion   
mean (SD) 
92.97 
(4.04) 
92.79 
(3.47) 
93.18 
(4.80) 
-0.39 
(-3.90, 3.12) 
0.819 
LMS 30   
mean (SD) 
89.59 
(6.62) 
87.26 
(7.04) 
92.33 
(5.11) 
-5.07 
(-10.27, 0.23) 
0.060 
LMS 0-30  
mean (SD) 
3.66 
(5.72) 
6.02 
(5.96) 
0.86 
(4.10) 
5.16 
(0.75, 9.57) 
0.024* 
LMS 3   
mean (SD) 
67.71 
(12.35) 
62.50 
(13.44) 
73.87 
(7.56) 
-11.36 
(-20.85, -1.88) 
0.021* 
LMS 30-3   
mean (SD) 
24.55 
(12.58) 
28.71 
(13.08) 
19.63 
(10.46) 
9.08 
(-1.08, 19.24) 
0.077 
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Individual impairments 
 
As well as looking at the overall group means for forgetting scores, impairment 
has been considered on an individual basis. Using the control mean and 
standard deviation as an estimate of the population mean and standard 
deviation, impairment has been defined as more than one standard deviation 
below the mean (table 10.12).  
 
Table 10.12: Individual impairment of verbal retention over 3 weeks 
LMS recall 30-3 Patient Control Difference  
Impaired 6 (46.2%) 1 (9.1%) p=0.078 
Not impaired 7 (53.8%) 10 (90.9%) 
LMS 30-3 = % of story forgotten between 30 minutes and 3 weeks 
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Figure 10.4: Recall of the story over time in patients and controls 
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Figure 10.5: Graphical representation of numbers of controls and patients impaired at 
LMS 30-3 
Patients
impaired
not
impaired
Controls
Impaired
not
impaired
 
LMS 30-3 = % of story forgotten between 30 minutes and 3 weeks 
 
 
 
Looking at LMS 30-3, it seems to be clearly shown by the pie charts (figure 10.5) 
that more patients than controls are impaired, but using Fisher‟s exact test (as 
the expected numbers are too small for Chi Square to be valid) the difference is 
non-significant (p=0.078). An odds ratio for impairment of retention over the 
three week delay with an „exposure‟ to epilepsy can be calculated as 8.57 (95% 
CI 0.84, 87.83) but again this is not significant as the confidence intervals 
include 1.  
 
Table 10.13: Individual impairment of verbal retention over 30 minutes 
LMS recall 0-30 Patient Control Difference 
Impaired 7 (53.8%) 1 (9.1%) p=0.033 
Not impaired 6 (46.2%) 10 (90.9%) 
LMS 0-30 = % of story forgotten between final trial and 30 minutes 
 
Considering LMS 0-30, Fisher‟s exact test demonstrates a significant difference 
in impairment between the patient and control groups at the 5% level (see table 
10.13). An exposure to epilepsy gives an odds ratio for impairment of retention 
over 30 minutes of 11.67 (95% CI 1.14, 119.54), which is significant. 
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10.2.1b) Verbal recognition over three weeks 
 
For the verbal recognition section a number of variables are indentified. „LMSR 
30‟ is the recognition score at 30 minutes, as a percentage, and „LMSR 3‟ is the 
recognition score at three weeks, as a percentage. „LMSR 30-3‟ is a forgetting 
score, noting the percentage of information recognised at 30 minutes no longer 
recognised after three weeks, calculating using the following formula: 
 
 
 
 
Differences between the mean and median (depending on whether measures 
were skewed) have been analysed between patients and controls (see table 
10.14). As for all long term forgetting scores, participants over the age of 70 
have been excluded to avoid confounding.  
 
Table 10.14: Performance of patients and controls in verbal recognition 
 All (n=24) Patients 
(n=13) 
Controls 
(n=11) 
Difference 
(95% CI) 
Significance 
(p value) 
LMSR 30  
median (IQR) 
 
100 
(100, 100) 
100 
(96.67, 100) 
100 
(100, 100) 
 0.370 
LMSR 3   
mean (SD) 
 
90.56 
(6.49) 
89.74 
(6.45) 
91.52 
(6.73) 
-1.77 
(-7.36, 3.82) 
0.518 
LMSR 30-3  
mean (SD) 
8.39 
(6.58) 
8.79 
(6.89) 
7.92 
(6.54) 
0.87 
(-4.83, 6.57) 
0.755 
LMSR 30 = % recognition of story at 30 minutes, LMSR 3 = % recognition of story at 3 weeks, 
LMSR 30-3 = % difference in recognition between 30 minutes and 3 weeks 
 
There is no significant difference between the groups in recognition at either 
time point, and also no significant difference in „recognition forgetting‟ between 
30 minutes and three weeks (see figure 10.6). 
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Figure 10.6: Recognition of the story over time in patients and controls 
 
 
 
Individual impairment 
 
As for LMS recall, individual impairment has also been investigated for LMs 
recognition using the control mean and standard deviation as an estimate of the 
population mean and standard deviation (see table 10.15). There is no 
difference in impairment between the groups as tested by Fisher‟s exact test 
(p=0.565), and the odds ratio for impairment of recognition following exposure 
to epilepsy is also not significant: 1.82 (95% CI 0.14, 23.25). 
 
Table 10.15: Individual impairment of verbal recognition over 3 weeks 
LMS recognition 
30-3 
Patient Control Difference  
Impaired 2 (15.4%) 1 (9.1%) p=0.565 
Not impaired 11 (84.6%) 10 (90.9%) 
LMSR 30-3 = % difference in recognition of story between 30 minutes and 3 weeks 
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10.2.1c) Visual recall over 3 weeks 
 
Participants over the age of 70 have again been excluded from the analysis of 
results from the visual scenes task (VST). Also, one patient under 70 failed to 
reach the criterion level of recall during the presentation trials, so their results 
have also been excluded from the analysis. 
 
A number of variables are presented measuring different parameters, as for the 
LMS subtest, and the differences between patients and controls investigated 
(see table 10.17).  
 
As with the LMS, number of trials is the number of presentations that it took 
for the participant to reach the criterion level required (75%), providing a 
measure of initial learning efficiency. „VST 0‟ is a measure of the participants‟ 
recall performance on their final trial (as a percentage of the total possible 
score), and is used for calculating the amount of information forgotten at 
delays. „VST 30‟ is a score for information recalled after a 30 minute delay (as a 
percentage of total possible score), and „VST 3‟ is a similar measure for 
information recalled after a three week delay. 
 
„VST 0-30‟ and „VST 30-3‟ are the forgetting scores. „VST 0-30‟ is the percentage 
of information which had initially been recalled when the participant reached 
criterion level which was not recalled after the 30 minute delay, and thus 
suggests the amount of information forgotten between the initial learning and 
the 30 minute delay. It is calculated with this formula: 
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Similarly, „VST 30-3‟ is calculated as a percentage of information forgotten 
between 30 minutes and three weeks, using a similar formula: 
 
 
 
 
 
Table 10.16: Key to visual long term forgetting variables 
Variable What it measures 
VST 30 % recall of scenes at 30 minutes 
VST 0-30 % of scenes forgotten between final trial and 30 minutes 
VST 3 % recall of scenes at 3 weeks 
VST 30-3 % of scenes forgotten between 30 minutes and 3 weeks 
VSTR 30 % recognition of scenes at 30 minutes 
VSTR 3 % recognition of scenes at 3 weeks 
VSTR 30-3 % difference in recognition between 30 minutes and 3 weeks 
 
 
Patients demonstrated worse learning efficiency than controls (p=0.018). There 
was no difference between patients‟ and controls‟ recall performance after 30 
minutes, or the percentage of information retained over the 30 minute delay 
(table 10.17). However, patients had significantly poorer recall after three weeks 
(p=0.002), and a significantly higher rate of forgetting, over a three week period 
(p=0.003). This can be seen graphically in figure 10.7. 
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Table 10.17: Performance of patients and controls in visual recall 
*p<0.05, **p<0.01 
VST 30 = % recall of scenes at 30 minutes; VST 0-30 = % of scenes forgotten between final trial 
and 30 minutes; VST 3 = % recall of scenes at 3 weeks; VST 30-3 = % of scenes forgotten 
between 30 minutes and 3 weeks 
 
 
 
Individual impairment 
 
Using the control mean and standard deviation as an estimation of population 
mean and standard deviation, participants were identified as impaired if they 
scored more than one standard deviation below the mean (see table 10.18, 
figure 10.8).  
 
Table 10.18: Individual impairment of visual recall over 3 weeks 
VST recall 30-3 Patient Control Difference 
Impaired 7 (58.3%) 1 (9.1%) p=0.027 
Not impaired 5 (41.7%) 10 (90.9%) 
VST 30-3 = % of scenes forgotten between 30 minutes and 3 weeks 
 
 
VST All 
(n=24) 
Patients 
(n=12) 
Controls 
(n=11) 
Difference 
(95% CI) 
Significance 
(p value) 
Number of trials  
Mean (SD) 
 
2.43  
(0.51) 
2.67  
(0.49) 
2.18  
(0.41) 
0.49 
(0.09, 0.88) 
0.018* 
Performance at 
criterion 
Mean (SD) 
 
90.15  
(6.95) 
88.55  
(5.86) 
91.90  
(7.87) 
-3.36 
(-9.34, 2.62) 
0.256 
VST 30  
Mean (SD) 
 
89.69  
(5.97) 
88.67  
(3.83) 
90.79  
(7.73) 
-2.11  
(-7.64, 3.41) 
0.426 
VST 0-30 
Mean (SD) 
 
0.02  
(4.91) 
-0.44  
(6.12) 
0.52  
(3.38) 
-0.95 
(-5.30, 3.39) 
0.652 
VST 3  
Mean (SD) 
 
63.53  
(24.92) 
49.48  
(23.84) 
78.86  
(15.68) 
-29.38 
(-47.06, -11.70) 
0.002** 
VST 30-3  
Mean (SD) 
29.36  
(26.49) 
44.05  
(26.74) 
13.33  
(14.69) 
30.71 
(11.97, 49.46) 
0.003** 
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Figure 10.7: Recall of the visual scenes over time in patients and controls 
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Figure 10.8: Graphical representation of numbers of controls and patients impaired at 
VST 30-3 
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Fisher‟s exact test demonstrates that there is a significant difference between 
patients and controls when it comes to the number impaired (p=0.027). The 
odds ratio for impairment of retention of visual information when exposed to 
epilepsy is 14.00 (95% CI 1.33, 147.43), which is significant as the confidence 
intervals do not include the value of 1. 
 
Table 10.19: Individual impairment of visual recall over 30 minutes 
VST recall 0-30 Patient Control Difference 
Impaired 1 (8.3%) 1 (9.1%) p=1.00 
Not impaired 11 (91.7%) 10 (90.9%) 
VST 0-30 = % of scenes forgotten between final trial and 30 minutes 
 
Considering forgetting scores over the 30 minute delay (table 10.19), there is no 
difference between groups as identified by Fisher‟s exact test (p=1.000). The 
odds ratio for impairment with epilepsy is 0.91 (95% CI 0.05, 16.54) which is not 
significant. 
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10.2.1d) Visual recognition over three weeks 
 
As for the verbal recognition section, a number of variables are indentified and 
compared. „VSTR 30‟ is the recognition score at 30 minutes, as a percentage, 
and „VSTR 3‟ is the recognition score at three weeks, as a percentage. „VSTR 30-
3‟ is a forgetting score, noting the percentage of information recognised at 30 
minutes no longer recognised after three weeks, calculating using the following 
formula: 
 
 
 
 
There is no significant difference in any of the recognition measures between 
patients and controls (see table 10.20 and figure 10.9). 
 
Table 10.20: Performance of patients and controls in visual recognition 
 All 
(n=23) 
Patients 
(n=12) 
Controls 
(n=11) 
Difference 
(95% CI) 
Significance 
(p value) 
VSTR 30  
Mean (SD) 
 
78.26 
(11.90) 
76.56 
(13.62) 
80.11 
(10.01) 
-3.55 
(-14.00, 6.90) 
0.487 
VSTR 3   
Mean (SD) 
 
71.74 
(12.34) 
67.71 
(12.16) 
76.14 
(11.46) 
-8.43  
(-18.70, 1.85) 
0.103 
VSTR 30-3 
Mean (SD) 
-7.57 
(16.14) 
-9.86 
(21.57) 
-5.07 
(6.94) 
4.79 
(-9.36, 18.94) 
0.478 
VSTR 30 = % recognition of scenes at 30 minutes; VSTR 3 = % recognition of scenes at 3 weeks; 
VSTR 30-3 = % difference in recognition between 30 minutes and 3 weeks 
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Figure 10.9: Recognition of the visual scenes over time in patients and controls 
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Individual impairment 
 
When individual impairment is considered (table 10.21), there are more 
patients than controls impaired at „recognition forgetting‟ over three weeks, but 
the difference is not significant using the Fisher‟s exact test (p=0.069). The odds 
ratio for impairment is 10.00 (95% CI 0.96, 104.49), which is also not significant.  
 
Table 10.21: Individual impairment of visual recognition over 3 weeks 
VST recognition 
30-3 
Patients Controls Difference 
Impaired 6 (50.0%) 1 (9.1%) p=0.069 
Not impaired 6 (50.0%) 10 (90.9%) 
VST recognition 30-3 = % difference in recognition between 30 minutes and 3 weeks 
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10.2.2 Hypothesis 2: Initial forgetting rates will be correlated with WMS subtest scores, 
but long term forgetting rates will not 
 
10.2.2a) Verbal 
The relationship between scores on the LMS subtest and corresponding 
auditory memory scores from the WMS has been examined, so that the validity 
of the WMS for predicting long term forgetting can be estimated. Correlations 
have been examined using Pearson‟s correlation coefficients in all participants, 
and also in patient and control groups separately (table 10.22). 
Table 10.22: LMS subtest correlations with auditory memory scores from WMS 
 All  
(n=24) 
Patients 
(n=13) 
Controls 
(n=11) 
LMS trials with Auditory 
immediate memory 
-0.595  
(0.002**) 
-0.480  
(0.097) 
-0.843  
(0.001**) 
LMS 30 with Auditory Delayed 
Memory 
0.503  
(0.012*) 
0.663  
(0.014*) 
0.381  
(0.247) 
LMS 0-30 with Auditory 
Delayed Memory 
-0.203  
(0.342) 
-0.533  
(0.061) 
0.240  
(0.477) 
LMS 0-30 with % recall story 
 
-0.284  
(0.178) 
-0.525  
(0.066) 
-0.234  
(0.488) 
LMS 0-30 with General 
Memory 
-0.334  
(0.111) 
-0.609  
(0.027*) 
0.163  
(0.641) 
LMSR 30 with Auditory 
recognition delayed memory 
0.115  
(0.592) 
0.000  
(1.000) 
0.192  
(0.571) 
LMS 3 with Auditory Delayed 
Memory 
0.431  
(0.036*) 
0.794  
(0.001**) 
0.009  
(0.979) 
LMS 30-3 with Auditory 
Delayed Memory 
-0.240  
(0.258) 
-0.601  
(0.030*) 
0.167  
(0.624) 
LMS 30-3 with % recall story 
 
-0.052  
(0.810) 
-0.536  
(0.059) 
0.327  
(0.326) 
LMS 30-3 with General 
Memory 
-0.199  
(0.350) 
-0.634  
(0.020*) 
0.446  
(0.169) 
LMSR 30-3 with Auditory 
Recognition Delayed Memory 
-0.172  
(0.422) 
-0.150  
(0.624) 
-0.172  
(0.613) 
Values are Pearson’s correlation coefficients with p values. *p<0.05, **p<0.01 
LMS trials = number of trials of story to reach criterion; LMS 30 = % recall of story at 30 
minutes; LMS 0-30 = % of story forgotten between final trial and 30 minutes; LMSR 30 = % 
recognition at 30 minutes; LMS 3= % recall of story at 3 weeks; LMS 30-3 = % of story forgotten 
between 30 minutes and 3 weeks; LMSR 30-3 = difference in recognition between 30 minutes 
and 3 weeks 
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The number of trials taken to reach criterion level for the story correlates 
significantly with Auditory Immediate Memory (AIM) in all participants 
(p=0.002) showing that this is a good measure of initial learning efficiency. 
When all participants are analysed together, the only other significant 
correlations are between 30 minute (p=0.012) and three week (p=0.036) recall 
scores and the Auditory Delayed Memory (ADM) score from the WMS. The 
correlation with 30 minute recall is as would be expected considering it is a 
very similar test, whilst the correlation with three week recall suggests that the 
ADM score may be predictive of recall over longer delays. 
 
Within the patient group, recall at 30 minutes (p=0.014) and three weeks 
(p=0.001) again correlate with ADM score. Forgetting rate over the 3 week 
delay also correlates with both ADM score (p=0.030) and General Memory 
(GM) score (p=0.020) suggesting that long term forgetting of a verbal story in 
this group of patients can be predicted by the WMS. GM score also correlates 
significantly with forgetting rate over the 30 minute delay (p=0.027). 
 
Within the control group, there are no significant correlations apart from 
number of trials with AIM. 
 
10.2.2b) Visual 
 
Correlations between corresponding variables of the Visual Scenes Test and 
visual memory scores from the WMS have also been examined (table 10.23). 
 
When all participants are considered together, there is significant correlation 
between number of trials taken to reach criterion and Visual Immediate 
Memory (VIM) scores in the WMS (p=0.016). However, when the groups are 
analysed separately this correlation is no longer apparent (p=0.114, p=0.248). 
There are no other significant correlations between the WMS visual memory 
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scores and the VST scores, despite similarities between the VST and the family 
pictures subtest of the WMS. 
 
Table 10.23: VST subtest correlations with visual memory scores from WMS 
 All  
(n=24) 
Patients 
(n=12) 
Controls 
(n=11) 
VST trials with Visual 
Immediate Memory 
-0.497  
(0.016*) 
-0.480  
(0.114) 
-0.380 
(0.248) 
VST 30 with Visual Delayed 
Memory 
0.312  
(0.148) 
0.503  
(0.096) 
0.207  
(0.542) 
VST 0-30 with Visual Delayed 
Memory 
0.371  
(0.081) 
0.292  
(0.357) 
0.549  
(0.080) 
VST 0-30 with % recall family 
pictures 
0.029  
(0.894) 
0.484 
 (0.111) 
-0.283  
(0.399) 
VST 0-30 with General Memory 0.170  
(0.437) 
0.102  
(0.753) 
0.273  
(0.417) 
VSTR 30 with Visual Delayed 
memory 
-0.058  
(0.794) 
0.050  
(0.876) 
-0.253  
(0.452) 
VST 3 with Visual Delayed 
Memory 
0.241  
(0.269) 
0.212  
(0.509) 
0.125  
(0.714) 
VST 30-3 with Visual Delayed 
Memory 
-0.203  
(0.353) 
-0.170  
(0.597) 
-0.063  
(0.853) 
VST 30-3 with % recall family 
pictures 
0.156  
(0.476) 
0.153  
(0.635) 
0.105  
(0.760) 
VST 30-3 with General Memory -0.320  
(0.137) 
-0.361  
(0.249) 
-0.194  
(0.567) 
VSTR 30-3 with Visual Delayed 
Memory 
-0.155  
(0.479) 
-0.216  
(0.500) 
-0.013  
(0.970) 
Values are Pearson’s correlation coefficients with p values. *p<0.05 
VST trials = number of trials to reach criterion; VST 30 = % recall of scenes at 30 minutes; VST 0-
30 = % of scenes forgotten between final trial and 30 minutes; VSTR 30 = % recognition of 
scenes at 30 minutes; VST 3 = % recall of scenes at 3 weeks; VST 30-3 = % of scenes forgotten 
between 30 minutes and 3 weeks; VSTR 30-3 = % difference in recognition between 30 minutes 
and 3 weeks 
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10.2.2c) Correlations between subtests of the experimental tests 
 
Within each experimental subtest, correlations between variables have been 
examined using Pearson‟s correlation coefficients, in all participants, patients 
and controls.  
 
In all participants together, and in patients, number of trials significantly 
correlates (p=0.038) with LMS 0-30 (see table 10.24). This suggests that patients 
needing more trials to reach criterion will also forget a larger percentage of the 
information after 30 minutes. This would suggest that repeated presentation of 
the story does not independently improve recall, but rather needing more trials 
to reach criterion is associated with poorer verbal memory so poorer recall after 
30 minutes. Number of trials does not correlate with longer term forgetting 
scores. Forgetting rates over the two intervals do not correlate, although when 
all participants are considered together recall scores at each delay correlate 
significantly (p=0.043). 
 
Table 10.24: Correlations between scores of LMS 
LMS All Patients Controls  
LMS trials with 
LMS 0-30 
 
0.425  
(0.038*) 
0.624  
(0.023*) 
-0.330  
(0.321) 
LMS trials with 
LMS 30-3 
 
0.187  
(0.381) 
0.181  
(0.554) 
-0.008  
(0.981) 
LMS 0-30 with LMS 
30-3 
 
0.187  
(0.382) 
-0.009  
(0.978) 
0.088  
(0.796) 
LMS 30 with LMS 3 0.417  
(0.043*) 
0.499  
(0.083) 
-0.324  
(0.331) 
Values are Pearson’s correlation coefficients with p values. *p<0.05 
LMS trials = number of trials of story to reach criterion; LMS 0-30 = % of story forgotten 
between final trial and 30 minutes; LMS 30-3 = % of story forgotten between 30 minutes and 3 
weeks; LMS 30 = % recall of story at 30 minutes; LMS 3 = % recall of story at 3 weeks 
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Table 10.25: Correlations between scores of VST 
VST All Patients Controls 
VST trials with VST 
0-30 
 
-0.396  
(0.062) 
-0.640  
(0.025*) 
0.160  
(0.639) 
VST trials with VST 
30-3 
 
0.340  
(0.112) 
0.205  
(0.523) 
-0.246  
(0.467) 
VST 0-30 with VST 
30-3 
 
-0.032  
(0.884) 
0.059  
(0.855) 
-0.061  
(0.859) 
VST 30 with VST 3 0.309  
(0.151) 
-0.053  
(0.869) 
0.585  
(0.059) 
Values are Pearson’s correlation coefficients with p values. *p<0.05 
VST trials = number of trials of scenes to reach criterion; VST 0-30 = % of scenes forgotten 
between final trial and 30 minutes; VST 30-3 = % of scenes forgotten between 30 minutes and 
3 weeks; VST 30 = % recall of scenes at 30 minutes; VST 3 = % recall of scenes at 3 weeks 
 
The only significant correlation between scores of the VST is between number 
of trials and VST 0-30 in patients (p=0.025) (see table 10.25). Unlike in the LMS 
subtest, this is a negative correlation, suggesting that patients having more 
presentations of the information will forget less of it over the 30 minute delay. 
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10.2.3 Hypothesis 3: Patients newly diagnosed with localisation related epilepsy will 
have higher rates of subjective memory complaints than controls 
 
Subjective memory complaints, as recorded on the Memory Questionnaire 
(MQ), can be considered as two scores: a score for the total reported frequency 
of all the memory problems questioned (MQ score), and a score for the rating of 
how much of a nuisance any memory and concentration problems are for the 
participant. As numbers are too small to do a valid Chi Square test on the 
categories of nuisance rating, the categories of „none‟ and „mild‟ have been 
combined and „moderate‟ and „severe‟ combined to allow for a Fisher‟s exact 
test to be carried out. 
 
The most frequently reported problems have also been examined to investigate 
if different problems are reported in patients and controls. As memory might 
be thought to worsen with age and the questionnaire scores are not adjusted in 
any way for age, the correlations between both scores and age in patients and 
controls were also examined, to see if this could be a potential cause of variance 
in memory complaints (see table 10.26).  
 
Figure 10.10: Nuisance rating of memory and concentration difficulties  
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In the study participants under the age of 70, there was no significant difference 
between total MQ score in patients and controls, or between the proportions of 
participants rating their memory a „moderate‟ or „severe‟ nuisance (using 
Fisher‟s exact test) (see figure 10.10). 
 
Table 10.26: Responses from MQ in patients and controls 
MQ = Memory Questionnaire 
 
The most commonly reported complaints were similar in the two groups, with 
losing things, finding a word is „on the tip of your tongue‟ and forgetting 
names in the top five problems reported at least daily in both groups. Patients 
seemed to report more going back to check and forgetting what happened 
yesterday. Controls on the other hand report that they might be more likely to 
forget what they are saying or ramble on. However, due to the small 
differences between frequencies and the small numbers involved it is 
MQ Patients (n=13) Controls (n=11) Difference 
(95%CI) 
Significance 
(p value) 
Total score  
Mean (SD)  
47.69 
(12.29) 
48.82 
(16.32) 
-1.13 
(-13.25, 10.99) 
0.849 
Nuisance 
rating 
No 
nuisance or 
mild 
nuisance 
8  
(61.5%) 
8  
(72.7%) 
 0.679 
Moderate 
or severe 
nuisance 
 
5  
(38.5%) 
3  
(27.3%) 
Problems reported at 
least daily 
Losing things (38%) 
Forgetting names (31%) 
Going back to check (31%) 
‘Tip of the tongue’ (31%) 
Forgetting what 
happened yesterday 
(23%) 
Forgetting what you’re saying (36%) 
Letting yourself ramble on (36%) 
Losing things (36%) 
‘Tip of the tongue’ (36%) 
Forgetting names (18%) 
 
 
MQ score correlation 
with age 
 
0.303 (p=0.314) 0.082 (p=0.810)   
Nuisance score 
correlation with age 
 
0.176 (p=0.565) -0.030 (p=0.929)   
Correlation between 
MQ score and MQ 
nuisance  
0.535 (p=0.059) 0.508 (p=0.111)   
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impossible to come to any real conclusions about group differences in nature of 
complaints.  
 
Neither total MQ score nor nuisance score correlated significantly with age in 
either patients or controls. Interestingly, total MQ score does not correlate 
significantly with nuisance rating, which would seem to suggest that these two 
scores are measuring different aspects of subjective memory. 
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10.2.4 Hypothesis 4: Long term forgetting rates will be a better predictor of subjective 
memory complaints than standard neuropsychological tests  
 
Table 10.27: Correlations between MQ scores and neuropsychological assessments 
Correlations with MQ 
score 
All 
(n=24) 
Patients 
(n=13) 
Controls 
(n=11) 
VIQ 0.065 
(0.763) 
0.431 
(0.142) 
-0.249 
(0.460) 
PIQ 0.031 
(0.886) 
0.341 
(0.255) 
-0.286 
(0.394) 
FSIQ 0.056 
(0.794) 
0.480 
(0.097) 
-0.327 
(0.326) 
WMS – General 
Memory 
-0.096 
(0.655) 
0.112 
(0.717) 
-0.261 
(0.439) 
Auditory Immediate 
Memory 
-0.209 
(0.327) 
-0.017 
(0.957) 
-0.374 
(0.257) 
Visual Immediate 
Memory 
-0.201 
(0.346) 
-0.190 
(0.535) 
-0.260 
(0.440) 
Immediate Memory -0.241 
(0.256) 
-0.093 
(0.763) 
-0.411 
(0.209) 
Auditory Delayed 
Memory 
-0.128 
(0.552) 
0.064 
(0.837) 
-0.257 
(0.446) 
Visual Delayed 
Memory 
-0.122 
(0.571) 
-0.120 
(0.696) 
-0.146 
(0.668) 
Auditory Recognition 
Delayed Memory 
0.103 
(0.631) 
0.421 
(0.152) 
-0.212 
(0.531) 
Working Memory -0.071 
(0.741) 
0.198 
(0.517) 
-0.366 
(0.269) 
LMS 30-3 score -0.061 
(0.777) 
-0.000 
(0.998) 
-0.109 
(0.749) 
LMSR 30-3 score -0.071 
(0.741) 
0.032 
(0.918) 
-0.166 
(0.627) 
VST 30-3 score 0.095 
(0.667) 
-0.069 
(0.832) 
0.528 
(0.095) 
VSTR 30-3 score 0.040 
(0.858) 
0.140 
(0.665) 
-0.169 
(0.620) 
Values are Pearson’s correlation coefficients with p values.  
VIQ = Verbal IQ; PIQ = Performance IQ; FSIQ = Full Scale IQ; LMS 30-3 = % of story forgotten 
between 30 minutes and 3 weeks; LMSR 30-3 = % difference in recognition of story between 30 
minutes and 3 weeks; VST 30-3 = % of scenes forgotten between 30 minutes and 3 weeks; VSTR 
30-3 = % difference in recognition of scenes between 30 minutes and 3 weeks 
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Table 10.28: Correlations between MQ nuisance ratings and neuropsychological 
assessments 
Correlations with MQ 
nuisance 
All 
N=24 
Patients 
N=13 
Controls 
N=11 
VIQ 0.030 
(0.888) 
-0.111 
(0.719) 
0.410  
(0.211) 
PIQ -0.020 
(0.926) 
0.123 
(0.688) 
0.005 
(0.988) 
FSIQ 0.024 
(0.912) 
0.010 
(0.973) 
0.347 
(0.296) 
WMS – General 
Memory 
-0.206 
(0.334) 
-0.504 
(0.079) 
0.174 
(0.609) 
Auditory Immediate 
Memory 
-0.206 
(0.334) 
-0.264 
(0.383) 
0.131 
(0.700) 
Visual Immediate 
Memory 
-0.204 
(0.339) 
-0.525 
(0.065) 
0.192 
(0.572) 
Immediate Memory -0.201 
(0.346) 
-0.403 
(0.172) 
0.212 
(0.532) 
Auditory Delayed 
Memory 
-0.082 
(0.703) 
-0.314 
(0.296) 
0.283 
(0.398) 
Visual Delayed 
Memory 
-0.320 
(0.127) 
-0.704 
(0.007**) 
-0.008 
(0.982) 
Auditory Recognition 
Delayed Memory  
-0.066 
(0.759) 
-0.143 
(0.641) 
0.090 
(0.793) 
Working Memory -0.076 
(0.723) 
0.231 
(0.448) 
-0.363 
(0.273) 
LMS 30-3 0.114 
(0.503) 
0.121 
(0.693) 
0.080 
(0.814) 
LMSR 30-3 0.384 
(0.064) 
0.248 
(0.414) 
0.543 
(0.085) 
VST 30-3 0.222 
(0.308) 
0.344 
(0.274) 
0.091 
(0.790) 
VSTR 30-3 0.125 
(0.571) 
0.231 
(0.470) 
-0.252 
(0.455) 
Values are Pearson’s correlation coefficients with p values. *p<0.05, **p<0.01 
VIQ = Verbal IQ; PIQ = Performance IQ; FSIQ = Full Scale IQ; LMS 30-3 = % of story forgotten 
between 30 minutes and 3 weeks; LMSR 30-3 = % difference in recognition of story between 30 
minutes and 3 weeks; VST 30-3 = % of scenes forgotten between 30 minutes and 3 weeks; VSTR 
30-3 = % difference in recognition of scenes between 30 minutes and 3 weeks 
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To investigate this hypothesis, correlations were examined between MQ score 
and measures of intellectual functioning, WMS index scores, and long term 
forgetting scores from the experimental subtests (using Pearson correlation 
coefficients) (see table 10.27). Correlations were also examined between the 
same neuropsychological measures and the nuisance rating from the MQ, using 
Spearman rank as the nuisance rating scores are ordinal data (see table 10.28). 
 
The only significant correlation was found between the Visual Delayed 
Memory score from the WMS and the MQ nuisance rating in patients (p=0.007). 
This suggests that long term forgetting scores are no better at predicting 
subjective memory than standard neuropsychological tests.  
    168 
10.2.5 Hypothesis 5: Patients newly diagnosed with localisation related epilepsy will 
have higher rates of anxiety and depression than controls 
 
The mean anxiety scores for each group have been compared using an 
independent sample t test, as well as consideration of the number of 
participants in each group falling into each category of anxiety. As the numbers 
are too small to do a valid chi squared test on categories of anxiety these were 
combined as „normal to mild‟ and „moderate to severe‟, to allow for a Fisher‟s 
exact test to be carried out. The data on depression rates was skewed, so the 
median and inter-quartile range have been used as a measure of central 
tendency, compared using Mann Whitney U test (see table 10.29). 
 
Table 10.29: Anxiety and depression scores in patients and controls 
HADS Patients 
(n=13) 
Controls 
(n=11) 
Difference  
(95% CI)  
Significance 
(p value) 
HADS anxiety score 
Mean (SD) 
 
8.85 
(4.06) 
6.91 
(2.43) 
1.94  
(-0.86, 4.74)  
0.165 
Anxiety  Normal-
mild 
7 
(53.8%) 
11 
(100.0%) 
 0.016* 
Moderate-
severe 
 
6 
(46.2%) 
0 
(0.0%) 
HADS depression score 
Median (IQR) 
 
3.0 
(1.0, 4.5) 
2.0 
(1.0, 6.0) 
 0.746 
Depression  Normal 12 10  1.000 
Mild 1 1 
Moderate 0 0 
Severe 0 0 
Values are Pearson’s correlation coefficients with p values. *p<0.05 
HADS = Hospital Anxiety and Depression Scale 
 
Results show that there is no significant difference in mean anxiety scores 
between patients and controls (p=0.165), however a significantly higher 
proportion of patients have scores in the moderate to severe range (p=0.016) 
(see figure 10.11). There are no differences between patients and controls in 
depression scores, or depression categories. 
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Figure 10.11: Anxiety and depression in patients and controls 
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10.2.6 Hypothesis 6: Measures of depression and anxiety will be a better predictor of 
subjective memory complaints than standard neuropsychological tests  
 
To investigate this hypothesis, the correlations of MQ total score and MQ 
nuisance rating with anxiety and depression scores were calculated (table 
10.30). Anxiety category was also correlated with both MQ total score and MQ 
nuisance rating, although correlations with depression category were not 
calculated as there was only one participant in each group not in the „normal‟ 
category. 
 
Table 10.30: Correlations between memory complaints and anxiety and depression 
All participants 
(n=24) 
MQ total score MQ nuisance 
Anxiety score 0.505a  
(0.012*) 
0.366b  
(0.078) 
Anxiety category 0.557b  
(0.005**) 
0.354b  
(0.089) 
Depression Score 0.345a  
(0.098) 
0.449b  
(0.028*) 
 
Patients (n=13) 
Anxiety score 0.716a  
(0.006**) 
0.517b  
(0.071) 
Anxiety category 0.742b  
(0.004**) 
0.498b  
(0.083) 
Depression Score 0.613a  
(0.026*) 
0.833b  
(<0.001***) 
 
Controls (n=11) 
Anxiety score 0.378a  
(0.251) 
-0.043b  
(0.899) 
Anxiety category 0.404b  
(0.218) 
0.128b  
(0.708) 
Depression Score 0.146a  
(0.669) 
-0.039b  
(0.909) 
Values are Pearson’s correlation coefficients (a) and Spearman rho correlation coefficients (b) 
with p values. *p<0.05, **p<0.01, ***p<0.001 
MQ = Memory Questionnaire 
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In all participants, anxiety scores were significantly correlated with total 
frequency of reported memory problems (p=0.012, p=0.005), while depression 
scores were significantly correlated with nuisance ratings (p=0.028). 
 
Considering patients only, a similar pattern emerges, with anxiety scores 
correlated at the with total MQ scores (p=0.006, p=0.004), but not significantly 
with nuisance ratings (p=0.071, p=0.083). Depression scores are correlated at 
the with nuisance ratings (p<0.001), and also with total MQ score (p=0.026). 
When compared to the correlations between memory complaints and 
neuropsychological performance, these results demonstrate that, in patients, 
anxiety and depression scores are more predictive of memory complaints than 
neuropsychological performance. 
 
In controls, there are no significant correlations between memory complaints 
and anxiety or depression scores. 
 
Unfortunately, given the small numbers of participants involved, it is not 
appropriate to undertake multiple regression analysis to determine predictors 
of subjective memory complaints. 
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10.2.7.1 Hypothesis 7a: Patients with secondary generalised seizures will have 
worse neuropsychological performance and higher rates of long term 
forgetting than those having complex or simple partial seizures and 
controls 
 
As there are only two patients who had not had generalised seizures, 
participants were split into two groups for this analysis: those having 
generalised seizures and those not (including both patients with partial 
seizures only and controls). The demographics of these groups have been 
compared to ensure that changing the groups has not created any significant 
differences (see table 10.31). There are no significant differences in age, gender 
or years of education between the two groups. 
 
Table 10.31: Demographic comparison of the ‘generalised seizure’ and ‘no generalised 
seizure’ groups 
 Generalised 
seizures 
(n=11) 
No generalised 
seizures  
(n=13) 
Difference  
(95% CI) 
 
Significance 
(p values) 
Age  
Mean (SD) 
38.45 
(16.05) 
34.31 
(15.87) 
4.15  
(-9.41, 17.70) 
 
0.532 
Gender Male 6 
(54.5%) 
7 
(53.8%) 
 1.000 
Female 5 
(45.5%) 
6 
(46.2%) 
 
 
Years of 
education 
Mean (SD) 
13.27  
(2.61) 
13.85  
(3.08) 
-0.57 (-3.02, 
1.87) 
0.631 
 
 
Differences between the two groups in neuropsychological performance have 
been examined, including scores from questionnaires, standard assessments 
and experimental long–term forgetting scores (see table 10.32). 
 
 
    173 
Table 10.32: Neuropsychological performance in those with and without generalised 
seizures 
 Generalised 
seizures 
(n=11) 
No 
generalised 
seizures  
(n=13) 
Difference  
(95% CI) 
 
Significanc
e (p 
values) 
HADS Anxiety 
Mean (SD) 
8.55 
(4.23) 
7.46 
(2.79) 
1.08  
(-2.06, 4.23) 
0.477 
HADS Depression 
Median (IQR) 
3.0 
(1.0, 5.0) 
2.0 
(1.0, 5.0) 
 1.000 
MQ score 
Mean (SD) 
48.00 
(12.95) 
48.38 
(15.29) 
-0.39  
(-12.51, 11.74) 
0.948 
MQ 
nuisance 
None  
– mild 
6  
(54.5%) 
10  
(76.9%) 
 0.397 
Moderate 
– severe  
5  
(45.5%) 
3  
(23.1%) 
 
FSIQ 
Mean (SD) 
99.18 
(11.51) 
115.54 
(11.48) 
-16.36  
(-26.12, -6.59) 
0.002** 
General Memory 
Mean (SD) 
100.09 
(9.83) 
111.31 
(14.99) 
-11.22  
(-22.18, -0.25) 
0.045* 
LMS trials 
Median (IQR) 
2.0 
(1.0, 3.0) 
1.0 
(1.0, 2.0) 
 0.213 
LMS 0-30 
Mean (SD) 
7.12 
(5.63) 
0.72 
(3.99) 
6.40  
(2.32, 10.49) 
0.004** 
LMS 0-30  impaired 7 
(63.6%) 
1 
(7.7%) 
 0.008** 
Not 
impaired 
4 
(36.4%) 
12 
(92.3%) 
 
LMS 30-3 
Mean (SD) 
31.28 
(11.52) 
18.85  
(10.76) 
12.43  
(2.98, 21.87) 
0.012* 
LMS 30-3  impaired 6  
(54.5%) 
1  
(7.7%) 
 0.023* 
 Not 
impaired 
5  
(45.5%) 
12  
(92.3%) 
 
LMSR 30-3 
Mean (SD) 
9.78  
(6.87) 
7.22  
(6.36) 
2.57  
(-3.04, 8.17) 
0.352 
LMSR 30-
3  
impaired 2  
(18.2%) 
1  
(7.7%) 
 0.576 
 Not 
impaired 
9 
(81.8%) 
12 
(92.3%) 
 
VST trials 
Median (IQR) 
3.00  
(2.75, 3.00) 
2.00  
(2.00, 2.00) 
 0.002** 
VST 0-30 
Mean (SD) 
-0.86  
(6.63) 
0.70  
(3.19) 
1.55  
(-2.79, 5.89) 
0.466 
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VST 0-30  impaired 1  
(10.0%) 
1  
(7.7%) 
 1.000 
Not 
impaired 
9  
(90.0%) 
12  
(92.3%) 
 
VST 30-3 
Mean (SD) 
49.93  
(24.97) 
13.54  
(13.97) 
36.39  
(19.37, 53.41) 
<0.001*** 
VST 30-3  impaired 7  
(70.0%) 
1  
(7.7%) 
 0.006** 
Not 
impaired 
3  
(30.0%) 
12  
(92.3%) 
 
VSTR 30-3 
Median (IQR) 
12.18  
(-2.50, 22.14) 
7.69  
(0.00, 9.55) 
 0.641 
VSTR 30-
3  
Impaired 5  
(50.0%) 
2  
(15.4%) 
 0.169 
Not 
impaired 
5  
(50.0%) 
11  
(84.6%) 
 
*p<0.05, **p<0.01, ***p<0.001 
HADS = Hospital Anxiety and Depression Scale; MQ = Memory Questionnaire; FSIQ = Full Scale 
IQ; LMS trials = number of trials of story to reach criterion; LMS 0-30 = % of story forgotten 
between final trial and 30 minutes; LMS 30-3 = % of story forgotten between 30 minutes and 3 
weeks; LMSR 30-3 = % difference in story recognition between 30 minutes and 3 weeks; VST 
trials = number of trials of scenes to reach criterion; VST 0-30 = % of scenes forgotten between 
final trial and 30 minutes; VST 30-3 = % of scenes forgotten between 30 minutes and 3 weeks; 
VSTR 30-3 = % difference in scene recognition between 30 minutes and 3 weeks 
 
Those having had generalised seizures had no significant difference in anxiety, 
depression or memory complaint scores from those not having had generalised 
seizures. However, they had significantly worse FSIQ scores (p=0.002) and 
WMS general memory scores (p=0.045). In the LMS subtest, patients having 
had generalised seizures forgot significantly more of the material over both 
delay intervals (p=0.004, p=0.012 respectively), with no difference in initial 
learning or recognition. In the VST subtest, patients with generalised seizures 
performed significantly worse at initial learning efficiency (p=0.002) and 
forgetting over the three week delay (p<0.001) with no significant difference in 
forgetting over 30 minutes or recognition performance. 
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10.2.7.2 Hypothesis 7b: Patients with a greater total number of seizures will have 
worse neuropsychological performance and higher rates of long term 
forgetting than those having fewer seizures  
 
To investigate this hypothesis, the correlation between a number of clinical 
seizure variables and scores from neuropsychological assessments has been 
examined (table 10.33). Total generalised seizure number is the number of 
generalised seizures the patient has had in their lifetime, seizure frequency is 
an estimation of the mean number of all seizures (partial and generalised) a 
patient would have in a year, and duration of seizures is the number of months 
since the patient‟s first seizure. Correlations between these variables and 
anxiety, depression, memory complaints, intellectual functioning, memory 
scores, and measures from the LMS and VST are examined, using Pearson 
correlation coefficients for continuous data and Spearman rank for ordinal data. 
 
There are significant correlations of total number of generalised seizures with 
WMS general memory score (p=0.006) and with three week forgetting of visual 
scenes (p=0.040). The only other significant correlation is a negative 
relationship between „recognition forgetting‟ of the LMS and duration of 
seizures, suggesting that patients with a longer duration of seizures have better 
verbal recognition over a three week interval, which is an unexpected finding. 
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Table 10.33: Correlations between seizure variables and neuropsychological 
assessment results 
Patients (n=13) Correlation with total 
generalised seizure number 
Correlation with duration of 
seizures  (months) 
HADS anxiety 0.149 
(0.626) 
-0.053  
(0.863) 
HADS depression 0.206 
(0.500) 
-0.228 
(0.455) 
MQ score 0.265 
(0.381) 
-0.217 
(0.477) 
MQ nuisance 0.530  
(0.062) 
-0.337 
(0.260) 
FSIQ -0.196 
(0.521) 
-0.239 
(0.432) 
General Memory -0.716 
(0.006**) 
-0.133 
(0.666) 
LMS trials 0.552 
(0.051) 
0.139 
(0.650) 
LMS 0-30 0.395 
(0.182) 
0.117 
(0.703) 
LMS 30-3 0.430 
(0.143) 
0.166 
(0.587) 
LMSR 30-3 0.323 
(0.282) 
-0.615 
(0.025*) 
VST trials 0.506 
(0.093) 
-0.519 
(0.084) 
VST 0-30 -0.028 
(0.930) 
0.410 
(0.185) 
VST 30-3 0.599 
(0.040*) 
-0.148 
(0.646) 
VSTR 30-3 -0.038 
(0.906) 
0.444 
(0.148) 
Values are Pearson’s correlation coefficients with p values. *p<0.05, **p<0.01 
HADS = Hospital Anxiety and Depression Scale; MQ = Memory Questionnaire; FSIQ = Full Scale 
IQ; LMS trials = number of trials of story to reach criterion; LMS 0-30 = % of story forgotten 
between final trial and 30 minutes; LMS 30-3 = % of story forgotten between 30 minutes and 3 
weeks; LMSR 30-3 = % difference in story recognition between 30 minutes and 3 weeks; VST 
trials = number of trials of scenes to reach criterion; VST 0-30 = % of scenes forgotten between 
final trial and 30 minutes; VST 30-3 = % of scenes forgotten between 30 minutes and 3 weeks; 
VSTR 30-3 = % difference in scene recognition between 30 minutes and 3 weeks 
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10.2.7.3 Hypothesis 7c: Patients with an abnormality found on MRI will have 
worse neuropsychological performance and higher rates of long term 
forgetting than those with normal imaging  
 
Unfortunately, given the small numbers of patients and the fact that only three 
had abnormal imaging results (one of whom failed to reach VST criterion so 
there are only two in VST analysis), it is not possible to make a reasonable 
comparison between those with normal and abnormal imaging results, so this 
hypothesis cannot be investigated. 
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10.2.7.4 Hypothesis 7d: Patients having a seizure during the delay between initial 
assessment and follow up will have worse rates of forgetting than those 
not having a seizure during the delay 
 
Patient participants have been split into those having any type of seizure 
during the delay between assessments (including both partial and generalised 
seizures) and those not. Their mean forgetting rates of LMS, LMSR, VST and 
VSTR over the three week delay are compared to each other using independent 
sample t tests, which demonstrate no significant difference between the two 
groups of patients in any measure (table 10.34). So, there is no difference in long 
term forgetting rates between those having seizures and those not, although the 
numbers involved are small. 
 
 
Table 10.34: Long term forgetting in patients with and without seizures during 3 week 
delay 
 Seizure 
during delay 
(n=5) 
No seizure 
during delay 
(n=8) 
Difference  
(95% CI) 
Significance  
(p values) 
LMS 30-3 
Mean (SD) 
23.84 
(12.42) 
31.75 
(13.33) 
-7.91  
(-24.23, 8.41) 
0.309 
LMSR 30-3 
Mean (SD) 
9.43 
(7.56) 
8.39 
(6.89) 
1.04  
(-7.92, 9.99) 
0.804 
VST 30-3 
Mean (SD) 
38.97 
(32.18) 
47.67 
(24.16) 
-8.70  
(-44.77, 23.37) 
0.603 
VSTR 30-3 
Mean (SD) 
17.44 
(16.22) 
4.44 
(21.40) 
13.01  
(-15.06, 41.07) 
0.326 
LMS 30-3 = % of story forgotten between 30 minutes and 3 weeks; LMSR 30-3 = % difference in 
story recognition between 30 minutes and 3 weeks; VST 30-3 = % of scenes forgotten between 
30 minutes and 3 weeks; VSTR 30-3 = % difference in scene recognition between 30 minutes 
and 3 weeks 
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10.3 Individual level analysis 
 
Figure 10.12 shows the percentage of patients and controls classed as „impaired‟ (>1 
SD below control mean) in each forgetting rate measure. This would seem to 
suggest that in four of the measures, LMS 0-30, LMS 30-3, VST 30-3 and VSTR 30-3, 
more patients are impaired than controls. However, as mentioned previously, only 
two of these differences in proportions are statistically significant (LMS 0-30 and 
VST 30-3). 
 
 
Figure 10.12: Percentage of patients and controls with scores >1 SD below control mean 
(‘impaired’) 
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*p<0.05 
LMS 30-3 = % of story forgotten between 30 minutes and 3 weeks; LMSR 30-3 = % difference in story 
recognition between 30 minutes and 3 weeks; VST 30-3 = % of scenes forgotten between 30 minutes 
and 3 weeks; VSTR 30-3 = % difference in scene recognition between 30 minutes and 3 weeks 
 
 
As the two measures of long term recall forgetting (LMS 30-3 and VST 30-3) are the 
main outcome measures, the characteristics of participants who are impaired on 
these measures will be analysed, and compared to the characteristics of those not 
impaired. 
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10.3.1 Individual-level analysis of those impaired at three week verbal recall 
Table 10.35: Characteristics of participants impaired at LMS 30-3 
Variable Impaired  
(n=7) 
Not impaired 
(n=17) 
Difference 
(95% CI) 
Significance 
(p value) 
Group Patient 6  
(85.7%) 
7  
(41.2%) 
Fishers exact 0.078 
Control 1  
(14.3%) 
10  
(58.8%) 
Age  
Median (IQR) 
31.0  
(24, 37.5) 
35.0  
(23, 54) 
 0.750 
Education years 
Mean (SD) 
13.86  
(2.67) 
13.47  
(2.96) 
-0.39  
(-3.07, 2.30) 
0.768 
Anxiety score 
Mean (SD) 
8.57  
(4.72) 
7.71  
(2.97) 
-0.87  
(-5.30, 3.57) 
0.665 
Depression score 
Mean (SD) 
2.43  
(1.99) 
3.41  
(2.62) 
0.98  
(-1.31, 3.28) 
0.384 
MQ score 
Mean (SD) 
47.57  
(12.61) 
48.47  
(14.85) 
0.90  
(-12.39, 14.19) 
0.890 
MQ 
nuisance 
None-mild 4  
(57.1%) 
12  
(70.6%) 
Fishers exact 0.647 
Mod-
severe 
3  
(42.9%) 
5  
(29.4%) 
VIQ 
Mean (SD) 
94.29  
(17.08) 
106.47  
(14.20) 
12.19  
(-1.82, 26.19) 
0.085 
FSIQ 
Mean (SD) 
98.29  
(15.09) 
112.06  
(11.71) 
13.77  
(1.93, 25.62) 
0.025* 
WMS- General Memory 
Mean (SD) 
98.57  
(9.66) 
109.29  
(14.33) 
10.72  
(-1.59, 23.03) 
0.085 
WMS - Auditory 
Delayed Memory 
Mean (SD) 
99.00  
(6.51) 
109.59  
(15.23) 
10.59  
(-1.92, 23.09) 
0.093 
LMS 0-30  Impaired 4  
(57.1%) 
4  
(23.5%) 
Fishers exact 0.167 
Not 3  
(42.9%) 
13  
(76.5%) 
LMSR 30-3  Impaired 1  
(14.3%) 
2  
(11.8%) 
Fishers exact 1.000 
Not 6  
(85.7%) 
15  
(88.2%) 
*p<0.05 
MQ = Memory Questionnaire; VIQ = Verbal IQ; FSIQ = Full Scale IQ; LMS 0-30 = % of story forgotten 
between final trial and 30 minutes; LMSR 30-3 = % difference in story recognition between 30 
minutes and 3 weeks 
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Table 10.35 compares the characteristics of participants impaired at verbal recall 
over three weeks with those not impaired. The only significant difference is in FSIQ, 
where those not impaired had a significantly higher FSIQ than those impaired 
(p=0.025). There are no significant differences in group, age, education, anxiety, 
depression, subjective memory complaints, or scores on the WMS indices. There is 
also no significant difference between the proportions of participants impaired at 
verbal recall over the 30 minute interval, suggesting that impairment over the 
longer delay does not necessarily follow from impairment over the short delay. 
 
Table 10.36: Characteristics of patients impaired at LMS 30-3 
Within patients Impaired 
(n=6) 
Not impaired 
(n=7) 
Difference 
(95% CI) 
Significance 
(p value) 
Seizure 
Type 
Partial only 0  
(0.0%) 
2  
(28.6%) 
Partial only 
vs any gen 
0.462 
Partial and gen 4 
(60.0%) 
3 
 (42.9%) 
Gen only 2 
(40.0%) 
2 
(28.6%) 
Duration of epilepsy 
Median (IQR) 
12  
(3, 66) 
18  
(8, 120) 
 0.471 
Total gen seizure no 
Median (IQR) 
2.5  
(2.0, 3.5) 
2.0  
(0.0, 3.0) 
 0.194 
Pathology Yes 0  
(0.0%) 
3  
(42.9%) 
 0.182 
No  5  
(83.3%) 
3 
(42.9%) 
Age of onset 
Mean (SD) 
26.17  
(8.33) 
41.14  
(19.56) 
14.98  
(-3.65, 33.60) 
0.101 
Medication None 0  
(0.0%) 
2  
(28.6%) 
None vs any 
med  
0.462 
CBZ 1  
(16.7%) 
2  
(28.6%) 
LTG 4  
(66.7%) 
1  
(14.3%) 
LEV 1  
(16.7%) 
0  
(0.0%) 
VPA 0  
(0.0%) 
2  
(28.6%) 
Any med 6 
(100.0%) 
5 
(71.4%) 
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The clinical characteristics of patients impaired at three week verbal recall have also 
been compared with those not impaired in table 10.34. Where the distribution of 
data is skewed the median and inter-quartile range have been used as measures of 
central tendency spread. For comparing the proportions with different seizure 
types, the expected numbers were too small for Chi square to be valid so the „partial 
and generalised‟ group were combined with the „generalised only‟ group. This 
allowed for the proportions with partial seizures only and the proportions with any 
generalised seizures to be compared using Fisher‟s exact test. Similarly, the 
numbers taking different types of medication are not enough for a valid Chi square 
so the proportions on no medication have been compared to proportions on any 
medication with a Fisher‟s exact test. There are no significant differences between 
any of these measures in those impaired and those not impaired. 
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10.3.2 Individual-level analysis of those impaired at three week visual recall 
 
Table 10.37: Characteristics of participants impaired at VST 30-3 
Variable Impaired   
(n=8) 
Not impaired 
(n=15) 
Difference 
(95% CI) 
Significance  
(p value) 
Group Patient 7  
(87.5%) 
5 
(33.3%) 
Fishers exact 0.027* 
Control 1  
(12.5%) 
10  
(66.7%) 
Age  
Mean (SD) 
36.88  
(18.45) 
35.67  
(15.36) 
-1.21  
(-16.19, 13.77) 
0.868 
Education years 
Median (IQR)  
12.00  
(10.25, 13.75) 
15.00  
(11.00, 17.00) 
Mann Whitney 0.160 
Anxiety score 
Mean (SD) 
6.63  
(3.34) 
8.40  
(3.46) 
1.78  
(-1.34, 4.89) 
0.249 
Depression score 
Mean (SD) 
2.00 
(1.77) 
3.67  
(2.69) 
1.67  
(-0.54, 3.87) 
0.131 
MQ score 
Mean (SD) 
48.00  
(18.06) 
48.27  
(12.54) 
0.27  
(-13.04, 13.57) 
0.967 
MQ 
nuisance 
None-mild 6  
(75.0%) 
10  
(66.7%) 
Fishers exact 1.000 
Mod-severe 2  
(25.0%) 
5  
(33.3%) 
PIQ 
Mean (SD) 
103.5  
(9.87) 
116.06  
(13.13) 
12.57  
(1.51, 26.19) 
0.028* 
FSIQ 
Mean (SD) 
97.38  
(13.41) 
114.53  
(10.54) 
17.16  
(6.62, 27.70) 
0.003** 
WMS – General Memory 
Mean (SD) 
99.38  
(11.43) 
111.07  
(13.10) 
11.69  
(0.25, 23.13) 
0.046* 
WMS - Visual Delayed 
Memory 
Mean (SD) 
94.50  
(11.23) 
102.53  
(13.72) 
8.03  
(-3.75, 19.81) 
0.171 
VST 0-30  Impaired 1  
(12.5%) 
1 
(6.7%) 
Fishers exact 1.000 
Not 7  
(87.5%) 
14  
(93.3%) 
VSTR 30-3  Impaired 3  
(37.5%) 
4  
(26.7%) 
Fishers exact 0.657 
Not 5  
(62.5%) 
11  
(73.3%) 
*p<0.05, **p<0.01 
MQ = Memory Questionnaire; PIQ = Performance IQ; FSIQ = Full Scale IQ; VST 0-30 = % of scenes 
forgotten between final trial and 30 minutes; VSTR 30-3 = % difference in scene recognition between 
30 minutes and 3 weeks 
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Table 10.37 shows the characteristics of participants impaired at three week visual 
recall compared to those not impaired. Those impaired include a significantly 
higher proportion of patients than those not impaired (p=0.027). Participants who 
are impaired have significantly lower PIQ and FSIQ scores (p=0.028 and p=0.003 
respectively) and significantly lower GM scores (p=0.046). The majority of those 
impaired are not impaired at the 30 minute forgetting score, suggesting that those 
impaired demonstrate isolated impairment over the longer delay. 
 
Table 10.38: Characteristics of patients impaired at VST 30-3 
Within patients Impaired  
(n=7) 
Not impaired 
(n=5) 
Difference 
(95% CI) 
Significance  
(p value) 
Seizure 
Type 
Partial only 0  
(0.0%) 
2  
(40.0%) 
Partial vs  
Any gen 
0.152 
Partial and 
gen 
4  
(57.1%) 
2  
(40.0%) 
Gen only 3  
(42.9%) 
1  
(20.0%) 
Duration of epilepsy 
Median (IQR) 
18.0  
(8, 60) 
3.0  
(2.5, 69) 
 0.219 
Total gen seizure no 
Median (IQR) 
2.0  
(2.0, 3.0) 
2.0  
(0.0, 2.5) 
 0.137 
Pathology Yes 0  
(0.0%) 
2  
(40.0%) 
 0.067 
No 7  
(100.0%) 
1  
(20.0%) 
Age of onset 
Mean (SD) 
36.29  
(20.01) 
32.40  
(13.91) 
3.89  
(-27.6, 19.79) 
0.722 
Medication None 1  
(14.3%) 
1  
(20.0%) 
None vs 
Any med 
1.000 
CBZ 1  
(14.3%) 
1  
(20.0%) 
LTG 2  
(28.6%) 
3  
(60.0%) 
LEV 1  
(14.3%) 
0  
(0.0%) 
VPA 2  
(28.6%) 
0  
(0.0%) 
Any 6  
(85.7%) 
4  
(80.0%) 
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Patients impaired at visual recall over three weeks have also been analysed to 
compare the clinical characteristics of those impaired and not impaired (see table 
10.38). As previously, the categories of seizure type and medication have been 
combined so that Fisher‟s exact tests can be carried out, as the numbers are too 
small for valid Chi square. No significant differences are found in any of the clinical 
measures compared between those impaired at visual recall and those not impaired. 
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Chapter 11.  Discussion 
 
 
11.1 Overview 
 
This chapter will be a discussion of the results reported in Chapter 10. The patterns 
of forgetting in both verbal and visual memory will be considered in newly 
diagnosed patients with epilepsy, and how these can be interpreted. As the patterns 
seen in the verbal and visual subtests were quite different, they will be discussed 
separately and the results compared. Factors that could be involved in forgetting 
and their influence will be considered. Subjective memory scores and the factors 
influencing these will also be discussed. The limitations that affect the interpretation 
of findings are very important, and these will be examined henceforth. The 
importance of the research will also be considered along with its implications for 
both clinical practice and further research.  
 
11.2 Long term forgetting – verbal 
 
The pattern of verbal recall in patients compared to controls was reported in 
Chapter 10 and demonstrated in figure 10.5. It was hypothesised that a proportion 
of patients would demonstrate accelerated long term forgetting, i.e. normal recall 
over the short delay but increased forgetting compared to controls over the longer 
three week delay. The pattern demonstrated by the results of this study was a little 
different. At initial learning there was no difference between patients and controls, 
but after 30 minutes patients recalled less, suggesting impairment of delayed verbal 
recall over a short delay. This would follow on from results in previous studies, as 
reviewed in Chapter 7, which show newly diagnosed partial epilepsy patients have 
a particular impairment in delayed recall of verbal information (Äikiä et al., 1995; 
Aikia et al., 1999). Over the three week delay, there was no significant difference in 
the rate of forgetting but recall at the three week assessment was significantly 
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poorer in patients than controls. This seems to suggest a pattern of impairment in 
delayed recall of verbal information that is present after 30 minutes and persists 
over longer delays, rather than a pattern of ALF.  
 
Of the patients classified as impaired at the 30 minute delay, nearly half (three out 
of seven) are no longer impaired after the three week delay. On the other hand, of 
those impaired at the three week delay a third (two out of six) were not impaired at 
the 30 minute delay. Although these numbers are very small this could possibly 
suggest that there is more than one pattern of impairment present in verbal recall in 
the patient group. A small number of patients could be showing ALF, whereas 
others have a pattern of poor retention over a short delay but good retention over 
the long delay. This second pattern could have come about because there was no 
distraction task administered after the presentation of the story to prevent the 
recency effect so initial recall could have been augmented by short term memory. If 
this was the case, and there was a problem encoding short term to long term 
memory, recall would be poor over the short delay but with no increased forgetting 
over a longer delay. Considering the multiple processes involved in memory, and 
the numerous ways that epilepsy can impact on memory, it would not be surprising 
if there was more than one pattern of impairment. 
 
The results from the verbal recall subtest seem to correlate reasonably well with the 
WMS scores, initially with the number of trials, and also over both the short delay 
and long delay there are measures that correlate to WMS index scores. This would 
seem to suggest that the WMS and other similar tests with a 30 minute delay to 
assess long term memory could be valid for the prediction of very long term verbal 
memory over extended delays. However, the WMS scores between the groups were 
not significantly different while the LMS scores showed significant impairment in 
the patient group, so it may be that the very long term impairment is only partially 
predicted by WMS scores. 
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If the pattern in patients is one of persistent delayed verbal recall impairment across 
both delays, the next question would be what type of memory problem is that 
demonstrating. As the initial learning of information (as shown by the number of 
trials to reach criterion) was not impaired in patients, this would suggest that there 
is not a problem with the initial acquisition of information. Rather, there must be a 
problem either transferring information from short term to long term memory, 
maintaining it once it is in long term memory, or retrieving it from long term 
memory. The intact recognition that has been demonstrated might lead one to 
suggest that it could be a problem with retrieval of the information, as intact 
recognition suggests that it is still there to be accessed. However, in the literature on 
ALF a number of studies have identified no impairment in recognition and 
accelerated forgetting, and have identified this as a consolidation problem, as it is 
stated that words can be stored poorly in a degraded form (i.e. demonstrating a 
consolidation problem) but still be accessible to recognition processes (Martin et al., 
1991). Unfortunately the design of this study and the small numbers prohibit a more 
extensive evaluation of which processes are affected. 
 
As there seems to be impairment in delayed verbal recall in patients, the causative 
factors behind this need to be examined. When those impaired over the three week 
delay were compared with those not impaired, the only significant difference was 
in full scale IQ. Patients generally had lower full scale IQs than controls, despite 
being matched to years of education. There was an interesting dissociation between 
years of education and intellectual functioning in patients, despite significant 
correlations in controls. This suggests that there might be other factors that have 
more of an impact on intellectual functioning than education in patients with 
epilepsy. However a further study would be required to identify what are likely to 
be epilepsy related factors interfering with this relationship in newly diagnosed 
patients. 
 
Whatever is causing the lower levels of intellectual functioning in patients, they 
seem to be related to the long term forgetting measures. Therefore, one suggestion 
might be that the impaired long term verbal recall scores in patients are merely the 
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result of poorly matched patient and control groups, with different levels of 
intellectual functioning that are impacting on their memory scores as a part of 
general cognitive impairment. However, if poor intellectual functioning was having 
a general detrimental effect on memory, then all memory scores (i.e. including 
WMS indices) might be expected to be impaired. The fact that there are no 
significant differences between patients and controls on WMS scores would suggest 
that the impaired delayed verbal recall demonstrated in patients is not purely the 
result of general cognitive and memory impairment. It could be that poor 
intellectual functioning has a particularly selective effect on longer term recall 
performance, or there could be other factors at play which are affecting both 
intellectual functioning and delayed verbal recall. The tests employed measured the 
participants‟ memory performance, but not how that performance was achieved. 
For example, participants with a higher IQ could be using more effective 
memorising strategies during the delay interval. Unfortunately, there were not 
enough participants in the study to undertake multiple regression analysis, which 
might have allowed the results to be considered adjusted for IQ differences, to 
identify other significant factors involved. 
 
Similarly, there were not enough participants to undertake thorough analysis of the 
influence of possible causative factors of the impairment, but they will be 
considered. As discussed in Chapter 4, there are many interacting factors that can 
combine to cause cognitive impairment in patients with epilepsy, including seizures 
and interictal discharges, pathology, AEDs and psychological factors. 
 
The patients in this study were recruited at diagnosis, in order to try and discover 
whether there was any evidence of very long term memory impairment from early 
on in the course of the condition. However, even at diagnosis patients have often 
had a number of seizures, particularly partial seizures, which may have been going 
on for months or even years, so the potential effects of these seizures must be 
considered. Neither the total lifetime number of generalised seizures nor the 
duration that seizures had been occurring was associated with the three week 
verbal forgetting rate in patients. Also, whether or not patients had seizures during 
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the three week delay did not seem to affect their forgetting over the delay. Whilst 
these results do not rule out an impact of seizures on verbal recall over a three week 
delay, particularly considering the small numbers, it seems it is unlikely that 
seizures are the only mechanism of interference with long term memory. However, 
interictal discharges were not considered, and as the majority of patients did not 
have any EEG results, it is impossible to say how much of a factor these could have 
been. 
 
In terms of pathology, unfortunately the numbers involved in the study were too 
small to undertake a meaningful analysis comparing those with pathological 
abnormalities on imaging to those without. This means that no comment can be 
made on the impact pathological lesions might have on delayed memory. However, 
there has been research suggesting that underlying pathology is associated with 
cognitive problems in newly diagnosed epilepsy (Helmstaedter et al., 1993; 
Pulliainen et al., 2000a). 
 
AEDs are often suggested, particularly by patients, as a causative factor in cognitive 
impairments (Baker et al., 1997; Carpay et al., 2005). Unfortunately it was not 
possible to assess patients before they started taking AEDs, as the assessment 
period was at least three weeks (not including arranging a convenient time) which 
would have substantially delayed starting treatment. So, patients were already 
taking a variety of medications, which must be considered at least a potential 
causative factor in memory impairment. Although nearly half the patients were on 
monotherapy (LTG) there were four different AEDs used in the study, and there 
were not enough participants to compare the results of individual AEDs on long 
term forgetting. However, it should be borne in mind that research into cognitive 
problems associated with AEDs has suggested cognitive problems to be dose-
dependent, occurring at higher doses (Vermeulen & Aldenkamp, 1995)(see section 
4.8 for further discussion), and the patients involved in the study were on low 
starting or maintenance doses. Also, cognitive problems particularly in the field of 
memory have previously been documented in newly diagnosed patients before 
starting medication, as discussed in Chapter 7. 
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Psychological factors such as anxiety and depression can be related to objective 
cognitive problems (Burt et al., 1995) as well as cognitive complaints as will be 
discussed later, but there was no difference in anxiety or depression levels between 
those impaired at long term forgetting and those not impaired, which would 
suggest that they do not have a major role here. 
 
Epileptogenesis, the process by which a normal brain is altered to become an 
environment in which spontaneous seizures occur, could be another causative 
factor in memory impairment in newly diagnosed patients. As discussed in Chapter 
7, complex changes to the structure and function of neurons seem to occur in 
epileptogenesis (Badawy et al., 2009a), and if these were occurring in neurons in the 
areas responsible for consolidation or retrieval of memories, then it is 
understandable why these functions might be impaired.   
 
11.3 Long term forgetting – visual 
 
The results of long term forgetting in the visual recall subtests seem to follow a 
different pattern from those of the verbal subtest, as shown in table 10.15 and figure 
10.8. The hypothesis, as for verbal forgetting, proposed that at least a subset of 
patients would demonstrate accelerated long term forgetting in visual recall over 
the three week delay, i.e. that they would remember the information normally over 
the short 30 minute delay and forget a larger proportion than controls over the three 
week delay. 
 
The results from this study demonstrated that patients had poorer initial learning 
performance than controls in the visual scenes test, taking on average more trials to 
reach the recall criterion of 75%. Over the 30 minute delay patients did not forget 
any more of the information than controls, and had a similar recall performance. 
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Over the three week delay, patients forgot a significantly higher proportion of the 
information than controls, and also considering participants individually a 
significantly higher proportion of patients than controls were impaired (58% vs 9%) 
at three week retention. Of those impaired after three weeks, only one (14%) had 
been impaired after 30 minutes. 
 
If the initial learning impairment is taken out of consideration, this would appear to 
be a clear pattern of ALF in patients in visual recall performance. However, the 
initial learning impairment needs to be taken into account, and the possible reasons 
why this would happen, with normal recall after 30 minutes, need to be considered. 
The relationship between number of trials and 30 minute recall performance was 
considered, and in patients there was a significant negative correlation. This would 
demonstrate that there was a significant effect of over-learning – that the more 
times the material was presented to the patients the better they remembered it over 
the 30 minute delay. This effect was not found when number of trials was compared 
to three week forgetting, suggesting that the over-learning was only a temporary 
effect.  Potentially, this could explain why 30 minute recall performance might be 
matched in patients and controls – theoretically if patients‟ visual memory is 
impaired they need more trials initially, then the over-learning effect will 
temporarily boost their 30 minute performance and when the effect wears off the 
three week memory will again be shown to be impaired. This would reduce the 
validity of the finding of intact recall at 30 minutes. However, greater number of 
trials was not associated with worse forgetting over the three week delay, which 
would seem to contradict this theory. It is interesting that an over-learning effect 
was seen in the visual test and not the verbal test, which could be because the visual 
test was more challenging, and reaching the recall criterion might involve 
processing the information at a deeper level rather than just repeating back a story, 
thus more effectively establishing it in long term memory. 
 
Learning to criterion can be criticised as a method for assessing long term memory, 
in that it may artificially „boost‟ memory performance with over-learning, as 
discussed above. It was used in this study to match the initial performance of 
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patients and controls so that the forgetting could be assessed without the problem 
of scaling, and is a method that has been used in a number of the previous studies 
on ALF (Butler, Butler, Davidson, Blake, Wilkinson). Other ALF studies have used a 
„Selective Reminding Test‟ method (Bell 05, Giovag, Martin) but this was not 
appropriate for the material being tested in this study. It was therefore felt on 
designing the study that learning to criterion would be the least biased way to 
ensure matched initial recall, but its potential for affecting delayed memory 
performance should be borne in mind. 
 
There is an alternative potential reason why recall was no different in patients and 
controls at 30 minutes in the visual task but not the verbal task. When the 
information was presented to the participants, in the visual test a distraction task 
(counting back from 100 in threes for 20 seconds) was used before immediate recall.  
This was to ensure all remembered information is from „long term‟ memory, in 
contrast to the verbal task where this was not done so recency and short term 
memory would have more impact on recall scores. If immediate recall is based on 
information in long term memory, participants may take longer to reach the 
criterion but once reached the information is more likely to stay for 30 minutes, as it 
has already been encoded. 
 
The pattern of impairment should help identify whereabouts in the memory process 
there is a problem. There was some initial learning impairment, as discussed, which 
would suggest an impairment encoding the information into long term memory. 
The visual test is felt to be more difficult than the verbal task (and a taxing test can 
expose more subtle impairments), and also included a distraction task, which could 
explain why this is different from the pattern seen in the verbal test. The lack of 
impairment over the 30 minute delay suggests that the material was well 
maintained over the short period once learnt, implying intact fast consolidation 
processes and retrieval. Based on this assumption, the significantly faster forgetting 
over the three week interval would demonstrate some interference with slow 
consolidation processes, however there is still a chance it could merely reflect the 
earlier encoding difficulties that were masked at the short delay by over-learning. 
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The recognition scores are difficult to interpret, as while there was no significant 
difference a larger proportion of patients than controls were impaired after the three 
week delay (50% vs 9%) which would match with the picture of a slow 
consolidation problem. 
 
When considering correlation between the visual scenes test scores and the WMS 
indices to assess the reliability of the WMS for predicting very long term visual 
recall scores, it was found that the only correlation was between the number of 
trials taken to reach criterion level and the visual immediate memory score, when 
all participants were analysed together. Three week forgetting scores demonstrated 
no correlation with the WMS, and interestingly, neither did 30 minute forgetting 
scores. Some correlation would be expected, particularly at 30 minutes, due to the 
similarity of the „family pictures‟ section of the WMS and the visual scenes test. This 
suggests that the WMS is not predictive of very long term visual memory. 
 
Patients seem to have poorer memory for the visual scenes than controls, whether it 
is a slow consolidation problem causing ALF or merely a persistent encoding 
problem masked at 30 minutes. The possible causative factors for this need to be 
considered.  As for the verbal results, there are a number to take into account. When 
those who are impaired at three week forgetting are compared to those not 
impaired, the significant differences are in group (more patients impaired), PIQ, 
FSIQ and WMS general memory score (those impaired have lower scores). 
 
As discussed in the previous section relating to the verbal subtest, it is possible that 
the long term delayed recall impairments seen in patients are a reflection of general 
worse cognitive functioning in patients compared to, in hindsight, a poorly matched 
control group (despite controls being well matched on education), as evidenced by 
lower scores on PIQ, FSIQ and GM in those impaired. Patients and controls did not 
perform significantly differently on the WMS, but it is difficult to prove or disprove 
this idea without multiple regression analysis, which would need more 
participants. 
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Seizures do seem to have had some impact on visual delayed memory, as the total 
lifetime number of generalised seizures correlates significantly with the three week 
visual forgetting scores, with those having had more seizures forgetting more over 
the three weeks, as well as correlating significantly with WMS general memory 
score. This would suggest that the generalised seizures have somehow damaged or 
affected the efficiency of the processes of retaining long term visual memories. In 
contrast, seizures during the three week delay interval seemed to have no impact on 
forgetting rates (in this small sample) so it is possible the problem may be one 
affecting the underlying substrate and its effectiveness rather than interference with 
consolidation of individual memories. This could also be the effect of 
epileptogenesis, as discussed above. 
 
Again, the effects of AEDs could not be analysed separately due to the small 
sample, so medication cannot be ruled out as a causative factor, despite the small 
doses used and the previous evidence of memory problems in patients newly 
diagnosed with epilepsy before starting medication. Similarly, there are not enough 
participants to analyse the effects of pathology in this study, and while it has 
previously been suggested not to be involved in ALF (Blake et al., 2000; Wilkinson et 
al., under review) it could potentially be involved in initial encoding problems. 
Psychological factors were also shown to have little impact on long term visual 
forgetting, with there being no difference in anxiety or depression in those impaired 
and not impaired. 
 
As the laterality of seizure focus could not be identified in the majority of patients, it 
is impossible to compare visual and verbal impairment in left and right sided 
epilepsy patients to look for material specific laterality effects. Impaired long term 
recall in the two domains does not appear to be related, because of those impaired 
at visual three week forgetting, nearly half (3/7) were not impaired at verbal three 
week forgetting. 
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11.4 Subjective memory and psychological factors 
 
Contrary to expectations, subjective memory scores were no worse in patients than 
controls. This is not in line with previous research on subjective rating of memory in 
people with epilepsy (Thompson, 1992; Vermeulen et al., 1993), but on the other 
hand the majority of previous research has been undertaken with patients with 
long-standing epilepsy, rather than those who are newly diagnosed. It could be that 
memory complaints increase with time over the course of the condition, and have a 
progressive nature. Also, there is a chance of selection bias in the controls, as they 
were volunteers rather than being recruited systematically like patients. It may be 
that people who volunteered to act as controls did so partly because they had 
concerns about their memory and so wished to have it tested, which would mean 
their memory complaint scores would be abnormally high and not representative of 
the population. 
 
There was little correlation between subjective and objective memory scores, as has 
been shown in previous literature (Vermeulen et al., 1993; Giovagnoli et al., 1997; 
Elixhauser et al., 1999; Piazzini et al., 2001; Baños et al., 2004; Au et al., 2006; Maarika 
et al., 2009). Only one measure (visual delayed memory from WMS) showed 
significant correlation with the memory questionnaire nuisance rating, in patients 
only. It was hoped that the forgetting scores over the longer intervals would 
correlate better with memory complaints, if ALF had a role to play in the 
discrepancy, but this did not seem to be the case, as none of the three week 
forgetting measures correlated with any memory complaint score in either group. 
This demonstrates that discrepancy between subjective and objective functioning 
remains even when long term scores are taken into account. 
 
In terms of psychological wellbeing, on the HADS, despite no significant difference 
in mean anxiety scores between patients and controls, significantly more patients 
had moderate or severe levels of anxiety than controls. This increased anxiety in 
patients just after diagnosis is understandable, considering the worrying time 
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patients are facing coming to terms with their condition and learning about it, and 
previous studies have found newly diagnosed patients to have higher levels of 
depression, tension, helplessness and confusion (Pulliainen & Jokelainen, 1994; 
Prevey et al., 1998; Pulliainen et al., 2000b; Taylor et al., 2010). There was no 
difference between patients and controls in terms of depression scores however, 
which would have been expected from the literature (Pulliainen et al., 2000b). 
 
In patients both anxiety and depression scores, particularly anxiety, showed 
significant correlation with the memory complaint score. Depression score also 
correlated significantly with the nuisance rating score. It is interesting that anxiety 
correlated more strongly with the frequency of problems, indicating perhaps 
heightened self consciousness leading to picking up on little irritations, while 
depression correlated strongly with the degree of nuisance that those problems 
caused. The significant correlations between anxiety and depression levels and 
memory complaints are as expected from previous literature identifying this as a 
major factor in the discrepancy between subjective and objective memory 
functioning (Giovagnoli et al., 1997; Elixhauser et al., 1999; Piazzini et al., 2001; 
Maarika et al., 2009). However, it is interesting to note that there were no significant 
correlations between anxiety and depression scores and memory complaints in 
controls, and no reasonable explanation other than the small sample size can be 
considered to explain this. 
 
It would be interesting to undertake multiple regression analysis to extrapolate the 
factors involved in predicting level of memory complaints. However, due to time 
constraints, recruiting numbers adequate to perform multiple regression was not 
possible. 
 
11.5 Limitations of the research 
 
There are a number of limitations identified, including the following: 
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1. The main and most frustrating limitation of the study is the small numbers 
of patients and controls involved. The sample size calculation undertaken 
prior to data collection suggested that a sample of 21 in each group would 
be needed to identify a difference of 15% between the patient and control 
groups in percentage of information forgotten over three weeks to a 5% 
significance level and power of 80%. However, only 14 patients and 13 
controls were recruited, and following the exclusion of those over 70, 
analysis of long term forgetting was undertaken on 13 patients and 11 
controls. 
 
This would suggest that the study is underpowered. Power analysis has 
been repeated post hoc, using the results and numbers found, using a 
statistical power calculator based on two sample tests using average values 
(DSS-Research). Considering the long term forgetting of the story, with 
mean values of 28.71 (13.08) in the patient group and 19.63 (10.46) in the 
control group, there is 47.2% power to detect a difference significant at the 
5% level, so the study is underpowered to detect this difference in long term 
forgetting in the verbal subtest. In the visual subtest, with long term 
forgetting mean values of 44.05 (26.74) in the patient group and 13.33 (14.69) 
in the control group, there is 93.2% power to detect this difference significant 
at the 5% level. This shows that, considering the difference between groups 
at long term visual forgetting, the difference was larger than expected so 
there is still adequate power to detect this as a true difference. 
 
Before the study was undertaken, consultant neurologists running epilepsy 
clinics were asked about the feasibility of recruiting 21 patients with recently 
diagnosed TLE in the short time period available for data collection, and it 
was felt that this was a realistic aim. Potential patients were identified firstly 
by looking through patients who had attended epilepsy clinics in the 
previous six months to see if they were diagnosed with TLE or localisation 
related epilepsy, and they were contacted by invitation letter if it was felt 
they were suitable. There was a response rate of 64% to these letters, with 
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57% of those responding agreeing to participate in the study (four patients). 
However, half of these positive responders (two patients) later withdrew 
when they were unable to arrange a convenient time to be seen within the 
time constraints of the data collection period (one was in prison, one was 
unwilling to come to the Walton Centre and was having their house 
redecorated so didn‟t want a home visit). This meant that just 18% of the 
patients initially contacted by invitation letter were assessed for the study 
(two patients). 
 
The author also recruited patients from epilepsy clinics. The author did as 
much as possible to ensure any suitable patients were identified and 
recruited, making sure all clinicians running clinics knew about the study, 
and the inclusion and exclusion criteria. Each week, the notes of the patients 
coming to all epilepsy clinics (new patient clinics, follow-up clinics and 
nurse-led clinics) were reviewed to identify any possible patients, and direct 
which clinics would be attended. The author sat in on at least two clinics a 
week, up to as many as five, and if a clinic with a potential patient was going 
to be missed a message was put into the notes to ask the clinician to tell the 
patient about the study, give them an information sheet and take their 
contact details if they were happy to give them so that the author could 
contact them after the clinic. A total of 17 suitable patients were seen by the 
researcher in clinics, of whom 76% initially agreed to participate in the 
study. One of these patients later was unable to arrange an assessment 
convenient for them, as they had to cancel arranged assessments four times 
at short notice, and was unable to rearrange within the data collection 
period. So 71% of suitable patients seen in clinic were assessed, showing that 
recruiting via meeting and explaining the study personally to patients was 
much more effective than inviting by letter, as would be expected. 
 
The high rate of positive response from patients seen in clinics shows that 
when suitable patients were personally approached, they were generally 
happy to participate. This suggests that the numbers of patients recruited 
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could have been low because of a lack of suitable patients. The exclusion 
criteria of the study did rule out quite a number of potential patients who 
were diagnosed with localisation related epilepsy, particularly as a number 
of patients had a history of previous severe head injury, and also a number 
of otherwise identified patients reported alcohol or drug abuse or concurrent 
major psychiatric illness. These exclusion criteria were in place to avoid 
extra confounding factors that could otherwise explain cognitive difficulties 
apart from epilepsy-related factors, so were necessary for the reliability of 
drawing conclusions from the results. Also, the time period for recruitment 
was four and a half months, from mid-January to the end of May 2010, 
which was restricted by gaining ethical permission at one end and allowing 
time to finish data collection and analysis at the other end. This was initially 
felt to be long enough to recruit sufficient suitable patients, but the number 
of patients diagnosed with localisation-related epilepsy and meeting the 
inclusion criteria was lower than expected. 
 
2. There was also a problem with recruiting enough matched healthy controls. 
Patients were asked at recruitment if they knew anyone of a similar age to 
them who might be willing to participate. This provided some of the 
controls, but 57% were unable to find somebody suitable who was willing to 
participate. The main problem with finding willing participants was the 
time commitment involved in participating in the study, which also 
discouraged the majority of those responding negatively to the invitation 
letter. The initial assessment took around three hours, and particularly 
potential controls who were working said they were unable to fit this in 
(despite offering evening or weekend assessments). As there was no 
reimbursement or incentive for participants, it is understandable that people 
were not willing to give up such a large chunk of time, but unfortunately it 
was necessary as full and comprehensive assessment of IQ and memory 
requires this length of time. 
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3. Apart from the small numbers of participants there were also a number of 
other limitations of the study, including difficulties with suitable participant 
groups. One of the difficulties with interpreting the long term forgetting 
results, as discussed in the previous sections, is identifying and controlling 
for the effect of participants‟ IQ on their long term forgetting scores. The 
significant differences in IQ between patients and controls make it difficult 
to assess memory results independently, as the differences in IQ not only 
reflect other cognitive processes, but can impact on memory scores via use 
of more effective memorisation strategies or recall strategies. Controls were 
recruited to be matched to patients at years of education, as IQ cannot be 
assessed prior to recruitment and it was felt that matching to education 
would be the most simple and effective way to try and find a control group 
similar to the patient group in terms of intellectual functioning. However, 
given the dissociation between years of education and IQ in patients, this 
was not the case. This dissociation cannot be fully examined as no pre-
morbid measure of IQ was used as part of the battery, so it is not possible to 
identify whether it represents a deterioration in IQ with epileptogenesis or 
seizures or merely lower intellectual functioning in that cohort. When 
designing the study, it was felt that years of education would give the 
required results and only with hindsight it was felt that a pre-morbid 
measure would have been useful. 
 
4. In terms of the patient group, it was initially hoped to recruit a group of 
patients all newly diagnosed with TLE. However, as there were problems 
with recruiting participants, this had to be expanded to patients newly 
diagnosed with any localisation related epilepsy. This made it slightly easier 
to identify suitable patients, not least because it is often difficult for 
clinicians to be confident about where an epileptic focus might be without 
imaging or electroencephalographic results, or even after these, but it is 
easier to say whether it is localisation related or generalised. However, a 
group of patients with an epileptogenic focus in the same area of the brain 
makes it easier to come to conclusions about the role of that area in long 
term forgetting. While TLE is the most common type of localisation related 
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epilepsy, the patients assessed could have had foci in other areas such as the 
frontal lobe, which might bring about a different memory profile. However, 
even within TLE patients there can be lesions in the lateral or mesial 
temporal lobe causing different profiles of impairment so focussing 
investigation on one type of epilepsy does not exclude variation within 
patients. Also, by assessing a wider population of patients the results are 
more generalisable to a population of newly diagnosed localisation related 
epilepsy patients.  
 
5. Another problem with interpreting results in the patient group is the 
confounding factor of medication use. All bar two patients were taking one 
AED at the time of assessment, and they were taking a number of different 
medications, so it was not possible (particularly given the small numbers) to 
factor AED use into analysis. This was difficult to avoid because the 
extended delay aspect to testing meant, if patients were to be tested before 
initiation of medication, it would entail a three week delay before 
commencing AED therapy which was deemed unethical.  
 
6. Another difficulty with trying to recruit and assess patients from diagnosis 
is that it is not the same as assessing at the start of epileptogenesis or even 
from their first seizure. Recruiting patients from diagnosis is the only way of 
identifying patients with epilepsy, but almost by definition patients have 
generally had at least two seizures at the time of diagnosis, and many have 
had more, particularly partial seizures, some for a number of months or 
years. If patients have had varying numbers of seizures, and a varying 
length of time with seizures (and therefore varying time with underlying 
epileptogenic changes in their brain substrate) this makes it difficult to draw 
conclusions about the effects of these variables on memory. 
 
7. Little investigation data was available from the patients – it was possible to 
obtain imaging results (CT or MRI) in all patients, but there were no 
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measures such as volumetrics employed to examine the relationship of these 
with memory. Controls did not have any imaging so it was impossible to say 
whether or not they had any asymptomatic abnormalities, and also whether 
their brain volumes would correlate with memory and intellectual 
functioning. Fewer EEG results were available, as often EEGs were not 
requested in newly diagnosed localisation related epilepsy as it was felt that 
the result would not affect management or prognosis. Due to this, and the 
few abnormalities on imaging, it was generally difficult to determine 
laterality of seizure onset, which meant that it was impossible to consider 
differences in neuropsychological profile according to laterality of epilepsy. 
 
8. The memory tests used to test long term forgetting are potentially restricting 
the usefulness of the findings. A logical memory story was used as a 
measure of verbal memory, because while word lists have identified more 
deficits, particularly in newly diagnosed patients with partial epilepsy 
(Äikiä et al., 1995; Aikia et al., 1999), it was felt that a story provides a more 
useful test of the kind of memory used in everyday life rather than a list of 
unrelated words with no semantic resonance. However, a story might be 
thought to be more easily rehearsed than other verbal measures, allowing 
for rehearsal strategies to have more of a confounding effect on results. A 
word list could have been used alongside the story, as has been done in 
previous studies (eg (Butler et al., 2009)), but considering the length of the 
assessment it was felt that this would be too much to ask participants to 
undertake in one session. The visual scenes test was a test that has been 
developed by Dr Muhlert specifically for this type of research into long term 
forgetting. Although some of the information tested can be verbalised so it is 
not a pure test of visual memory, similarly it is felt that it tests memory 
similar to that used for everyday tasks and thus provides a useful relevant 
guide for a person‟s level of memory functioning on a day-to-day basis 
rather than merely in an isolated testing environment. 
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9. One problem with the interpretation of the tests and the comparison of 
results from them was a slight difference in procedure between the two 
subtests. As mentioned above, in the visual subtest a distraction task was 
used after presentation of the scenes to remove recency effects, but this was 
not done in the verbal subtest. This was an oversight on the author‟s behalf 
when initially designing the battery, and was only picked up after a number 
of participants had been tested. At that point it was felt that consistency of 
administration of the tests between subjects was more important than 
consistency of administration between subtests. 
 
10. The testing of long term forgetting was undertaken at only one interval, 
three weeks after initial presentation of the material. Results were highly 
dependent on this assessment, and if participants had just had a busy day or 
were distracted on that one occasion their performance might be adversely 
affected. Also, assessing long term forgetting on one occasion means that the 
trajectory of forgetting over time cannot be fully assessed, and when the 
forgetting was accelerated. 
 
11. Previous studies have suggested a link between ALF and TEA (Butler, 
Butler, Manes). As TEA originates in the temporal lobes, whether or not the 
patients with TLE had coexisting TEA could be relevant to the long-term 
forgetting results. However, no information was gathered specifically 
regarding possible episodes of amnesia. Detailed histories were taken in the 
clinic when patients were diagnosed (and often recruited), and classification 
of patients‟ seizures was based on their consultants‟ opinions. Seizure 
history was confirmed at the first assessment, but no further questions about 
episodes of amnesia were asked because the researcher does not have the 
experience to distinguish TEA from other differential causes. This means 
that no information is available to the researcher regarding the possibility of 
TEA co-existing with ALF in TLE. 
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12. From the perspective of investigating the subjective memory functioning of 
the patients, there were also a number of potential limitations. Within the 
testing battery there were no specific tests of language functions, or verbal 
fluency, which have been shown to be related to subjective memory 
complaints (Helmstaedter & Elger, 2000). There were also no attention or 
concentration measures used as part of the assessment battery, which might 
influence memory results. 
 
13. Within the subjective memory questionnaire, there was no specific question 
about experience of accelerated forgetting. If this had been the case, it might 
have been possible to compare scores on that question with long term 
forgetting scores to see if that provided better correlation between subjective 
and objective measures. 
 
14. There were also limitations caused by the statistical tests used. As 
mentioned in Chapter 9, a large number of comparisons and correlations 
were undertaken, which increases the chance of finding a false positive 
result, or type I error. In this situation, a Bonferroni correction can be used to 
reduce the chances of type I errors but this was not done in this study. It 
limits the ability of research, particularly with small sample sizes, to identify 
„small‟ or „medium‟ effect sizes, and increases the risk of type II errors. It has 
also been said that a Bonferroni correction discourages detailed analysis, as 
the more detailed analysis is undertaken the less the chance of significant 
findings (Moran, 2003).  Moran suggests, instead, „using the accepted p<0.05 
cut-off and making reasonable interpretations based on experimental design, 
power analyses, differences between control and treatment groups, and 
basic logic‟ p405 (Moran, 2003). In this study, where there were a lot of 
interacting factors to be considered which require detailed analysis, and 
where the aim was to look for patterns and trends, it was felt that this was 
an approach more likely to yield findings of interest. However, the 
likelihood of type I errors needs to be borne in mind when interpreting these 
findings. 
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11.6 Strengths of research 
. 
Despite the limitations, there were also a number of strengths of this study: 
1. Patients were recruited and assessed as close to diagnosis as possible, so as 
to identify long term memory patterns from early on in the course of 
epilepsy. 
2. The strict exclusion criteria employed reduced the impact of other potential 
influences on memory functioning. 
3. A thorough battery including standardised assessment of IQ and memory 
was used alongside the long term forgetting tests. 
4. A control group was also assessed with whom to compare the patients‟ 
results, who were well matched in terms of age, gender and education. 
5. Long term forgetting was assessed in both verbal and visual domains, and 
also in both recall and recognition performance. 
6. A measure of subjective memory was also employed to compare to the long 
term forgetting results. 
7. A measure of psychological wellbeing was used, so that this could be taken 
into account in the analysis of both objective and subjective memory results. 
8. All the assessments were carried out and scored by the author (and then 
checked) so that administration would be consistent. 
 
11.7 Importance of this research, and clinical indications 
 
This research provides the first indication of anterograde memory performance over 
extended delays in patients recently diagnosed with localisation related epilepsy. 
This has not been considered in previous studies in this area. Increased forgetting 
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was found in patients, in both verbal and visual domains over a three week delay 
from early on in the course of epilepsy, confirming previous research findings that 
patients are cognitively compromised from diagnosis (eg (Taylor et al., 2010)).  
 
Patients remembered nearly 10% less of the verbal information and over 30% less of 
the visual information than controls over three weeks. For the sample size 
calculation, a minimum clinically significant difference was felt to be a 15% 
difference in proportion of material forgotten over the time interval. This would 
suggest that the difference in forgetting of visual information over three weeks was 
not only statistically significant at the 1% level, but also clinically significant. This 
pattern of accelerated long term forgetting has not previously been identified in this 
population, and it is also particularly interesting that it is in this domain. 
 
One of the key questions from the point of view of the clinical impications of the 
research is regarding whether or not standard memory tests are adequate for the 
assessment of memory in patients with epilepsy (particularly in this case in those 
newly diagnosed). The WMS was used as an example of a standard well-used 
memory battery, and scores in verbal long term forgetting seemed to be partially 
predicted by the WMS but those from the visual long term forgetting subtest were 
not. This gives a mixed picture, and whether extended testing delays are necessary 
in this population is still somewhat unclear. 
 
Subjective and objective memory discrepancies in newly diagnosed patients were 
another focus of this research and it was found that they were not explained by long 
term forgetting, but were well correlated with psychological wellbeing. 
 
Although in many ways this study has thrown up more questions than it can 
answer, this is to a large extent due to the small sample size, and it has provided an 
idea and outline design for a larger study that would be able to look into many of 
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these issues in more depth, with the advantage of a greater number of participants. 
With this in mind, the possibilities for future research directions are outlined below. 
 
11.8 Future research directions 
 
If this study can be adjusted for its methodological flaws and repeated on a larger 
sample of patients and controls, a lot more analysis would be possible and more 
interesting information extracted, particularly around the potential causative factors 
of extended long term memory impairment. It is frustrating for the author that 
recruiting more numbers was not possible in the timeframe, and the potential 
opportunities to discover some very interesting patterns and relations in this 
population are noted. 
 
If possible, future investigations in this area could also look at long term forgetting 
rates in patients prior to medication. Because of the necessity of an extended delay 
within assessment due to the nature of the problem, this may be difficult, but so far 
no investigations into long term forgetting in epilepsy patients have been 
undertaken without medication, and it is important to exclude it as a causative 
factor, or at least try to extrapolate its influence through the use of statistical 
regression models. 
 
More research is needed on accelerated forgetting generally, not only in newly 
diagnosed patients with epilepsy. One of the major problems with both reviewing 
the literature on ALF and designing the study was the lack of a standardised test for 
long term forgetting over an extended delay. This makes it difficult to compare the 
results of different studies using different measures over different lengths of time, 
and also means that there are no standardised population norms to identify levels 
of impairment, which is why a control group is needed. Testing of long term 
forgetting with a range of verbal and non-verbal tests might help identify the most 
effective type of test to be used for extended delays that provides the most useful 
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information whilst allowing for the least possible bias. Also, testing of long term 
forgetting in a healthy normal population considering a range of ages would allow 
for the creation of age-adjusted standardised norms with which to compare not just 
epilepsy patients but people with many varying conditions that could affect 
memory. 
 
11.9 Summary 
 
 The aim of this research was to investigate long term forgetting in patients 
newly diagnosed with localisation related epilepsy, in both verbal and visual 
domains. Overall, long term anterograde memory impairment was found in 
recently diagnosed patients. 
 In the verbal domain, patients demonstrated impaired delayed recall over 
both the short and long delays.  
 In the visual domain, patients demonstrated poorer initial recall than 
controls followed by ALF over the three week delay, to a clinically 
significant level, which was related to a greater number of lifetime 
generalised seizures.  
 Verbal long term memory performance was partially predicted by WMS 
scores, but visual long term memory was not, which leaves the need for 
extended testing delays under question. 
 There was no difference between patients and controls in subjective memory 
scores. Memory complaints were related to anxiety and depression, but not 
to any long term forgetting measures, suggesting that ALF is not the cause 
of reported discrepancies between subjective and objective memory. 
 A number of limitations related to participants and study design, notably 
the small numbers involved in the study and discrepancies in IQ between 
the patient and control groups restrict the conclusions that can be drawn 
from the findings, particularly regarding specific mechanisms of impairment 
and causative factors.
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Dear  
 
My name is Professor Gus Baker, I am a clinical neuropsychologist based at the Walton Centre, 
Liverpool. As a patient with epilepsy treated at the Walton Centre, you have been identified as 
somebody who might be able to participate in a study I am undertaking. I would be most grateful if 
you could read through the information sheet attached to find out more about the study and decide 
whether or not you would like to be involved in it. 
 
There is no pressure to take part, and your decision will not affect your care in any way. If you would 
like any more information, or once you come to a decision, feel free to contact me by phoning me or 
my researcher Marion Ashe on 0151 529 5417, emailing us at ‘m.f.ashe@liv.ac.uk’ or returning the 
slip below in the enclosed stamped addressed envelope. Even if you do not wish to participate I 
would appreciate a response, so that I can remove you from my contact lists and not bother you 
again.  
 
If you decide you would like to be involved, thank you. We will contact you to arrange two sessions 
together. Also, as we are looking for healthy control participants, we will ask if you think you know 
of anybody, family or friends, of a similar age to you, whom you wouldn’t mind telling about the 
study, giving an information sheet, and asking them to contact me to get involved too. If you would 
rather not, that is not a problem and you are still most welcome to participate. 
 
Thank you for your time, 
Yours sincerely 
 
 
 
 
Professor G A Baker 
Professor of Clinical Neuropsychology and Consultant Clinical Neuropsychologist 
 
 
 
 
I, ……………………………………, (name) am / am not (delete as appropriate) interested in participating in 
the study ‘Accelerated forgetting in newly diagnosed temporal lobe epilepsy’. 
 
If you would like to participate, please fill out your details below: 
Address: _____________________________ 
 _______________________________ 
 _______________________________ 
 _______________________________ 
Phone: _______________________________ 
Email: _______________________________ 
Appendix 1: Letter of Invitation 
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Appendix 2: Participant Information Sheet  
Accelerated forgetting in newly diagnosed focal epilepsy. 
This is an invitation to take part in a research study. Before you decide whether or not to take 
part, it is important to understand why the study is being done and what will be involved. Please 
take your time to read the information below carefully and discuss it with friends, family or your 
GP if you wish, before making a decision. You do not have to accept this invitation. If you would 
like any more information or something is not clear please contact us (see below for details).  
Thank you for reading this. 
Why is the study being done? 
Memory problems are a major issue for many patients with epilepsy. Recent research has 
identified ‘accelerated forgetting’, a difficulty remembering things over long periods, as a 
possible cause. This research will investigate accelerated forgetting in newly diagnosed 
epilepsy, to try and understand how it happens. 
This research is also being undertaken as part of an academic qualification. 
Why me? 
You may have been invited to take part because you have a diagnosis of focal epilepsy. We 
also need participants to act as healthy controls to compare their results with patients, so 
you may have been asked because you do not have epilepsy but know someone who does. 
If you have ever had a serious head injury, brain surgery or a recent history of alcohol or 
drug abuse I am afraid you may not be able to take part, as these issues may interfere with 
your results. If this is the case, or you are unsure, please let us know. 
What will I need to do if I take part? 
If you are happy to take part, please contact us by ringing, emailing or writing (details 
below). We will go through this information with you and make sure you want to be 
involved. If you do, we will need access to your personal contact information.  
We will arrange two sessions with you, 3 weeks apart, to carry out the assessments. Ideally, 
these sessions will be at the Walton Centre, but if necessary we can arrange home visits. At 
the first session we will give you questionnaires about mood and your view of your memory, 
assess your intellectual functioning, then go through a memory test including stories and 
pictures we will ask you to remember. This will take up to 3 hours, and the following session 
will last around 15 minutes. You will also be asked to keep a record of any seizures you have 
between sessions. 
What will I get out of it? 
On a personal level, we can’t promise the study will help you. You will have a thorough 
memory assessment, and if any concerns are found you will be referred to the appropriate 
services. Also, you will be contributing to research that will increase understanding of 
memory problems in epilepsy, so that management can be improved. 
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What are the risks? 
There will be no physical risks involved in this study. There is a chance that if 
memory difficulties are found, some people might be distressed. If this is the case 
we will provide support, both immediately and with referrals to appropriate 
services. 
What if I don’t want to take part? 
If you don’t want to take part, it will not affect your care in any way. Also you are 
welcome to withdraw at any point during the study if you change your mind, 
without needing to give a reason. 
Will the information collected be confidential? 
Yes. Personal contact details will be kept in a locked cabinet and only the 
researchers will have access to them. All results will be anonymised before analysis 
and care will be taken that nobody can be identified from the reports. 
What if I want to complain? 
If you are unhappy, or if there is a problem, please feel free to let us know by 
contacting Marion Ashe on 0151 529 5417 and we will try to help. If you remain 
unhappy or have a complaint which you feel you cannot come to us with then you 
should contact the Research Governance Officer on 0151 794 8290 
(ethics@liv.ac.uk). When contacting the Research Governance Officer, please 
provide details of the name or description of the study (so that it can be identified), 
the researcher(s) involved, and the details of the complaint you wish to make.  
If you wish, you can also use the hospital complaints procedure. To do so, contact 
Fran Seagreaves, Complaints & Legal Services Manager, The Walton Centre for 
Neurology & Neurosurgery NHS Trust, Lower Lane, Fazakerley, Liverpool, L9 7LJ.  
Contact number: 0151 5295530. 
Will I hear the results? 
Yes, we will contact all participants with a summary of the research findings (with 
no personal information) once the study is completed. Also if there are any 
individual problems identified by the study we will contact those involved to 
discuss their future care. We aim to publish the study findings in peer-reviewed 
journals.  
Anything else? 
 All participants will be covered by a University insurance scheme. 
If you would like any further information, or to discuss your participation in the study, 
please contact Marion Ashe on 0151 529 5417 (email m.f.ashe@liv.ac.uk) or Professor 
Gus Baker on 0151 529 5948 (email G.A.Baker@liverpool.ac.uk) or write to 
Neurological Science, Clinical Sciences Centre, Lower Lane, Liverpool, L9 7LJ. 
 231 
 
 
 
 
CONSENT FORM –  
Accelerated Forgetting in Newly Diagnosed Focal Epilepsy 
 
 
         
Participant Name                                                       Date                    Signature 
 
                 
Name of Person taking consent                                  Date                     Signature 
 
       
Researcher                                                                      Date                     Signature 
 
The contact details of lead Researcher (Principal Investigator) are: 
Professor GA Baker, 
Division of Neurological Science, 
Clinical Sciences Centre, 
Lower Lane,  
Liverpool, L9 7JL. 
0151 529 5948 
g.baker@liverpool.ac.uk 
Researcher:   Marion Ashe   
1. I confirm that I have read and have understood the information sheet dated 
15/04/10 for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my rights being affected.   
 
3. I understand that, under the Data Protection Act,  I can at any time ask for 
access to the information I provide and I can also request the destruction of that 
information if I wish. 
 
4. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from University of Liverpool, 
from regulatory authorities or from the NHS Trust, where it is relevant to my 
taking part in this research 
 
5. I agree to take part in the above study.    
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Appendix 4:  Logical Memory Story 
 
The logical memory story used for the assessment of long term forgetting was story A from 
the WMS-III which reads as follows: 
 
‘Anna Thompson of South London, employed as a cook in a school canteen, reported at the 
police station that she had been held up on the High Street the night before and robbed of 
fifty-six pounds. She had four small children, the rent was due, and they had not eaten for 
two days. The police, touched by the woman’s story, made up a collection for her.’ 
 
This is split into 25 sub-units of recall, such as ‘Anna’, a point given for each correctly 
recalled. There are also seven additional thematic units, such as ‘indication of a main 
character who is female’ for which a point is given, so that those who remember the vague 
gist but not the exact story are still credited to a degree. 
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Appendix 5:  Visual Scenes Test 
 
 
Beach scene 
 
 
Park scene 
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Stage scene 
 
 
Street scene 
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Example recall sheet: 
Table 1a. Beach recall score sheet 
BEACH SCENE    
Objects Full Point Half Point Spatial 
Man AND golf club   Top Left (1) 
Man    
   First Descriptor     
   Second Descriptor    
    
Boat   Top Right (2) 
   First Descriptor    
   Second Descriptor     
    
Crocodile/ Alligator AND Bucket and Spade   Bottom Left (3) 
Crocodile/ Alligator OR Bucket and Spade    
   First Descriptor    
   Second Descriptor    
    
Parasol/ Umbrella   Bottom Right (4) 
   First Descriptor    
   Second Descriptor    
    
Total Items (Max=4)    
Total Spatial (Max=4)    
Total Descriptors (Max=8)    
 
Descriptors: 
Man & Golf club: 
He was ready to swing the golf club; the golf club was on the man’s right hand side; he was 
playing left-handed; he was wearing a white hat/cap; he was wearing a short-sleeve/ 
checked shirt; wearing beige/ light brown clothes; he had black shoes; he had a black belt; 
he had one (white) glove; he was facing the R side of the picture. 
Boat: 
It was a rowing/ fishing boat; it was a blue boat; the boat was lying on its side; there were 
two oars inside; there were some (green) nets inside the boat; there was a plank/thwart 
across the boat. 
Crocodile/alligator & bucket and spade: 
The alligator had its mouth open; alligator was facing the middle / head to R / head 
towards sea; there was a blue spade; the spade was half buried / upright in sand; there was 
a green bucket; the bucket and spade were in front of the alligator. 
Parasol: 
It was green/turquoise/greeny-blue on the outside; it was white on the inside; it was 
spotted on the inside; it had a curled handle; it had a frilly/ruffled edge; the outside of the 
umbrella was facing the water OR the inside was facing the alligator/ beach OR handle to L. 
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Example recognition sheet: 
 
Table 2b. PARK Scene recognition questions 
 Question Possible Responses 
Plane      
 What colour was 
the plane? 
White  Black Grey Blue 
 What was painted 
on the plane? 
Some stars A bird Some 
numbers 
A shark 
Ice-cream Van      
 What was on the 
sign of the ice-
cream van? 
Two ice-
creams 
Three ice-
creams  
A child  A flag 
 What was written 
inside the 
window of the 
ice-cream van? 
D 2 D 1 C 2 C 1 
Wheelbarrow      
 What colour was 
the 
wheelbarrow? 
Red Black Green Blue 
 What was inside 
the 
wheelbarrow? 
Two 
watermelo
ns  
Three large 
rocks 
A pile of 
leaves 
Two plants 
Books & Cricket 
bat 
     
 Where was the 
cricket bat? 
To the left 
of the 
books 
To the right 
of the books 
In front of 
the books 
Behind the 
books 
 What colour was 
the cricket bat? 
Black and 
white 
Green and 
black 
Blue and 
yellow 
Yellow and 
red  
 Total 
(Max=8) 
 
__________ 
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Appendix 6:  Baseline characteristics of all participants including those 
over 70 
 
 
The demographic, clinical and baseline neuropsychological characteristics of the 
participant groups were analysed prior to the exclusion of participants over 70 to 
assess if this affected differences between groups. The results from all participants 
are presented below. There are no significant differences between groups in 
demographic variables, or procedural details. 
 
Participants’ Demographic Information 
 
 
 
 
 
 
 
Demographics All Patients Controls Difference  
(95% CI) 
Significance 
(p-value) 
Number of participants 27 14 13   
Age/yrs 
Mean (SD) 
40.37 
(19.07) 
40.07 
(18.05) 
40.69 
(20.85) 
-0.62 
(-16.05, 14.81) 
0.935 
Gender  Male 
 
13 
(48.1%) 
6 
(42.9%) 
7 
(53.8%) 
 0.706 
Female 
 
14 
(51.9%) 
8 
(57.1%) 
6 
(46.2%) 
Handedness  R 
 
24 
(88.9%) 
12 
(85.7%) 
12 
(92.3%) 
 1.000 
L 
 
3 
(11.1%) 
2 
(14.3%) 
1 
(7.7%) 
Education /years  
Mean (SD) 
13.56 
(2.75) 
13.21 
(2.52) 
13.92 
(3.04) 
-0.71 
(-2.91, 1.50) 
0.514 
Education 
/level  
school 10 
(37.0%) 
5 
(35.7%) 
5 
(38.5%) 
School vs higher 
education 
1.000 
college 7 
(25.9%) 
5 
(35.7%) 
2 
(15.4%) 
university 10 
(37.0%) 
4 
(28.6%) 
6 
(46.2%) 
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Procedural details of assessments in patients and controls 
 
 
 
 
Clinical variables in patients 
Patients n=14 
Seizure type Partial only 3 (21.4%) 
Partial and generalised 7 (50.0%) 
Secondary generalised only 
 
4 (28.6%) 
Total number of generalised seizures 
Mean (SD) 
 
2.07 
(1.39) 
Time since diagnosis / weeks 
Median (IQR) 
 
4.00 
(1.75, 12.75) 
Time since first seizure / months 
Median (IQR) 
 
18.00 
(5.25, 66.00) 
Number of medications 
Median (IQR) 
 
1 
(1, 1) 
Age of onset  
Mean (SD) 
36.93 
(19.00) 
 
Procedure All 
(n=27) 
Patients 
(n=14) 
Controls 
(n=13) 
Difference 
(95% CI) 
p-value 
Location of 
initial 
assessment  
CTU 8 
(29.6%) 
5 
(35.7%) 
3 
(23.1%) 
 0.678 
Home 
 
 
19 
(70.4%) 
9 
(64.3%) 
10 
(76.9%) 
 
Location of 
follow up 
assessment 
CTU 7 
(25.9%) 
4 
(28.6%) 
3 
(23.1%) 
 1.000 
Home 
 
 
20 
(74.1%) 
10 
(71.4%) 
10 
(76.9%) 
 
Interval between 
assessments/ days 
Mean (SD) 
21.04 
(0.85) 
20.93 
(0.62) 
21.15 
(1.07) 
-0.23 
(-0.91, 0.46) 
0.504 
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Investigation results 
Investigation results Patients n=14 
Imaging Normal 11 (78.6%) 
Abnormal 3 (21.4%) 
EEG Normal 8 (57.1%) 
Abnormal 1 (7.1%) 
Not done 5 (35.7%) 
Laterality of 
seizure onset 
Left 1 (7.1%) 
Right 2 (14.3%) 
Unknown 11 (78.6%) 
 
 
 
 
Distribution of age of onset of epilepsy 
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Background Intellectual Functioning - WASI 
**p<0.01 
 
 
 
Correlations between years of education and WASI scores 
All participants (n=27) Years of education 
VIQ 0.389 (p=0.045)* 
PIQ 0.227 (p=0.255) 
FSIQ 0.387 (p=0.046)* 
Patients (n=14)  
VIQ 0.210 (p=0.472) 
PIQ -0.273 (p=0.344) 
FSIQ -0.015 (p=0.959) 
Controls (n=13)  
VIQ 0.508 (p=0.076) 
PIQ 0.505 (p=0.079) 
FSIQ 0.699 (p=0.008)** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Overall 
(n=27) 
Patient 
(n=14) 
Control 
(n=13) 
Difference 
(95% CI) 
p-value 
VIQ 
Mean (SD) 
 
104.22 
(15.34) 
98.29 
(13.88) 
110.62 
(14.70) 
-12.330 
(-23.655, -1.004) 
0.034* 
PIQ 
Mean (SD) 
 
110.41 
(13.12) 
104.29 
(10.04) 
117.00 
(13.14) 
-12.714 
(-21.942, -3.487) 
0.009** 
FSIQ 
Mean (SD) 
108.07 
(13.37) 
101.50 
(11.15) 
115.15 
(12.16) 
-13.654 
(-22.890, -4.418) 
0.005** 
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Mean scores in WMS indices 
 
 All 
(n=27) 
Patients 
(n=14) 
Controls 
(n=13) 
Difference 
(95% CI) 
p-value 
Auditory Immediate 
Memory (AIM) 
107.48 
(14.87) 
104.50 
(13.06) 
110.69 
(16.51) 
-6.19 
(-17.95, 5.56) 
0.288 
Visual Immediate 
Memory (VIM)  
96.74 
(13.46) 
91.50 
(11.41) 
102.38 
(13.52) 
-10.89 
(-20.81, -0.96) 
0.033* 
Immediate Memory 
(IM) 
102.85 
(14.24) 
98.00 
(12.55) 
108.08 
(14.56) 
-10.08 
(-20.83, 0.67) 
0.065 
Auditory Delayed 
Memory (ADM) 
106.48 
(13.61) 
104.86 
(11.24) 
108.23 
(16.06) 
-3.37 
(-14.29, 7.55) 
0.530 
Visual Delayed 
Memory (VDM) 
100.37 
(14.32) 
96.00 
(11.67) 
105.08 
(15.82) 
-9.08 
(-20.04, 1.88) 
0.100 
Auditory Recognition 
Delayed Memory 
(ARDM) 
112.59 
(10.60) 
 
111.07 
(11.13) 
114.23 
(10.18) 
-3.16 
(-11.63, 5.31) 
0.450 
General Memory 
(GM) 
106.85 
(13.53) 
103.57 
(11.56) 
110.38 
(15.02) 
-6.81 
(-17.39, 3.76) 
0.197 
Working Memory 
(WM) 
105.81 
(16.33) 
101.64 
(16.62) 
110.31 
(15.38) 
-8.67 
(-21.39, 4.06) 
0.173 
 
Patients scored lower than controls on VIQ (p=0.034), PIQ (p=0.009) and FSIQ 
(p=0.005) and lower than controls in visual immediate memory (p=0.033) but there 
were no other significant differences in neuropsychological measures. 
 
